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PART I: 
OUTLINE AND 
GENERAL INTRODUCTION

CHAPTER 1 
Outline of the Thesis
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Glucose homeostasis 
Homeostasis is a constant process in the human body that maintains stability of the 
body’s internal conditions by constant adaptation to changing external conditions. The 
homeostatic system needs a sensor to detect changes, an effector mechanism to adapt 
to these changes and a feedback loop to connect the sensor and effector. Examples of 
homeostatic processes include temperature regulation, controlling the pH in the blood 
and regulating blood glucose levels (glucose homeostasis) (Figure 1).
Figure 1: Glucose homeostasis. Insulin and glucagon work together to maintain glucose 
homeostasis. Insulin, secreted by the beta cells (red pathway), decreases glycemia after food intake 
by glycogen storage. When glycemia decreases under a critical threshold, glucagon, secreted by the 
alpha cells (blue pathway), will increase glycemia by breakdown of glycogen storage in de liver 
(reprinted with permission of Dr. Anica Schraenen) [1].
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When the blood glucose level (glycemia) rises after food intake, insulin will be secreted 
from the pancreatic beta cells. Insulin increases glucose storage in the liver and glucose 
deposition in skeletal muscles and adipocytes. When glycemia decreases below a critical 
threshold, the counter regulating system will be activated. Glucagon will be released 
from the pancreatic alpha cells and insulin secretion from the beta cells will be inhibited. 
Together with adrenaline, glucagon will increase glycemia by activation of glycogenolysis 
and inhibition of glycogen synthesis, glycolysis and synthesis of free fatty acids. When 
deficient control of glucose homeostasis occurs, this can result in a variety of pathologies 
of which diabetes mellitus is the most prominent. 
Diabetes Mellitus
The main characteristic of diabetes is chronically elevated glycemia as a consequence 
of progressive beta cell failure. The main forms of the disease are type 1 and type 2 
diabetes. Although both disease types show similar clinical outcomes, they show distinct 
mechanisms of beta cell failure [2]. In type 1 diabetes (T1D), autoimmune destruction 
of the insulin producing beta cells causes deficient glucose homeostasis. These patients 
have no or at most very limited insulin levels, which results in seriously elevated blood 
glucose levels, causing keto-acidosis, coma and even death. Type 2 diabetes (T2D), which 
is often associated with obesity, occurs when the beta cells become unable to release 
sufficient insulin levels to compensate for insulin resistance of the insulin receptor 
expressing organs, resulting in increased blood glucose levels (Figure 2). Despite 
appropriate insulin therapy and good glycemic control, both types of diabetes can 
cause several macro- and microvascular complications such as cardiovascular diseases, 
retinopathy, nephropathy, neuropathy and diabetic foot disorder which might result in 
amputation. With over 350 million people suffering from diabetes worldwide and the 
knowledge that diabetes related healthcare costs amount to 2.5-15% of the total national 
annual healthcare budgets, it is a major challenge without high hopes for improvement 
in the near future, since the prevalence of diabetes is expected to rise to over 590 million 
people in 2035 [3, 4].
Despite major research efforts during the last few decades, our knowledge of the 
pathogenesis of diabetes remains limited. Improved comprehension of disease onset 
and progression could be the key to novel and better therapeutic options. Nowadays, 
therapeutic options for both T1D and T2D are mainly limited to daily insulin injections 
and dietary interventions. A novel, promising therapy for T1D patients with poor 
glycemic control is islet transplantation, which results in improved blood glucose levels 
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and reduced risk of very low blood glucose levels (hypoglycemia). However, insulin 
independence drops to less than 15%, 5 years after transplantation [5], demonstrating the 
poor long-term transplantation outcome. 
Until now, beta cell function and glycemic control are mainly examined by measuring 
functional markers such as insulin release, C-peptide levels, blood glucose levels and 
HbA1c values. Unfortunately, these measures show large inter-individual differences. 
Moreover, it has been shown that beta cell function does not always correlate with beta 
cell mass (BCM) during disease progression [6, 7] Therefore, a method that can provide 
real time information on BCM, in the native pancreas but also after transplantation, may 
help to improve diabetes prevention and therapy. 
Figure 2: Disease mechanisms. In the healthy situation, insulin is secreted from the beta cells and 
binds its receptor on the target cells to generates a signal to clear glucose from the blood stream. In 
T1D, insulin secreting beta cells are destructed, while in T2D insufficient insulin levels are secreted 
to compensate for insulin resistance (extracted from [8]).
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An interesting approach to gain real-time information about disease pathogenesis 
and progression is in vivo non-invasive beta cell imaging using Positron Emission 
Tomography (PET) and Single Photon Emission Computed Tomography (SPECT). In 
view of their high sensitivity, these imaging modalities may reveal important, early stage 
disease information since they allow monitoring of BCM dynamics in the native pancreas 
over time. Also after islet transplantation, longitudinal and quantitative imaging might 
help to gain more knowledge about post-transplantation pathologic processes such as 
metabolic stress, inflammation and rejection and eventually, might help to improve long-
term transplantation outcome. Finding the ideal target and radiotracer for in vivo beta 
cell imaging is a challenging process. To obtain optimal target-to-background ratios, the 
ideal target is specifically expressed on the beta cells and not on other endocrine cell 
types nor in the exocrine pancreas. Furthermore, to obtain accurate disease information, 
radiotracer uptake should correlate with BCM in the native pancreas and, with viable 
graft volume after islet transplantation. 
Outline of the Thesis 
In this thesis, we describe the characterization of different receptors, expressed on the 
beta cells, as targets for in vivo beta cell imaging, both in the native pancreas and after islet 
transplantation. In Chapter 2 we provide an overview of different imaging modalities 
and potential targets suitable for imaging islets and/or beta cells. The remainder of the 
thesis describes the characterization of potential target receptors and their tracers/probes 
for BCM imaging in the native pancreas and after islet transplantation. The first target 
that we investigated is the Glucagon-like peptide 1 receptor (GLP-1R). In Chapter 3 we 
determined how the chosen rodent model affects BCM assessment via GLP-1R targeting 
using radiolabeled exendin. In Chapter 4, we characterized the suitability of the GLP-
1R as a target for islet transplant visualization. The second target that we evaluated as 
a potential imaging marker for transplanted islets is the dopamine 2 receptor (D2R) 
(Chapter 5). Afterwards, the ability of [123I]Iodobenzamide ([123I]IBZM), a strong D2R 
antagonist, to quantitatively and longitudinally image islet grafts was examined. The 
results of the latter study are presented in Chapter 6. The last target that we studied is 
the Glucose-dependent Insulinotropic Polypeptide (GIP) receptor. In Chapter 7, a first 
attempt to visualize the islets of Langerhans in the native pancreas using a fluorescent 
GIP probe is described. The potential of the GIP receptor as a target for neuro-endocrine 
tumor imaging, using a radiolabeled GIP analogue, is presented in Chapter 8. Finally, in 
Chapter 9 the experimental results and the future perspectives are discussed. 
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CHAPTER 2 
General Introduction: Imaging Modalities  
and Targets for Beta Cell Imaging
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For almost 2 decades, researchers around the world have been making extensive efforts to 
develop non-invasive imaging techniques for the visualization and in vivo monitoring of 
viable beta cells. Improved imaging methodologies, that enable visualization of beta cell 
mass (BCM), might reveal important novel aspects of diabetes onset, development and 
progression. Furthermore, beta cell imaging might help to improve the development of 
novel diabetes drugs and promising therapies such as islet transplantation by providing 
real-time information on the state of the islet graft. Despite these major efforts, the search 
for the ideal imaging method has been a true struggle and only few tracers have been 
clinically tested until now. One of the main challenges is the dispersion of the islets 
of Langerhans throughout the exocrine pancreas parenchyma. Therefore, high spatial 
resolution of the applied imaging modality or high chemical resolution (high uptake 
and specificity of the tracer for its target, in combination with low uptake in surrounding 
tissues) of the applied tracer molecule is required. This brings us towards the second 
challenge, namely that imaging modalities have either high sensitivity or high spatial 
resolution, but never a combination of both.
Imaging Modalities for Islet Imaging 
Various imaging techniques can be used to visualize the islets of Langerhans. Each 
technique harbors its own advantages and drawbacks depending on the imaging modality, 
the characteristics of the targeting agent and the features of the islets of Langerhans (for 
example native or engrafted islets). In the first part of this general introduction, we will 
discuss 2 imaging modalities that are currently used for beta cell imaging in the native 
pancreas and after islet transplantation. 
Magnetic Resonance Imaging (MRI) 
MRI is an imaging modality that generates images by nuclear magnetic resonance. This 
means that a magnetic field forces the nuclear spin of the nuclei into a certain orientation, 
which can be detected by the scanner using a polarized radiofrequency. Major advantages 
of MRI are its unmet high spatial resolution and its high potential for non-invasive islet 
monitoring by enabling non-invasive longitudinal measurements. Nevertheless, the 
sensitivity of this imaging modality is low as compared to radionuclide imaging. Since 
the native contrast between the islets of Langerhans, containing the beta cells, and the 
exocrine tissue is not sufficient, the use of contrast agents is required. Development of 
successful contrast agents for human islet monitoring is challenging since they need to 
be beta cell specific, remain stable with high signal intensity and should not cause toxic 
effects.
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To visualize islet grafts by MRI, the islets are labeled with contrast agent before 
transplantation, a technique referred to as the pre-labeling approach. A first class of 
applied contrast agents to visualize transplanted islets with MRI is the class of the 
superparamagnetic iron oxide (SPIO) nanoparticles. When ex vivo labeled islets are 
transplanted into the liver, islets can be detected as hypo-intense spots after internalization 
of these particles [1]. A clinical study showed detection of SPIO-labeled islets 6 months 
after transplantation, but the detected signal did not correlate with the number of 
transplanted islets [2]. Unfortunately, metal-ion-based contrast agents show poor signal-
to-noise ratios for pancreas imaging. A second class of contrast agents are the gadolinium 
chelates, which can be applied for in vivo imaging of ex vivo labeled islets, transplanted 
under the kidney capsule or in the liver [3]. Also using this technique, islets are pre-
labeled with contrast agents before transplantation. Another option for islet imaging is 
the use of perfluoropolyether (PFPE) agents, which can be detected using [19F]-MRI. This 
technique was successfully used to monitor ex vivo labeled dendritic cells in a mouse 
model of type 1 diabetes and may therefore have potential for islet monitoring [4, 5]. 
One important drawback of these pre-labeling methods is that large amounts of contrast 
agent are needed, which may affect islet viability and islet function.
To image the beta cells in the native pancreas by in vivo targeting, the need for a highly 
selective contrast agent is even higher. Such a contrast agent should specifically bind 
pancreatic beta cells, but not to other neighboring tissues and show an intense signal 
without toxic effects for the beta cells. In 2009, Antkowiak et al. showed the potential of 
manganese ions (Mn2+) as a contrast agent for in vivo monitoring of the beta cell response 
to glucose challenge [6]. Later, in 2013, they detected declining BCM in a mouse model 
for type 1 diabetes using Mn2+-enhanced MRI [7]. Furthermore, Zinc [8] and exendin 
probes [9] are being applied to detect differences in BCM by MRI.
 
Radionuclide Imaging (PET and SPECT)
Both Positron Emission Tomography (PET) and Single Photon Emission Computed 
Tomography (SPECT) can be applied for quantification of an amount of radioactivity 
(uptake/accumulation) in a certain region of interest (ROI). The major advantage of 
both PET and SPECT over other imaging modalities, such as MRI and CT, is their high 
sensitivity. To visualize the islets of Langerhans with radiolabeled tracers using PET or 
SPECT, a tracer characterized by high “chemical resolution” is needed. This means that 
the tracer is highly specific for the beta cells, combined with high uptake in the target 
as compared to background, resulting in a signal originating specifically from the beta 
cells. In the ideal situation, a beta cell tracer should 1) have a target specifically expressed 
in the beta cells, 2) have a target not expressed on other islet cells (ie. alpha and delta 
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cells), 3) show high endocrine and low exocrine uptake, 4) correlate linearly with BCM 5) 
show clear differences in uptake between healthy and diabetic subjects and 6) show high 
target-to-background ratios [10]. 
In PET imaging, positron-emitting radionuclides such as 11C, 18F, 68Ga and 64Cu are used. 
The scanner detects co-incidence of 2 high-energy (511 keV) photons originating from 
annihilation. Thus, the crystal detection ring detects 2 signals on a straight line through 
the annihilation point. After image reconstruction, 3D images of tracer distribution 
can be obtained. Major advantages of PET are for example its high sensitivity which 
allows detection of picomolar tracer concentrations and its straightforward and reliable 
quantification. Therefore, PET can provide information about biochemical changes by 
quantitative determination of tracer uptake in a certain target. Since PET images provide 
limited anatomical information they are fused with CT or MRI images for anatomical 
reference. The spatial resolution of PET is limited to 2 mm in clinical systems and 1.5 
mm in preclinical systems. Together with image sampling into voxels, this causes a 
phenomenon called the partial volume effect (PVE) when the observed objects approach 
the spatial resolution of the scanner [11]. Since PET systems are unable to detect single 
islets, the region of interest (ROI) is drawn around the entire pancreas to quantify total 
tracer uptake in the islets of Langerhans. Quantification of pancreatic tracer uptake is 
prone to PVE’s, resulting in spill-out of radioactivity into the surrounding tissue and 
an underestimation of tracer uptake in the ROI. It was shown that pancreatic volume is 
decreased in patients with T1D [12], resulting in more distinct PVE’s. Therefore, accurate 
partial volume correction (PVC) is required when comparing pancreatic uptake of type 
1 diabetic patients with healthy controls. Next to spill-out PVE’s, spill-in of radioactivity, 
originating from surrounding organs with high radioactivity accumulation (such as the 
kidneys) into the ROI can occur, leading to an overestimation of the signal in the ROI. 
For SPECT imaging, gamma-emitting radionuclides such as 111In, 99mTc and 123I, with low-
energy photons, are used. Since the detected photons are not coincident, a collimator is 
localized anterior to the scintillation crystal to obtain 3D images. A collimator is a grid 
which avoids detection of non-perpendicular photons that blur the image. Unfortunately, 
collimators absorb part of the emitted radiation which lowers the systems sensitivity. In 
preclinical SPECT systems, use of multi-pinhole collimators can increase the sensitivity 
and provide a spatial resolution as low as 0.3 mm [13]. Advantages of SPECT over PET 
are for example the lower costs and higher availability of the radionuclides, and the fact 
that an on-site cyclotron is not required to produce these tracers.
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Targets and Radiotracers for Islet Imaging 
Until now, several molecules including receptors, antigens and transporters have been 
proposed as potential targets for in vivo islet and/or beta cell imaging. In the following 
section of this general introduction, a selection of attractive target receptors and their 
corresponding radiotracers will be discussed in more detail. 
GLP-1 Receptor
The glucagon-like peptide 1 receptor (GLP-1R) is a prominent target for non-invasive in 
vivo beta cell imaging. The receptor belongs to a 7-transmembrane-spanning, G-protein-
coupled receptor family that also contains the glucagon, glucagon-like peptide 2 (GLP-
2) and glucose-dependent insulinotropic polypeptide (GIP) receptors [14]. GLP-1R is 
expressed on pancreatic beta cells, where receptor activation stimulates insulin secretion, 
insulin gene transcription and biosynthesis (Figure 1), a phenomenon called the incretin 
effect [15, 16]. In all other endocrine cell types however, receptor expression is absent 
[17-19]. Furthermore, very limited expression is found in the exocrine pancreas [20, 21] 
and the surrounding organs, such as the stomach and duodenum. This expression profile 
makes the GLP-1R an excellent potential target for beta cell imaging.
 
Figure 1: GLP-1R-dependent signal transduction pathways in the pancreatic beta cell. GLP-1R 
activation is coupled to 1) insulin synthesis and secretion (green), 2) beta cell proliferation and 
neogenesis (blue), 3) inhibition of apoptosis (red) and 4) reduction of ER stress (purple). Adapted 
from [22]
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Since the half-life of GLP-1, the natural GLP-1R ligand, is less than 2 minutes in circulation 
[23], it is unsuitable for in vivo GLP-1R targeting. Therefore, stable GLP-1R agonists, such 
as exendin-3 and exendin-4 [24, 25], are applied for in vivo beta cell imaging via GLP-1R 
targeting. Initial studies were performed with [123I]-labeled exendin and showed high 
uptake in the pancreas and in insulinomas [26]. However, [111In]-labeled exendin displays 
much higher uptake and retention in insulinomas, since the radiometal is trapped in the 
lysosomes upon internalization by the target, while 123I is released from the cell after 
degradation [26, 27]. Nowadays, [111In]-exendin SPECT can be successfully applied to 
visualize neuro-endocrine tumors (NET) in both rodents and patients [28].
Radiolabeled exendin cannot only target insulinomas, it can also target GLP-1R on beta 
cells, both in the native pancreas and after transplantation in the liver or the muscle [29]. 
Pancreatic [111In]-exendin uptake can be visualized in vivo using SPECT and quantitative 
SPECT analysis shows a linear correlation of pancreatic tracer uptake and BCM in a 
rat model of alloxan-induced diabetes [30]. These observations indicate the possibility 
of this technique to detect small changes in BCM. Furthermore, pancreatic uptake of 
radiolabeled exendin is not influenced by the alpha cells [17], which is of great importance 
for the beta cell specificity of the tracer. The potential of this radiotracer to visualize the 
beta cells in the pancreas was not only proven in rodents but also in humans. The uptake 
in the pancreas of type 1 diabetic patients was clearly decreased when compared to 
healthy volunteers [30]. Another application of radiolabeled exendin is non-invasive in 
vivo imaging of transplanted islets of Langerhans. Both after transplantation in the liver 
and the muscle, islet grafts can be visualized by [111In]-exendin SPECT and [18F]-exendin 
PET, respectively [31]. Next to radiolabeling for PET and SPECT imaging, exendin can 
also be coupled to an iron oxide nanoparticle for in vivo MRI [9] or with fluorescent dyes 
for optical imaging [32].
GIP Receptor
Together with GLP-1, the glucose-dependent insulinotropic polypeptide (GIP) is 
responsible for the incretin effect [15, 16] and potentiates glucose-stimulated insulin 
secretion upon receptor binding in the islets of Langerhans. Next to its action in the 
pancreas, GIP is responsible for unique anabolic actions in other tissues, such as brain, 
bone and adipose tissue (Figure 2) [22]. The peptide exerts its action through activation 
of the GIP receptor (GIPR), a 7-transmembrane-spanning, G-protein-coupled receptor 
[33]. The expression of GIPR on beta cells, and its suggested involvement in diabetes 
pathogenesis [34], makes this receptor an interesting potential target for in vivo beta cell 
imaging.
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Since GIP is prone to cleavage by dipeptidyl peptidase IV (DPP IV), the half-life of the 
natural receptor ligand in circulation is about 2 minutes [35], which hampers its use as a 
tracer for in vivo GIPR targeting. However, it was shown that N-terminal modifications 
of GIP at the DPP IV cleavage site, such as acetylation and glycation, can dramatically 
increase its half-life [36, 37]. Therefore, these modified GIP analogues may be more 
suitable for in vivo GIPR targeting.
Figure 2: Anabolic GIP actions in peripheral tissues. Apart from its stimulating effect on insulin 
secretion (incretin effect), GIP also exerts a variety of anabolic effects in various tissues, such as the 
brain, bone and adipose tissue. Adapted from [22]. 
During the last few years, the interest in the GIPR as a target for imaging and therapy 
of NETs has been rising [38], since its expression was revealed in a variety of tumor 
types such as gastric, pancreatic, bronchial and duodenal NETs [39-41]. Furthermore, the 
feasibility of GIPR positive tumor targeting was demonstrated using a radiolabeled GIP 
analogue [42]. Next to tumor imaging, GIPR targeting might also be a valuable tool for 
islet imaging. 
Serotonin receptor
The endocrine pancreas mainly consists of the islets of Langerhans, but also contains 
some nervous tissue. Therefore, it is not surprising that some neurotransmitters found in 
the central nerve system are also expressed in the endocrine pancreas [43]. One of these 
neurotransmitters, present in the islets of Langerhans, is serotonin (5-hydroxytryptamine 
(5-HT)). Serotonin has a function in insulin secretion [44] and influences beta cell 
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proliferation during pregnancy [45, 46]. Furthermore, alterations in the serotonergic 
system are observed in diabetic animal models and patients, suggesting involvement 
of serotonin in diabetes pathogenesis. 5-hydroxytryptohane (5-HTP), a precursor of 
serotonin, can be taken up in the islets via L-type amino acid transporters (LAT) and is 
decarboxylated by L-amino acid decarboxylase (AADC) to form serotonin which is then 
stored in secretory vesicles via the vesicular monoamine transporter 2 (VMAT2) (Figure 
3) [47, 48]. Interestingly, the serotonin pathway is absent in the exocrine pancreas [49], 
which renders it an attractive target for beta cell imaging. 
Figure 3: Mechanism of 5-HTP accumulation in the pancreatic beta cell. 5-HTP is taken up in the 
cell by LAT’s, decarboxylated by ADCC and stored in the secretory vesicles as 5-HT. This figure 
was originally printed in JNM, Valentina Di Gialleonardo, Alberto Signore, Ena A Scheerstra, 
Anniek KD Visser, Aren van Waarde, Rudi AJO Dierckx, Erik FJ de Vries. [11C]-hydroxytryptophan 
uptake and metabolism in endocrine and exocrine pancreas. J Nucl Med. 2012:53;1755-1763 © by 
the Society of Nuclear Medicine and Molecular Imaging, Inc. [50]
[11C]-5-HTP is a PET tracer originally designed for in vivo assessment of serotonin 
biosynthesis in the central nervous system [51]. Nowadays, [11C]-5-HTP PET is clinically 
applied for the localization of NETs [52]. For specific islet cell tumor detection, it is 
even more successful than [18F]-DOPA PET [53]. Apart from tumor imaging, [11C]-5-
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HTP can also be applied for quantitative islet imaging. In mixtures of isolated human 
islets and exocrine cells, [11C]-5-HTP uptake correlates linearly with the amount of islets 
[54]. Initially, [11C]-5-HTP is taken up by both endocrine and exocrine tissue via LAT’s. 
However, the tracer only accumulates in cells harboring the serotonin synthesis pathway. 
Therefore, the tracer accumulates in the islets and is not retained in the exocrine tissue. 
Theoretically, [11C]-5-HTP is a marker for both alpha and beta cells since both cell types 
are serotonin positive. However, tracer retention is significantly higher in beta cells 
resulting in increased accumulation in the beta cells 1 hour post-injection (pi.) [55].
 
In streptozotocin-induced diabetic rats with 10-20% remaining BCM, pancreatic [11C]-
5-HTP uptake was 66% lower on average than in healthy animals. Furthermore, the 
tracer could discriminate between rats with severe and less severe beta cell loss [54]. 
Both in type 1 and type 2 diabetic patients, [11C]-5-HTP uptake was decreased compared 
to healthy volunteers. Clinical studies in type 1 diabetic patients show a decrease in 
tracer uptake of 66% 1 hour pi. when compared to healthy volunteers and the main 
decrease was observed in beta cell rich areas of the pancreas [56]. Furthermore, in vivo 
[11C]-5-HTP uptake correlated with C-peptide levels in type 1 diabetic patients. These 
studies clearly demonstrate negligible non-specific uptake in vivo and preferential beta 
cell targeting. Nevertheless, one should keep in mind that total beta cell depletion will 
only partly reduce endocrine [11C]-5-HTP uptake due to the presence of other neuro-
endocrine pancreatic tissues retaining [11C]-5-HTP.
Dopamine receptor
A second neurotransmitter system, expressed in the islets of Langerhans is the 
dopaminergic system. Dopamine receptors are expressed in the islets of rodents and 
humans and receptor expression co-localizes with insulin secretion [57]. It is known 
that dopamine exerts an effect on insulin secretion, but its exact function remains to be 
elucidated [57, 58]. Ever since the presence of dopamine receptors on islets was revealed, 
it was pointed out as a potential target for beta cell imaging.
[18F]-DOPA is a PET radioligand which has been used extensively to investigate 
dopaminergic transmission in patients with neurodegenerative diseases [59]. The tracer 
accumulates in the islets using the same mechanism as [11C]-5-HTP (Figure 3). After 
[18F]-DOPA is taken up via LAT’s, it is decarboxylated by AADC and [18F]-dopamine is 
stored in the secretory granules of the islets. However, in vitro specific beta cell binding 
is rather low. [18F]-DOPA displays high uptake in the exocrine pancreas which precludes 
islet imaging in the native pancreas using this tracer. Nevertheless, [18F]-DOPA PET is 
successfully applied to visualize NETs such as insulinomas [60] and to non-invasively 
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distinguish between the focal and diffuse form of congenital hyperinsulinism of infancy 
[61, 62]. In these conditions, elevated L-DOPA decarboxylase activity is observed, which 
results in increased tracer accumulation. Although islet imaging using [18F]-DOPA PET 
is not feasible in the native pancreas, it might be a valuable tool to visualize the islets 
after transplantation. Indeed, subcutaneously transplanted islets, could be imaged 
successfully using [18F]-DOPA PET [63]. Also by using other dopamine receptor ligands 
such as [18F]-fallypride [64] and [123I]IBZM, it is possible to visualize islet grafts. 
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Abstract 
Aims: Non-invasive beta cell mass (BCM) quantification is a crucial tool to 
understand diabetes development and progression. [111In]-exendin is a promising 
agent for in vivo beta cell imaging, but tracer testing has been hampered by the lack 
of well defined rodent models. 
Methods: Biodistribution and pancreatic uptake of [111In]-exendin were compared in 
rats and mice. In selected animal models, the amount of [111In]-exendin accumulation 
in the pancreas and other organs was determined using a model of alloxan-
induced beta cell loss. GLP-1R expression levels were analyzed by RT-PCR and 
immunohistochemistry.
Results: Namely Brown Norway rats showed beta cell specific tracer accumulation 
and favorable pancreas-to-background ratios for non-invasive BCM determination. 
Mice displayed receptor mediated [111In]-exendin uptake in endocrine and exocrine 
pancreas, in spite of very low GLP-1R expression in exocrine tissue. 
Conclusions: Rats display better characteristics for in vivo BCM determination with 
radiolabeled exendin than mice, and are suggested as a more adequate model for 
humans.
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Introduction
Diabetes mellitus is characterized by defective glucose homeostasis and consequent 
chronic hyperglycemia. Maintenance of glycemic control by daily insulin injections or 
anti-diabetogenic drugs is difficult and patients affected by both type 1 and type 2 diabetes 
are at risk for severe complications, such as cardiovascular disease, blindness and kidney 
failure, increasing the risk for premature death. Changes in beta cell mass (BCM) occur 
in both forms of diabetes [1-3], but the mechanisms and evolution underlying these BCM 
changes are poorly understood [4, 5].
Beta cell function is usually monitored by measurements of insulin secretion, such as 
insulin and C-peptide, analyzed in parallel to glucose levels. However, it was shown 
that beta cell function and BCM do not diminish equally during disease progression 
[5, 6], indicating that beta cell function is not an adequate measure for BCM. A reliable 
and reproducible method to monitor BCM dynamics over time, such as longitudinal 
quantitative imaging, could unravel the importance of BCM during the course of diabetes. 
During the past decade, major efforts have been made to image BCM in vivo in animal 
models using a variety of imaging methodologies [7], such as near infrared optical 
projection tomography (OPT) [8], bioluminescence [9] or magnetic resonance imaging 
(MRI) [10-12]. While MRI offers the highest resolution (still not allowing resolution 
of single islets in vivo), nuclear medicine imaging modalities, such as single photon 
emission computed tomography (SPECT) and positron emission tomography (PET) 
have the potential to reach sufficient sensitivity to detect small numbers of beta cells 
when targeted with a radiolabeled beta cell specific tracer. Importantly, the first clinical 
trial results show that SPECT and PET are the most likely approaches to reach human 
translation at this point in time [13-15].
A variety of antibodies, such as IC2 [16], small molecules, such as [18F]-fluorodeoxyglucose 
([18F]-FDG) [17], neurotransmitter precursors, such as [11C]-5-hydroxytryptophan ([11C]-
5-HTP) [18], organic compounds, such as dihydrotetrabenazine (DTBZ) targeting 
the vesicular monoamine transporter 2 (VMAT2) [19] and peptides, such as exendin 
targeting the glucagon-like peptide 1 (GLP-1) receptor [13] have been evaluated as 
tracers for in vivo BCM determination. Very recent findings indicate that [11C]-5-HTP can 
successfully discriminate between rats with severe or moderate beta cell loss [15, 18], 
while radiolabeled exendin, a stable GLP-1R agonist specifically targeting the pancreatic 
beta cells [20], was shown to successfully detect small changes in BCM in a preclinical 
model for beta cell loss [14]. In order to further validate the use of GLP-1R radionuclide 
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imaging to evaluate the dynamics of BCM changes in diabetes, further studies in animal 
models are required. 
A variety of preclinical models has been used to investigate BCM dynamics, but the 
obtained results showed differences in biodistribution and in tracer uptake in relation 
to BCM [14, 21-24]. We hypothesize that the observed differences in these studies can be 
related to the use of animal models. Therefore, in the present study we aimed to evaluate 
the differences between various animal models to select the most suitable model for 
preclinical, non-invasive BCM determination using [111In]-exendin. Ideally, this optimal 
model should allow accurate, quantitative BCM determination and its features should 
reflect the human situation. We compared the biodistribution and pancreatic uptake of 
[111In]-exendin in various rat and mouse strains and compared their specific GLP-1R 
expression pattern. Finally, we determined the specificity of [111In]-exendin accumulation 
in beta cells using an alloxan-induced model for beta cell loss.
Materials and Methods
Radiolabeling 
[Lys40(DTPA)]exendin-3 (Peptides Specialty Laboratories, Heidelberg, Germany) was 
radiolabeled as previously described [25]. Briefly, 150 MBq [111In]Cl3 was added to 1 µg 
[Lys40(DTPA)]exendin-3 dissolved in 0.1 M 2-(N-morpholino)ethanesulfonic acid (MES), 
pH 5.5 (Sigma Aldrich, St. Louis, MO, USA) and incubated for 20 minutes at room 
temperature (RT). After incubation, EDTA (Sigma Aldrich) and Tween80 (Sigma Aldrich) 
were added to a final concentration of 5 mM and 0.1%, respectively. The radiochemical 
purity of [111In]-exendin-3 was determined by instant thin-layer chromatography (ITLC) 
(ITLC-SG, Agilent Technologies, Lake Forest, CA, USA), using 0.1 M EDTA in 0.1 M 
NH4Ac (Sigma Aldrich), pH 5.5 as a mobile agent.
Animals 
All animal experiments were approved by the Animal Welfare Committee of the 
Radboud University, Nijmegen and carried out in accordance with the local and national 
guidelines. Six to eight weeks old, male animals were used for all experiments. For the 
experiments in mice, BALB/c, DBA, CBA and C57Bl/6J mice were purchased from 
Janvier Labs (Le Genest Saint Isle, France) and the NMRI mice from Harlan (Horst, The 
Netherlands). For the experiments in rats, Brown Norway, F344, WAG/Rij and Sprague 
Dawley rats were purchased from Harlan. 
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Alloxan Treatment 
To determine the specificity of [111In]-exendin accumulation in the beta cells, animals were 
injected with various doses (25 – 75 mg/kg) of alloxan monohydrate (Sigma chemicals, 
St Louis, MO, USA) to deplete the beta cells. Alloxan was dissolved in ice cold 10 mM 
HCl with a concentration of 0,1 mg/µl and diluted with ice cold phosphate buffered 
saline (PBS). During storage and dilution, alloxan was protected from light and kept on 
ice. Animals were injected intravenously with 200 µl alloxan solution within 5 minutes 
after dilution. Control animals were injected with vehicle (10 mM HCl diluted with PBS). 
Blood glucose concentrations were monitored for 1 week after alloxan injection using a 
blood glucose meter (Accu-Chek Sensor, Roche Diagnostics, Almere, The Netherlands). 
Biodistribution Studies 
Biodistribution studies were performed to compare the [111In]-exendin uptake in 
different mouse and rat strains. Based on the pancreatic uptake, endocrine-to-exocrine 
ratio, pancreas-to-stomach ratio and pancreas-to-duodenum ratio, 1 strain was chosen 
to determine the specificity of [111In]-exendin accumulation in the beta cells, as described 
above. To determine the effect of alloxan over time, biodistribution studies were performed 
on day 1, 3, 5 and 7 after alloxan injection. All animals, used for biodistribution studies, 
were injected intravenously with 15 MBq [111In]-exendin-3 (peptide dose: 20 pmol/rat, 
mouse). Non-GLP-1R mediated exendin uptake was determined in a separate group 
of animals that were co-injected with an excess of unlabeled exendin (25 µg/animal). 
Four hours after injection of the radiolabeled exendin, animals were euthanized and 
the pancreas and other relevant tissues (blood, muscle, heart, lung, spleen, kidney, liver, 
stomach and duodenum) were dissected, weighed and counted in a well type gamma 
counter (Wallac 1480 Wizard, Perkin Elmer, Boston, MA, USA). The percentage injected 
dose per gram tissue (%ID/g) was determined for each tissue.
Digital Autoradiography
Ex vivo autoradiography was performed to visualize the uptake in the islets and the 
exocrine pancreas. After dissection, pancreata were fixed in 4% formalin (w/v), 
dehydrated and embedded in paraffin. Sections of the pancreas (4 µm) were prepared 
and exposed to a phosphorimaging plate (Fuji Film BAS-SR 2025, Raytest, Straubenhardt, 
Germany) for 7 days. Images were acquired with a radioluminography laser imager (Fuji 
Film BAS 1800 II system, Raytest) and analyzed using Aida Image Analyzer software 
(Raytest). 
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Endocrine-to-Exocrine Ratio Determination 
To quantitatively compare tracer uptake in the islets and the exocrine pancreas, 
endocrine-exocrine uptake ratios were determined in the autoradiographs of pancreatic 
sections. The digital images were analyzed using imageJ, a public domain software 
(http://imagej.nih.gov/ij/). Three pancreatic sections were analyzed per mouse and rat 
strain. Per pancreatic section, 3 regions of interest (ROI) were drawn in both the exocrine 
and endocrine pancreas and the mean density values (photostimulated luminescence) 
were determined. These values were used to calculate the endocrine-exocrine uptake 
ratio. 
Immunohistochemistry
Pancreatic sections (4 µm) of C57Bl/6 mice, Brown Norway rats and humans were stained 
for the presence of GLP-1R. Antigen retrieval was performed in 10 mM sodium citrate, 
pH 6.0 for 10 minutes at 96oC. Subsequently, sections were incubated for 10 minutes with 
3% H2O2 in PBS at RT in the dark, to block endogenous peroxidase activity. Non-specific 
binding was blocked by incubation for 30 minutes with 5% normal swine serum. The 
primary anti-GLP-1R antibody (ab39072, Abcam, Cambridge, UK) was diluted in PBS 
containing 1% BSA (1:500). Primary antibody incubation for 90 minutes was followed 
by incubation with swine-anti-rabbit peroxidase (1:50) (p0271, DAKO, Copenhagen, 
Denmark) for 30 minutes at RT in the dark. Finally, 3,3’diaminobenzidine (DAB) was 
used to develop the pancreatic sections.
Pancreatic Islet Isolation, mRNA Extraction and Real Time PCR 
mRNA extraction and real time PCR (RT-PCR) was performed as described previously 
[26]. Briefly, poly(A)+ mRNA was isolated from pancreatic islets (rat islets were isolated 
by collagenase digestion and handpicking and mouse islets using the Histopaque 
method [27]) or exocrine tissue (the tissue remaining after islet isolation) from C57Bl/6 
mice and Wistar rats using the Dynabeads mRNA DIRECTTM kit (Invitrogen, Merelbeke, 
Belgium) and reversely transcribed. Exocrine mRNA samples used in the study were 
evaluated with Biodrop (Cambridge, United Kingdom) and showed a 260/280 ratio 
>1.9, suggesting that the mRNA was well preserved. RT-PCR amplification of Glp-1r was 
performed using IQ SyBR Green Supermix on iCycler MyiQ Single Color (BIO-RAD, 
Hercules, CA, USA) and compared to a standard curve. Amy2 was calculated with the 
deltaCT method [28]. In all assays, the geometrical means of the house keeping genes 
β-actin and Gapdh were used as a reference. The pancreatic islet and exocrine tissue 
preparations were selected based on the expression levels of respectively the endocrine 
marker Pdx1 and the exocrine marker Amy2. The primers used are listed in Table 1. 
Standard curves of the reference genes (β-actin and Gapdh) and Glp-1r mRNA expression 
assays of both rat and mouse are provided in Figure 1. 
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Figure 1: mRNA estimation of glucagon-like peptide 1 receptor (Glp-1r) expression was performed 
by quantitative PCR where β-actin (actb) and glyceraldehyde-3-phosphate dehydrogenase (gapdh) 
were used as reference genes. Standard curves of β-act, Gapdh and Glp-1r genes for both mouse 
(Mm, Mouse musculus, A, C, E) and rat (Rn, Rattus norvegicus, B, D, F) (mRNA expression assays, 
with plotted CT values of pancreatic islets samples (red squares) and exocrine tissue (black circles). 
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Table 1: Primers used for RT-PCR on rat and mouse cDNA with the length of amplification in base 
pairs. 
Primer Sequence Base pairs
Rat GLP-1R RT
Forward (5’-3’)
Reverse (5’-3’)
GGCTCCTCTCGTATCAGGAC
GATAACGAACAGCAGCGGAAC
200
Rat GLP-1R std
Forward (5’-3’)
Reverse (5’-3’)
ATCCACCTGAACCTGTTTGC
CTTGGCTATCACGATGCAGA
468
Mouse GLP-1R RT
Forward (5’-3’)
Reverse (5’-3’)
GCGTGGCAGCCAACTACTA
ATAACGAACAGCAGCGGAAC
139
Mouse GLP-1R std
Forward (5’-3’)
Reverse (5’-3’)
ATCCACCTGAACCTGTTTGC
AGCTTGATGAAGCGTAGGGT
617
Rat insulin RT
Forward (5’-3’)
Reverse (5’-3’)
TGTGGTTCTCACTTGGTGGA
CTCCAGTTGTGCCACTTGTG
111
Rat insulin std
Forward (5’-3’)
Reverse (5’-3’)
TGACCAGCTACAGTCGGAA
GTTGCAGTAGTTCTCCAGTTGG
390
Mouse insulin RT
Forward (5’-3’)
Reverse (5’-3’)
GGAAGCCCCGGGGACCTTCAGA
GGCGGGTCGAGGTGGGCCTTA
138
Mouse insulin std
Forward (5’-3’)
Reverse (5’-3’)
CACCCAAGTCCCGCCGTGAAG
TCAGTGGCATTTACACGGTTGCCTA
449
β-Actin RT
Forward (5’-3’)
Reverse (5’-3’)
CTGTACGCCAACACAGTGCT
GCTCAGGAGGAGCAATGATC
127
β-Actin std
Forward (5’-3’)
Reverse (5’-3’)
AAATCTGGCACCACACCTTC
CCGATCCACACGGAGTACTT
805
Rat Pdx-1 RT
Forward (5’-3’)
Reverse (5’-3’)
GGTATACCAGCGAGATGCT
TCAGTTGGGAGCCTGATTCT
152
Rat Pdx-1 std
Forward (5’-3’)
Reverse (5’-3’)
GAGGACCCGTACAGCCTACA
GGGACCGCTCAAGTTTGTAA
748
Mouse Pdx-1 RT
Forward (5’-3’)
Reverse (5’-3’)
GAGGTGCTTACACAGCGGAA
GGGCCGGGAGATGTATTTGT
116
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Mouse Pdx-1 std
Forward (5’-3’)
Reverse (5’-3’)
CCTTTCCCGAATGGAACCGA
GCTCTCGTGCCCTCAAGAAT
679
Rat Amy2 RT
Forward (5’-3’)
Reverse (5’-3’)
ATTGATCTTGGTGGTGAAGCA
GGCTCTGTCAGTAGGCACAA
174
Rat Amy2 std
Forward (5’-3’)
Reverse (5’-3’)
CGAACCAAGGTGGCTGACTAT
TCGATGTTCACAGACCCAGT
636
 Mouse amy2 RT
Forward (5’-3’)
Reverse (5’-3’)
   
CATGGTGACAAGGTGCAACA
CAGGTACTGCTTGTTCCTGC
102
Mouse Amy2 std
Forward (5’-3’)
Reverse (5’-3’)
TCTGCACAAGGTCTGGAAATGA
ACCCAGATCAATGACCTCTTGG
500
Gadph RT
Forward (5’-3’)
Reverse (5’-3’)
GCCTGGAGAAACCTGCCAAGTATGA
AACCTGGTCCTCAGTGTAGCCC
101
Gadph std
Forward (5’-3’)
Reverse (5’-3’)
ATGACTCTACCCACGGCAAG
TGTGAGGGAGATGCTCAGTG
975
Results 
[111In]-exendin Uptake in Various Mouse Strains 
Figure 2 shows the biodistribution (2 mice per strain) of [111In]-exendin in 5 mouse strains. 
As reported previously [25], tracer uptake was observed not only in the pancreas but also 
in various other organs, such as the lung, stomach, duodenum and the kidneys. Based 
on these results, BALB/c mice showed favorable features for in vivo beta cell targeting, 
namely: high pancreatic uptake (36.8 %ID/g) and relatively low uptake in lung (26.4 
%ID/g), stomach (7.37 %ID/g) and duodenum (9.42 %ID/g). Therefore, BALB/c mice 
were selected to determine the specificity of tracer accumulation in the beta cells. C57Bl/6 
mice, a strain often used in diabetes research, was also evaluated. 
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Figure 2: Biodistribution of [111In]-exendin in C57Bl/6, BALB/c, NMRI, CBA and DBA mice. values 
are expressed as percentage injected dose per gram tissue (n=2). Mice were dissected 4 hours after 
injection.
Beta Cell Specificity of [111In]-exendin Uptake in BALB/c and C57Bl/6 Mice
In BALB/c mice, the pancreatic uptake did not decline after injection of 25, 32.5, 50 and 
62.5 mg/kg alloxan (Figure 3A). Mice treated with even higher doses of alloxan (75, 
100, 150 and 200 mg/kg) showed increased total pancreatic tracer uptake. In animals 
treated with high alloxan doses, elevated tracer levels in the blood were observed and 
thus, higher uptake in all other tissues, including the exocrine pancreas, was noticed 
(Figure 3A-B). This is most probably the result of dehydration secondary to severe 
hyperglycemia, leading to slower blood clearance. In addition, direct toxic effects of 
alloxan cannot be excluded at high doses. Co-injection of an excess unlabeled exendin 
decreased the pancreatic uptake from 7.9 ± 0.6 %ID/g to 0.23 ± 0.04 %ID/g (Figure 3A) 
which was also reflected by the autoradiographic images (Figure 3C). Due to the high 
uptake in exocrine tissue, the endocrine-exocrine ratio in these mice was only 4.11 ± 0.93 
(Table 2), which is very low when compared to rats (see below). These results – especially 
the reduced uptake after co-injection of unlabeled exendin – indicate specific, receptor 
mediated tracer binding in the exocrine pancreas of BALB/c mice. 
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Figure 3: A) Biodistribution of [111In]-exendin in control and alloxan treated BALB/c mice. Values 
are expressed as percentage injected dose per gram tissue (n=5 mice). Blocking was performed by 
co-injection of 25 µg unlabeled exendin (n=5). B) Pancreatic uptake of [111In]-exendin in BALB/c 
mice treated with 100 mg/kg (n=5), 150 mg/kg (n=4) and 200 mg/kg (n=3) of alloxan. Values are 
expressed as percentage injected dose per gram tissue. C) Ex vivo autoradiography of pancreatic 
sections of BALB/c mice treated with vehicle (control) and 50 mg/kg alloxan. Blocking was 
performed by co-injection of 25 µg unlabeled exendin. 
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Because of this high exocrine uptake, [111In]-exendin uptake after alloxan treatment was 
further investigated in C57Bl/6 mice for validation of the results described above. Figure 
4A summarizes pancreatic uptake of [111In]-exendin in C57Bl/6 mice on various days 
after alloxan treatment. After 3 days, a clear decrease in pancreatic uptake was observed, 
while the maximum decrease was observed 7 days after alloxan treatment. However, 
the decrease did not exceed 40% compared to control mice injected with vehicle (PBS). 
Furthermore, similar to the findings observed in BALB/c mice, tracer uptake in the 
exocrine pancreas of C57Bl/6 mice could be blocked with an excess of unlabeled exendin 
(Figure 4B-C). Additionally, the calculated endocrine-to-exocrine uptake ratio in these 
mice (4.56 ± 0.91) (Table 2) was in the same range as the ratio observed in BALB/c mice.
Figure 4: A) Pancreatic uptake of [111In]-exendin in C57Bl/6 mice (n=2) on different days after 
alloxan treatment (50 mg/kg). B) Pancreatic uptake of [111In]-exendin in C57Bl/6 mice treated with 
vehicle (control) (n=2) and 50 mg/kg alloxan (n=2). Blocking was performed by co-injection of 25 
µg unlabeled exendin (n=1). C) Autoradiography of pancreatic sections of C57Bl/6 mice, treated 
with vehicle (control) and 50 mg/kg alloxan. Blocking was performed by co-injection of 25 µg 
unlabeled exendin. 
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Table 2: Endocrine-exocrine ratio of [111In]-exendin uptake in BALB/c and C57Bl/6 mice calculated 
from autoradiography of pancreatic sections
Mouse strain Endocrine-exocrine ratio
BALB/c 4.11 ± 0.93
C57Bl/6 4.56 ± 0.91
[111In]-exendin Uptake in Different Rat Strains 
Figure 5A summarizes the biodistribution (2 rats per strain) of [111In]-exendin in 4 rat 
strains. In all rat strains there was very high lung uptake (> 10%ID/g), which was even 
higher than the uptake observed in the kidneys. The biodistribution profiles indicated 
that WAG/Rij rats have the highest pancreatic [111In]-exendin uptake (0.45%ID/g). In 
addition, the endocrine-to-exocrine uptake ratio, calculated from the autoradiographs 
shown in figure 5B, was highest for WAG/Rij rats as well (Table 3). The uptake in the 
stomach (1.7 %ID/g) of WAG/Rij rats is relatively high (Figure 5A), resulting in a 
pancreas-to-stomach uptake ratio of 0.27 ± 0.02 (Table 4). Since high stomach uptake 
might hamper BCM visualization in vivo, we selected Brown Norway rats to investigate 
the beta cell specificity of pancreatic [111In]-exendin accumulation due to their higher 
pancreas-to-stomach (1.39 ± 0.11) and acceptable pancreas-to-duodenum (0.70 ± 0.1) 
ratios (Table 4), despite their lower pancreatic uptake (0.27 %ID/g) (Figure 5a) and 
endocrine-to-exocrine ratio (57.1 ± 12.5) (Table 3). 
Table 3: Overview of the endocrine-exocrine ratios of [111In]-exendin uptake in various rat strains 
calculated from autoradiography of pancreatic sections. 
Rat strain Endocrine-exocrine ratio
WAG/Rij 105.66 ± 29.84
Brown Norway 57.06 ± 12.53
Sprague Dawley 44.00 ± 13.33
F344 44.83 ± 2.85
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Figure 5: A) Biodistribution of [111In]-exendin in Sprague Dawley, F344, Wag/Rij and Brown 
Norway rats. Values are expressed as percentage injected dose per gram tissue (n=2 rats). Rats 
were dissected 4 hours after injection. B) Autoradiography of pancreatic section of Sprague Dawley, 
F344, Wag/Rij and Brown Norway rats showing focal hotspots of tracer accumulation representing 
the islets. 
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Beta Cell Specificity of [111In]-exendin Uptake in Brown Norway Rats
In Brown Norway rats, treated with 60 mg/kg alloxan (2 rats), pancreatic uptake was 
reduced by more than 80% compared to control rats, that were injected with vehicle (PBS) 
(2 rats) (Figure 6). Co-administration of an excess unlabeled exendin (1 rat) reduced the 
pancreatic uptake to similar uptake levels observed in alloxan-treated rats, suggesting 
no or very low non-specific [111In]-exendin uptake in the exocrine pancreas. Furthermore, 
autoradiographical analysis showed similar results: high, specific tracer uptake in the 
islets of Langerhans and low, non-specific uptake in the exocrine pancreas (Figure 5B), 
resulting in an endocrine-to-exocrine uptake ratio of 57.1 ± 12.5 (Table 4). These results 
indicate high beta cell specificity of [111In]-exendin in these rats.
Figure 6: Pancreatic uptake of [111In]-exendin in Brown Norway rats treated with vehicle (control) 
(n=2) and alloxan (60 mg/kg) (n=2). Values are expressed as percentage injected dose per gram 
tissue. Blocking was performed by co-injection of 25 µg unlabeled exendin (n=1). 
Table 4: Overview of the pancreas-to-stomach and pancreas-to-duodenum ratios of [111In]-exendin 
uptake in the different rat strains. 
Rat strain Pancreas-to-stomach ratio Pancreas-to-duodenum ratio
Sprague Dawley 0.08 ± 0.02 0.33 ± 0.02
F344 0.11 ± 0.00 0.31 ± 0.07
Wag/Rij 0.27 ± 0.02 1.15 ± 0.78
Brown Norway 1.39 ± 0.11 0.70 ± 0.10
Quantitative RT-PCR
Since receptor mediated [111In]-exendin uptake was observed in exocrine pancreas of 
mice, Glp-1r mRNA expression was compared in endocrine and exocrine pancreatic 
tissue of rats and mice. Quantitative RT-PCR revealed similar Glp-1r mRNA expression 
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levels in endocrine and exocrine tissue of rat and mouse (Figure 7A-B) with endocrine-
to-exocrine ratios of 45.8 and 55.6, respectively. Individual expression levels of all cell 
markers (Glp-1r, Pdx1, Ins and Amy2b) in endocrine and exocrine tissue are provided in 
Figure 8.
Immunohistochemistry
To investigate GLP-1R expression in endocrine and exocrine pancreatic tissue, GLP-1R 
staining was performed on rat, mouse and human pancreatic tissue. Figure 7C-E shows 
the results of the immunohistochemical analysis. In all pancreatic tissues analyzed, the 
islets of Langerhans showed clear GLP-1R staining while no, or very limited, staining 
was observed in the exocrine portion of the pancreatic tissue.
Figure 7: Quantitative RT-PCR for the Glp-1r in endocrine and exocrine pancreatic tissue of rat 
(A) and mouse (B) and immunohistochemical analysis of GLP-1R expression in pancreatic tissue 
(embedded in paraffin) of rat (C), mouse (D) and human (E). Both analyses show high GLP-1R 
expression in the islets and no, or very low expression in exocrine tissue. For quantitative RT-PCR, 
paired t-test was performed and p <0.05 was considered as significant.
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Figure 8: Quantitative RT-PCR of -like peptide 1 receptor Glp-1r mRNA expression in pancreatic 
islets and exocrine tissue with additional pancreatic endocrine and exocrine cell markers for mouse 
(Mm, Mouse musculus); A) Glp-1r, B) Pdx1 (Pancreatic and duodenal homeobox 1), and C) Ins1 
(insulin) and D) Amy2b (pancreatic α-Amylase), and for rat (Rn, Rattus novergicus); E) Glp-1r, F) 
Pdx1, G) Ins2 (Insulin) and H) Amy2b. In both species the pancreatic islets were positive for Glp-
1r and the endocrine cell markers Pdx1 and Ins, while the exocrine material was positive for the 
exocrine cell marker Amy2b but had a decreased expression of Glp-1r, Pdx1 and Ins. N=3 in all 
experimental conditions. Paired t-test was performed and p<0.05 was considered significant (**).
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Discussion 
In this study, we assessed differences between rodent models for non-invasive in vivo 
BCM assessment via GLP-1R targeting. We investigated the biodistribution of [111In]-
exendin in various rat and mouse strains and determined the specificity of tracer 
accumulation in the beta cells. Our present findings indicate that Brown Norway rats 
display the most favorable characteristics for non-invasive BCM assessment using 
radiolabeled exendin as a tracer. Mice seem to display receptor mediated tracer uptake in 
the exocrine pancreas, an observation explaining the limited reduction of exendin uptake 
in the pancreas of mouse models after beta cell destruction [22, 24]. 
In view of the spatial resolution of present imaging modalities and the small size of 
the islets, preventing visualization of single islets in vivo, the optimal model for in vivo 
BCM determination must display high and specific [111In]-exendin accumulation in 
the endocrine pancreas [29, 30] with no or low uptake in the exocrine pancreas and 
surrounding tissues, in particular stomach and duodenum that are localized in the 
vicinity of the pancreas. Since [111In]-exendin is excreted via the kidneys, high tracer 
uptake is observed in this organ, which renders accurate quantification of pancreatic 
tracer uptake challenging in rodents. However, spill over signal from the kidneys can 
be excluded by analyzing a particular region of interest in the pancreas localized cranial 
and anterior of the kidneys [14]. Another option to overcome spill over effects of the 
kidneys is co-injection of a second radiotracer, specifically targeting the exocrine tissue, 
such as [99mTc]-demobesin and [123I]-L-phenylalanine in combination with [111In]-exendin, 
which facilitates exact delineation of the pancreas and therefore improves accurate 
quantification of pancreatic [111In]-exendin uptake [22]. Of all investigated rat strains, 
WAG/Rij rats showed the highest pancreatic [111In]-exendin uptake. However, due to 
their less favorable pancreas-to-stomach and pancreas-to duodenum ratios, WAG/Rij 
rats are expected to be less suited for in vivo BCM determination using [111In]-exendin 
SPECT than Brown Norway rats. 
To evaluate the beta cell specificity of the tracer, ex vivo autoradiography was performed. 
In rats, focal hotspots of tracer accumulation, representing the beta cells, were observed 
while there was a low background signal in the exocrine tissue (Figure 5B). Beta cell 
depletion by alloxan injection resulted in disappearance of the tracer accumulating 
hotspots, confirming beta cell specificity of GLP-1R targeting using [111In]-exendin, 
allowing accurate BCM determination. Based on autoradiographic analysis, we showed 
endocrine-to-exocrine ratios of 105.7 ± 29.8 in WAG/Rij rats, 57.1 ± 12.5 in Brown 
Norway rats, 44.0 ± 13.3 in Sprague Dawley rats and 44.8 ± 2.9 in F344 rats, which is 
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in line with previous observations [23]. Furthermore, pancreatic [111In]-exendin uptake 
in Brown Norway rats is similarly decreased after alloxan-induced beta cell depletion 
and co-injection with an excess unlabeled exendin, confirming beta cell specific tracer 
accumulation in this model. We have previously shown clear differences in [111In]-exendin 
uptake in the pancreas of Brown Norway rats treated with various concentrations of 
alloxan, resulting in a linear correlation of SPECT signal and BCM [14]. These observations 
confirm that this rat strain provides an optimal model for in vivo BCM assessment via 
GLP-1R targeting.
Several groups have reported a decrease in pancreatic tracer uptake in mice after 
alloxan or streptozotocin-induced beta cell destruction [22, 24]. However, the maximum 
decrease did not exceed 40%, an observation which can be explained by our data. After 
co-injection of an excess unlabeled exendin in mice, tracer uptake was much lower than 
the remaining uptake observed after alloxan-induced beta cell depletion. These results 
strongly suggest that the limited decrease in tracer uptake after alloxan-induced beta cell 
destruction is caused by receptor mediated [111In]-exendin uptake in the exocrine pancreas 
of mice. Nevertheless, there was no detectable GLP-1R expression in exocrine pancreatic 
tissue of mice by immunohistochemistry and only very low Glp-1r mRNA expression 
was observed by RT-PCR. Furthermore, endocrine-to-exocrine ratios of Glp-1r mRNA 
expression are similar in mice and rats. These observations suggest that [111In]-exendin 
probably binds to a receptor, other than the GLP-1R, in the exocrine pancreatic tissue 
of mice, which could also explain the observations of Nalin et al. [31]. These findings 
preclude the use of this model for additional characterization of [111In]-exendin uptake 
for BCM determination. In contrast with observations in mice after beta cell destruction 
[22, 24](present data), and similar to the above described rat data, patients with long 
standing type 1 diabetes can show very low [111In]-exendin uptake similar to background 
values [14], suggesting no or negligible uptake in the exocrine pancreas. Therefore, the 
situation in humans appears to be better reflected by rat models than by mouse models. 
At this point in time, it remains unclear which receptor is responsible for exendin uptake 
in the exocrine pancreas of mice but it is highly likely that this receptor shows differences 
with the rat and human receptors in a way that only the variant expressed in mice can 
bind exendin. 
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Conclusion
The choice of a certain rodent model can greatly influence studies investigating BCM 
dynamics. The present findings indicate that mice have binding in the exocrine pancreas 
which is mediated by a receptor that is not the GLP-1R, rendering them an inadequate 
model for BCM assessment by radiolabeled exendin. On the other hand, rats do not show 
receptor mediated exendin binding in the exocrine pancreas, and are therefore a better 
suited model for further studies. Among the investigated rat models, Brown Norway rats 
are the optimal model for non-invasive GLP-1R targeting, given their favorable pancreas-
to-background uptake ratios. In view of these results and the very low remaining uptake 
in patients with T1D, rats appear to display better characteristics for in vivo investigation 
of BCM dynamics when compared to mice, and are thus considered a suitable model 
better reflecting the human situation than other animal models.
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Abstract
Aims: Islet transplantation is a promising treatment for type 1 diabetic patients. 
However, there is acute as well as chronic loss of islets after transplantation. A non-
invasive imaging method, that could monitor islet mass, might help to improve 
transplantation outcome. In this study, islets were visualized after transplantation in 
a rat model with a dedicated small animal SPECT scanner by targeting the glucagon-
like peptide-1 receptor (GLP-1R), specifically expressed on beta cells, with [111In]-
labeled exendin-3. 
Methods: Targeting of [111In]-exendin-3 to the GLP-1R was tested in vitro on 
isolated islets of WAG/Rij rats. For in vivo evaluation, WAG/Rij rats (6-8 weeks 
old) were transplanted in the calf muscle with 400 or 800 islets. Four weeks after 
transplantation, SPECT/CT images were acquired, 1 hour post-injection of [111In]-
labeled exendin-3. After SPECT acquisition, the muscles containing the transplant 
were analyzed immunohistochemically and by autoradiography. 
Results: The binding assay, performed on isolated islets, showed a linear correlation 
between the number of islets and [111In]-exendin-3 accumulation (Pearson r=0.98). In 
vivo, a 1.70 ± 0.44 fold difference in tracer uptake between 400 and 800 transplanted 
islets was observed. Ex vivo analysis of the islet transplant showed co-localization of 
tracer accumulation, as shown by autoradiography, with insulin-positive cells and 
GLP-1R expression, as determined immunohistochemically. 
Conclusion: [111In]-exendin-3 accumulates specifically in the beta cells after islet 
transplantation and is a promising tracer to monitor the islet mass non-invasively.
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Introduction
For type 1 diabetic patients with poor glycemic control, pancreatic islet transplantation is 
a promising but still experimental treatment. The standard transplantation procedure is 
infusion of pancreatic islets in the portal vein, where islets are trapped in the sinusoidal 
capillaries of the liver. Most patients become insulin independent for more than 1 year 
after transplantation. However, insulin independency drops to approximately 10%, 5 
years after transplantation [1]. Even though these insulin dependent patients still profit 
from this treatment, because instability of blood glucose levels and risk of hypoglycemia 
is reduced, further improvement of transplant survival and islet function is desired. This 
is of special importance in view of the side effects of the immunosuppressive treatment 
that is required to prevent rejection of the transplanted islets [1-3]. 
Current methods to monitor islets after transplantation, such as measurement of HbA1C, 
C-peptide, and insulin levels, only provide functional information and cannot accurately 
predict the number of surviving islets. Medical imaging methods may offer the possibility 
to monitor the number of surviving islets after transplantation, which could provide 
information (complementary to functional capacity) about the effect of interventions 
on transplantation outcome. This might help to further improve this new therapeutic 
approach, in order to achieve longer lasting insulin independency.
Numerous studies have investigated the feasibility of imaging transplanted islets non-
invasively. Islets were transfected to express luciferase [4], or islets from transgenic 
animals expressing luciferase were used [5]. Although feasibility has been proven in 
preclinical transplantation models, these methods require transfection of beta cells or 
the use of transgenic animals and are therefore relatively difficult to translate to humans. 
In several studies, pancreatic islets, pre-labeled with iron oxide contrast agents, were 
transplanted allowing monitoring with MRI [6, 7]. Although these methods can show 
the presence of transplanted islets, it remains a matter of debate to which degree the 
presence of iron oxide contrast agents represents the amount of viable and functional 
islets. Determination of the relation between viable beta cell mass and beta cell function 
might therefore be difficult to achieve.
Transplanted islets also have been visualized using tracers targeting receptors specifically 
expressed on beta cells in the islets, such as the glucagon-like peptide-1 receptor (GLP-
1R) [8]. Wu et al. [9] have demonstrated the feasibility to visualize islets, transplanted in 
the liver, by targeting the GLP-1R using PET with radiolabeled exendin-4. Targeting a 
receptor, specifically expressed on beta cells, with a radiotracer allows serial imaging in 
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vivo. In order to fully exploit the potential of this imaging method, quantification of true 
beta cell mass in islet transplants should be established for validation of in vivo imaging 
results.
The establishment and characterization of quantitative beta cell imaging by targeting 
the GLP-1R, requires a simple transplantation model, allowing accurate evaluation of 
tracer accumulation and histological verification of imaging findings. A suitable location 
for islet transplantation is the muscle. The muscle has already been used in clinical islet 
transplantation [10-13] and since all islets are clustered in 1 location, tracer uptake can 
be determined by quantitative analysis of PET and SPECT images, while islet survival 
can easily be verified histologically. In this study, we demonstrate the feasibility of non-
invasive in vivo imaging of different numbers of islets, transplanted in the calf muscle, by 
targeting the GLP-1R with [111In]-labeled exendin-3.
Materials and Methods
Radiolabeling
[Lys40(DTPA)]exendin-3 (Peptides Specialty Laboratories, Heidelberg, Germany) (Figure 
1) (referred to as exendin-3 in the remainder of the text) was radiolabeled as described 
previously [14]. Briefly, 150 MBq [111In]Cl3 was added to 1 µg exendin-3 dissolved in 
0.1 M 2-(N-morpholino) ethanesulfonic acid (MES), pH 5.5 (Sigma Aldrich, St. Louis, 
MO, USA) and incubated for 20 minutes at room temperature (RT). After incubation, 
Ethyleendiaminetetra-azijnzuur (EDTA) (Sigma Aldrich) and Polysorbate 80 (tween80) 
(Sigma Aldrich) were added to a final concentration of 5 mM and 0.1%, respectively. 
The radiochemical purity of [111In]-exendin-3 was determined by instant thin-layer 
chromatography (ITLC) (ITLC-SG, Agilent Technologies, Lake Forest, CA, USA), using 
0.1 M NH4Ac (Sigma Aldrich) in 0.1 M EDTA, pH 5.5. The reaction mixture was purified 
by solid-phase extraction using hydrophilic-lipophilic balance (HLB) cartridge (30 mg, 
Water Oasis, Milford, MA, USA), to remove unlabeled In-111. The cartridge was activated 
with 1 ml ethanol, washed with 2 ml water and conditioned with 1 ml of 0.1 M MES, pH 
5.5. Subsequently, the labeling mixture was loaded on the cartridge and washed with 
1 ml 0.1 M MES and 2 ml water. [111In]-exendin-3 was eluted from the cartridge with 
200 µl 100% ethanol. For injection, the purified labeling solution was diluted in 0.5% 
Phosphate Buffered Saline (PBS)/Bovine Serum Albumin (BSA) (w/v) to obtain a final 
ethanol concentration of less than 10%. 
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Figure 1: Chemical structure of [Lys40(DTPA)]exendin-3
Animals
Six to eight weeks old female WAG/Rij rats were purchased from Charles River 
Laboratories (Erkrath, Sulzfeld, Germany). WAG/Rij rats were used both as islet donor 
and recipient. The animal experiments were approved by the animal welfare committee 
of the Radboud University Nijmegen.
Islet Isolation
Pancreatic islets were isolated from female WAG/Rij rats by collagenase digestion. Rats 
were suffocated with CO2/O2, the abdominal cavity was opened and a canula was placed 
in the common bile duct. The pancreas was perfused with 8 ml Roswell Park Memorial 
Institute (RPMI) medium (R0883, GIBCO, BRL Life Sciences Technologies, Bleiswijk, The 
Netherlands), containing 1 mg/ml collagenase Type V (Sigma Aldrich). Subsequently, the 
pancreas was dissected and kept in ice-cold RPMI containing collagenase until digestion. 
The pancreata were digested for 11.5 minutes at 37oC. The digestion was stopped by 
adding complete RPMI medium (RPMI medium supplemented with 10% fetal calf 
serum (FCS) (HyClone, Celbio, Logan, UT, USA), 2 mM L-glutamine (Sigma Aldrich), 
100 U/ml penicillin and 100 U/ml streptomycin (Sigma Aldrich)). The digested tissue 
was washed twice in complete RPMI medium (2 minutes at 210 x g) and passed through 
a 500 µm mesh. Subsequently, the islets were purified on a discontinuous Ficoll gradient 
(densities 1.108, 1.096, 1.037 g/ml) ( Cellgro by Mediatech Inc., Manassas, VA, USA) by 
centrifugation at 625 x g for 16 minutes (without brake). The islets were collected from 
the interface of the second and third layer. Finally, the remaining Ficoll was removed by 
washing twice with complete RPMI medium (2 minutes at 210 x g). The purified islets 
were cultured overnight at 37oC with 5% CO2 in complete RPMI medium. Both islet 
viability and purity exceeded 90% after the isolation procedure.
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In vitro Function Assay
Islet function after isolation was assessed by a static glucose incubation assay. After 
isolation and overnight recovery, islets were collected, counted and resuspended in 
complete RPMI. Islets were seeded in a 24 well plate (Corning Inc, Tewksbury, MA, 
USA), 30 islets per well (n=5), and pre-incubated for 1 hour (37oC, 5% CO2) in 600 µl 
Krebs buffer (115 mM NaCl, 24 mM NaHCO3, 5 mM KCl, 2.2 mM CaCl2, 1 mM MgCl2, 20 
mM C8H18N2O4S and 0.2% BSA (Sigma Aldrich)) supplemented with 1.67 mM D-glucose 
(Sigma Aldrich). After 1 hour, the incubation buffer was replaced by 600 µl fresh Krebs 
buffer supplemented with 1.67 mM D-glucose. Subsequently, islets were incubated in 
Krebs buffer supplemented with 16.7 mM D-glucose and 1.67 mM D-glucose respectively, 
1 hour for both conditions. After each incubation step, the supernatant was collected and 
samples were stored at -20oC until insulin determination by insulin ELISA immunoassay 
(Mercodia AB, Uppsala, Sweden) performed according to the manufacturer’s protocol.
In Vitro Binding to Isolated Islets
After overnight recovery, islets were collected, counted and resuspended in complete 
RPMI. After transwell saturation, using binding buffer (RPMI containing 0.5% BSA 
(v/w)), islets were transferred to 24 well transwell plates (50, 100, 200 or 400 islets per 
transwell, n=3 per condition) (Corning Inc.) and incubated in 500 µl Krebs buffer for 
30 minutes at 37⁰C. Subsequently, islets were washed with 500 µl binding buffer and 
approximately 2 kBq of [111In]-exendin-3 was added, followed by incubation for 4 hours 
at 37⁰C. To determine whether the binding was GLP-1R mediated, 1 µg unlabeled 
exendin-3 was added together with the radiolabeled exendin-3 in separate wells (n=3 
per condition). After incubation, islets were washed 5 times using binding buffer and 
islet associated radioactivity was measured in a well type gamma counter (Wallac 1480 
wizard, Perkin Elmer, Waltham, MA, USA).
Islet Transplantation
After overnight recovery, isolated islets were collected, spun down at 15 x g for 2 minutes 
and resuspended in RPMI without FCS. Recipient rats were anesthetized with isoflurane 
(induction 4-5%, maintenance 1.5-2% in 50% O2 and 50% air) (Abbott Laboratories, 
Toronto, Canada) and the right hind leg of the rat was shaved and disinfected with 
Betadine® (Meda Pharma B.V., Amstelveen, The Netherlands) before islet inoculation. 
Islets were aspirated into a catheter line and infused manually in the calf muscle at low 
speed (injected volume 100 ± 10 µl) using a Hamilton syringe (Hamilton Company, Reno, 
NV, USA). Rats were transplanted with either 400 (n=6) or 800 (n=6) islets.
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SPECT Acquisition and Biodistribution
Four weeks after transplantation, rats were injected intravenously with 15 ± 0.4 MBq 
[111In]-exendin-3 via the tail vein (peptide dose 0.1 µg in 200 µl PBS, 0.5% BSA). One 
hour after injection of the radiolabeled exendin-3, rats were anesthetized with isoflurane 
(induction 4-5%, maintenance 1.5-2% in O2 and air) and SPECT/CT was acquired 
using a dedicated small animal SPECT/CT scanner (U-SPECT-II, MILabs, Utrecht, The 
Netherlands). SPECT images were acquired with a 1 mm pinhole general purpose rat 
and mouse collimator, 36 bed positions and with a total acquisition time of 50 minutes. 
CT images were acquired for anatomical information (65 kV, 615 µA, 1 bed position, 
spatial resolution 160 µm). After the SPECT/CT acquisition (2 hour post-injection (pi)), 
rats were euthanized by CO2/O2 suffocation and the muscle containing the transplant 
and other relevant tissues were dissected, weighed and measured in a well type gamma 
counter. Muscles were fixed in 4% formalin (w/v). 
SPECT Reconstruction and Quantitative SPECT Analysis 
The SPECT images were reconstructed using the U-SPECT reconstruction software 
(U-SPECT-Rec, MILabs, Utrecht, The Netherlands) with the following settings: OSEM, 1 
iteration, 16 subsets, voxel size 0.75 mm3. The uptake of [111In]-exendin-3 in the transplant 
was quantified using Inveon Research Workplace (IRW) (Siemens Healthcare, Den Haag, 
the Netherlands). A volume of interest (VOI) was placed over the transplant. Total voxel 
intensity in the islet transplant was corrected for the background by subtracting the 
background signal in the contra-lateral control muscle using an identical VOI and the 
injected activity.
Immunohistochemical Analysis
The formalin-fixed muscle, containing the transplant, was dehydrated and embedded 
in paraffin. Four µm sections were cut and stained with Hematoxilin and Eosin (HE) to 
localize the transplant. Consecutive sections were stained for the presence of insulin, 
as described previously [15] and the presence of GLP-1R. The GLP-1R staining was 
performed as follows: antigen retrieval was performed in 10 mM sodium citrate, pH 
6.0 for 10 minutes at 99oC. Subsequently, sections were incubated for 10 minutes with 
3% H2O2 in PBS at RT in the dark, to block endogenous peroxidase activity. Non-specific 
binding was blocked by incubation for 30 minutes with 5% swine serum. The primary 
anti-GLP-1R antibody (ab39072, Abcam, Cambridge, UK) was diluted in PBS, 1% BSA 
(1:1,000). Primary antibody incubation for 90 minutes was followed by incubation with 
swine-anti-rabbit peroxidase (1:100) (p0271, DAKO, Copenhagen, Denmark). Finally, 
Bright DAB (BS04500, Immunologic BV, Duiven, The Netherlands) was used to visualize 
peroxidase activity. Micro-autoradiography, to visualize tracer accumulation, was 
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performed on 4 µm sections as described by Brom et al. [15]. Sections, stained for insulin 
and GLP-1R, were analyzed using a Leica DM5000 microscope and images were obtained 
with a color camera (Evolution MP; Leica using Axio Vision 4.4 software). To determine 
transplant volume, the insulin positive area of the transplant per section was multiplied 
with the inter-section distance. Three animals were excluded from the analysis since no 
transplant was found immunohistochemically.
Statistical Analysis
All mean values are expressed as mean ± standard deviation (SD). Statistical analysis 
was performed using unpaired two-tailed t-test, the correlation described in this paper 
was calculated using the Pearson correlation coefficient (r) using GraphPad Prism v5.03 
(GraphPad Software, Inc., San Diego, CA, USA). The level of significance was set at 
p<0.05.
Results 
Radiolabeling
Exendin-3 was labeled with In-111 with a specific activity of 700 GBq/µmol. Radiochemical 
purity exceeded 99% as determined by ITLC.
In Vitro Functionality of Isolated Islets
The results of the in vitro islet function assay are summarized in Figure 2. Islets responded 
to high glucose stimulation with an increase in insulin production from 41.1 ± 18.6 
ng/ml/hour to 792 ± 176 ng/ml/hour. After high glucose stimulation, insulin levels 
decreased to basal levels when incubated in low glucose buffer: 80.3 ± 31.4 ng/ml/hour, 
indicating normal function. The stimulation index, defined as a ratio of stimulated to 
basal insulin secretion, was 10.4 ± 1.98 (n=5).
Binding Capacity of [111In]-exendin-3 to Isolated Islets
Figure 3 shows the binding of [111In]-exendin-3 to rat islets in vitro. After 4 hours, 31 ± 
3.6 amol of the 1.28 fmol added [111In]-exendin-3 accumulated in 50 islets. Accumulation 
of [111In]-exendin-3 increased with increasing numbers of islets (100 islets: 39 ± 7.6 amol, 
200 islets: 80 ± 1.2 amol and 400 islets: 112 ± 2.9 amol). This resulted in an excellent linear 
correlation between [111In]-exendin-3 accumulation and the number of islets (Pearson 
r=0.98, p=0.02). Co-incubation with 1 µg (0.2 nmol) of unlabeled exendin-3 blocked the 
accumulation of [111In]-exendin-3 >80% in all conditions, indicating GLP-1R mediated 
accumulation.
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Figure 2: Insulin release of isolated WAG/Rij islets at low (1.67 mM) and high (16.7 mM) glucose 
concentrations. Insulin release is expressed as ng/ml/hour. 
Figure 3: Binding of [111In]-exendin-3 (circles) to 50, 100, 200 and 400 isolated islets of WAG/Rij rats 
after 4 hours of incubation at 37oC. The black circles indicate total specific binding to the isolated 
islets. Non-specific binding (squares) was determined by co-incubation with an excess unlabeled 
exendin-3. Values are expressed as mean ± SD (n=3/condition).
SPECT/CT Imaging
Islets, transplanted in the right calf muscle were clearly visible in SPECT/CT images 
4 weeks after transplantation, 1 hour after injection of [111In]-exendin-3 (Figure 4), 
with hardly any uptake in the surrounding muscle tissue. Besides accumulation in the 
transplant, signal was also observed in the bladder (Figure 4A), kidneys and the lungs. 
Furthermore, a clear difference in SPECT signal was observed between rats transplanted 
with 400 (n=4) and 800 islets (n=5) (Figures 4B and 4C). Three animals were excluded 
from the analysis since no transplant was found immunohistochemically. The mean 
uptake in the group transplanted with 800 islets was 177 ± 59 Bq (signal-to-noise ratio 
(SNR): 13 ± 3.5) and the uptake in the group transplanted with 400 islets was 104 ± 4.5 
Bq (Figure 5B) (p<0.05), with a SNR of 8.8 ± 1.0. On average, the SPECT signal in the 800 
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group was 1.70 ± 0.44 times higher than in the 400 group. All SPECT images were fused 
with CT images for anatomical reference.
Figure 4: A) Maximum intensity projection of a SPECT/CT image of islets, transplanted in the 
right calf muscle of a rat (red arrow). Images were acquired 1 hour pi. of 15 MBq [111In]-exendin-3. 
Besides the signal from the transplant, radioactivity was observed in the bladder (green arrow). A 
clear difference in SPECT signal was observed between rats transplanted with either B) 400 islets 
(white arrow) or C) 800 islets (blue arrow) (coronal slices). 
Figure 5: A) Average transplant size based on histology of animals transplanted with 400 or 800 
islets respectively, p<0.05 and B) Average SPECT signal of animals transplanted with 400 or 800 
islets, p<0.05.
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Biodistribution Study
The results of the biodistribution are summarized in Figure 6. [111In]-exendin-3 showed 
low accumulation in blood, heart, spleen and liver (maximum 0.1 %ID/g). Uptake was 
observed in the stomach, duodenum and lungs (0.74 ± 0.45, 0.51 ± 0.32 and 10.0 ± 5.28 
%ID/g, respectively), which corresponds with observations described previously [15]. 
Kidney accumulation was very high (31.9 ± 11.5 %ID/g), and was not GLP-1R mediated. 
No difference in uptake was observed between muscles containing the transplant and 
control muscles, due to the small transplant size compared to the muscle tissue (± 2 g).
Figure 6: Biodistribution of [111In]-exendin-3 in WAG/Rij rats (n=12). Values are expressed as 
%ID/g ± SD. Rats were dissected 2 hours pi. 
Immunohistochemical Analysis 
Ex vivo autoradiography showed [111In]-exendin-3 accumulation in the islets, transplanted 
in the muscle (Figure 7C). Hardly any background activity was observed in the muscle. 
Tracer accumulation showed co-localization with insulin and GLP-1R expression (Figures 
7A-C). The positive insulin staining indicates viable and insulin-producing beta cells in 
the transplant. The average transplant volume in the group transplanted with 400 islets 
was 2.02 ± 0.16 x 105 µm3 and the transplants in the group transplanted with 800 islets 
were 4.30 ± 0.47 x 105 µm3 (Figure 5A) (p<0.05). On average, the transplant volume in the 
800 group was 1.92 ± 0.24 times larger than that in the 400 islets group. 
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Figure 7: [111In]-exendin-3 accumulated in the transplanted islets and co-localized with anti-insulin 
and GLP-1R staining. A) Insulin staining B) GLP-1R staining and C) micro autoradiography of the 
transplant.
Discussion
In the present study, the feasibility to non-invasively visualize islets of Langerhans, 
transplanted in the calf muscle, by SPECT using [111In]-exendin-3 as a tracer is 
demonstrated. Binding of [111In]-exendin-3 to isolated islets in vitro showed a linear 
correlation between uptake and the number of islets. Furthermore, differences in the 
amount of transplanted islets could be detected by in vivo SPECT. Therefore, this non-
invasive imaging method is suitable to provide real-time information about beta cell 
mass in the islet transplant.
Targeting the GLP-1R, specifically expressed on the beta cells of the pancreatic islets, 
offers an attractive alternative for methods using islets, pre-labeled with USPIOs as 
described by Evgenov et al. [6] and others [7, 16-18]. Targeting a receptor, such as the 
GLP-1R, may potentially offer higher specificity and does not require pre-labeling of 
islets. Furthermore, radiotracer imaging allows quantification of tracer uptake. It has 
previously been demonstrated that targeting the GLP-1R with radiolabeled exendin is an 
elegant method to image beta cells, mainly in insulinoma models [14, 19] and the native 
pancreas [15]. Wu et al. applied this strategy to visualize islets transplanted in the liver 
by PET after injection of exendin-4, labeled with copper-64 or fluorine-18 [9, 20]. In these 
studies relatively high background signal was observed, caused by non-specific tracer 
uptake in the liver [20], which might hamper accurate quantification of islet mediated 
tracer accumulation. We believe that the transplantation model described here may offer 
significant advantages to determine the number of viable islets in the transplant, because 
1) the complete transplant can be visualized in the muscle with low background signal 
and 2) the complete transplant can be evaluated immunohistologically, because of the 
focal localization of the islets in a predefined area of the calf muscle. Another commonly 
used focal islet transplantation site, in preclinical setting, is the kidney capsule. However, 
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this transplantation site is less suitable than the muscle when using radiotracers, due to 
their often high kidney uptake (31.9 ± 11.5 %ID/g for exendin-3).
SPECT/CT images showed clear uptake of radiolabeled exendin-3 with an average SNR 
of 13 ± 3.5 after transplantation of only 800 islets. Furthermore, a difference in SPECT 
signal between 400 and 800 islets was observed, with the signal of 800 islets being 1.70 
± 0.44 fold higher than the uptake in 400 islets. Based on histological analysis, a 1.92 ± 
0.24 fold difference in transplant volume between the 400 and 800 group was observed. 
An explanation for this difference between imaging and the histological data might be 
the partial volume effect. The transplant volume is small compared to the resolution of 
the SPECT system. This, in combination with the low uptake, might result in a difference 
between actual and quantified signal in the transplant. Considering that 400 islets are 
not sufficient to restore normoglycemia in a clinical setting, this method shows great 
promise for detecting even small amounts of islets. This would also allow to detect 
small changes in beta cell mass due to rejection or recurrent autoimmunity. Seen the low 
uptake of our tracer in the liver (0.1 %ID/g), this tracer might also be suited to follow 
islets transplanted in the liver. However, dispersion of the islets throughout the organ 
might impair the detection capacity of this tracer and histological evaluation of the islet 
transplant size in the liver is highly challenging.
Immunohistochemical analysis of the transplants showed excellent co-localization of 
tracer accumulation (as determined with autoradiography) with insulin and GLP-1R 
staining. These findings, in combination with the shown in vitro tracer accumulation, 
demonstrate specific binding of the tracer to the beta cells in the transplanted islets. 
Moreover, these histological findings confirm insulin production of the transplanted 
islets, 4 weeks after transplantation. Further evaluation of the correlation of tracer uptake 
in islet transplants of different sizes over time should be considered for validation of this 
method for longitudinal imaging of islet transplants. Since this tracer is already used in 
clinical trials [15], this technique can easily be translated and would have the potential to 
longitudinally measure the effect of therapeutic interventions on transplanted islet mass.
Conclusion
In this study, islets transplanted in the muscle of rats were visualized using [111In]-
exendin-3. Both in vitro and histological data support specific tracer uptake and we 
propose the muscle transplantation model as a highly suitable controlled model for 
validation of this imaging technology. In vitro, a linear relation between the number of 
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islets and exendin uptake was observed. Furthermore a significant difference in uptake 
between 400 and 800 islets was observed in vivo. Since the radiotracer can be injected 
repeatedly, this method will allow longitudinal monitoring of islet mass in vivo. Because 
the tracer molecule is already under clinical evaluation [15], clinical studies in patients, 
transplanted with islets appear to be feasible.
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Abstract 
Aims: Pancreatic islet transplantation can be a more permanent treatment for type 
1 diabetes compared to daily insulin administration. Quantitative and longitudinal 
non-invasive imaging of viable transplanted islets might help to further improve 
this novel therapy. Since islets express dopamine 2 (D2) receptors, they could be 
visualized by targeting this receptor. Therefore, the D2 receptor antagonist based 
tracer [125/123I] IBZM was selected to visualize transplanted islets in a rat model.
Methods: BZM was radioiodinated and the labeling was optimized for position 3 
of the aromatic ring. [125I]-3-IBZM was characterized in vitro using INS-1 cells and 
isolated islets. Subsequently, 1000 islets were transplanted in the calf muscle of WAG/
Rij rats and SPECT/CT images were acquired 6 weeks after transplantation. Finally, 
the graft containing muscle was dissected and analyzed immunohistochemically.
Results: Oxidative radioiodination resulted in 3 IBZM isomers with different 
receptor affinities. The use of 0.6 mg/ml chloramine-T hydrate resulted in high yield 
formation of predominantly [125I]-3-IBZM, the isomer harboring the highest receptor 
affinity. The tracer showed D2 receptor mediated binding to isolated islets in vitro. 
The transplant could be visualized by SPECT 6 weeks after transplantation. The 
transplants could be localized in the calf muscle and showed insulin and glucagon 
expression, indicating targeting of viable and functional islets in the transplant.
Conclusion: Radioiodination was optimized to produce high yields of [125I]-3-
IBZM, the isomer showing optimal D2 receptor binding. Furthermore, [123I]IBZM 
specifically targets the D2 receptors on transplanted islets. In conclusion, this tracer 
shows potential for non-invasive in vivo detection of islets, engrafted in the muscle, 
by D2 receptor targeting.
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Introduction 
For patients suffering from type 1 diabetes, insulin is never a cure, only a treatment. 
Pancreatic islet transplantation could be a permanent solution for these patients. 
Unfortunately, insulin independency drops to less than 15%, 5 years after transplantation 
[1]. Currently, graft function is monitored by measuring functional biomarkers, such 
as C-peptide and HbA1c levels, which show large inter-individual differences and are 
delayed markers for islet loss [2]. Furthermore, it has been shown that beta cell function 
is not always a representative measure for the remaining beta cell mass [3, 4]. Therefore, 
visualization of the remaining viable graft volume might provide important information 
on the metabolic state of the islet graft [5]. A possible method to accurately monitor 
islet loss is longitudinal quantitative imaging. Non-invasive imaging modalities, such 
as Single Photon Emission Computed Tomography (SPECT) and Positron Emission 
Tomography (PET), could provide important insights into the fate of transplanted islets 
[6] and could help to improve the outcome of this promising therapeutic approach. 
Several attempts have been made to visualize transplanted islets, using different imaging 
modalities. Transplanted islets, pre-labeled with a paramagnetic contrast agent, could be 
visualized using magnetic resonance imaging (MRI) [7, 8]. Besides MRI, transplanted 
islets can also be imaged using PET or SPECT. The first results of imaging the islet graft 
by PET date from 2006, where islets, transfected with a reporter gene or an adenoviral 
vector, could be visualized using [18F]Fluorohydroxybutylguanine ([18F]FHBG) as a 
tracer [9, 10]. Furthermore, [18F]Fluorodeoxyglucose ([18F]FDG) showed potential to 
image immediate events following transplantation [11, 12]. Transplanted islets were also 
imaged by SPECT and PET using [111In]-labeled exendin-4 [13]. In fact, exendin appears to 
be useful for longitudinal graft imaging [14]. Nevertheless, the use of alternative tracers, 
in addition to exendin, might help to gain important complementary information about 
the islet graft, such as metabolic stress, inflammatory processes, dedifferentiation and 
rejection. In other words, alternative tracers might allow more complete characterization 
of islet grafts.
One of these potential alternative tracers is iodobenzamide (IBZM) (Figure 1), a molecule 
with strong anti-dopaminergic activity and very high specificity for the dopamine 2 (D2) 
receptor. Labeled with Iodine-123, this molecule is clinically applied for D2 receptor 
imaging in neurodegenerative diseases [15, 16]. Furthermore, D2 receptors are expressed 
in pancreatic islets, where they mediate insulin secretion upon dopamine binding [17, 
18]. Consequently, [123I]IBZM may be a promising candidate to target transplanted islets 
via the D2 receptor. 
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Figure 1: Chemical structures of A) 3-IBZM B) 5-IBZM and C) 3,5-di-IBZM
In this study, we determined the potential of iodinated benzamide (BZM) for imaging 
of transplanted islets of Langerhans. The radioiodination of BZM was optimized for 
iodination of the 3 position of the aromatic ring, since different substitutions on this 
ring resulted in molecules with different affinity for the receptor. The in vitro binding 
properties of the tracer were characterized and finally, islets engrafted in the calf muscle 
of WAG/Rij rats were visualized by SPECT after injection of [123I]IBZM.
Materials and Methods
Compounds and Radionuclides
BZM and IBZM were purchased from ABX (advanced biochemical compounds, Radeberg, 
Germany). [123I]IBZM and sodium[125I]Iodide were obtained from GE healthcare 
(Eindhoven, The Netherlands) and Perkin Elmer (Boston, MA, USA), respectively.
Radiolabeling 
BZM was iodinated using oxidative iodination, as described previously [15]. The effect 
of the chloramine-T concentration on the reaction product was determined. Briefly, 
chloramine-T hydrate (15 µl; 0.6 mg/ml; 0.9 mg/ml or 1.2 mg/ml) was added to a 
mixture of BZM (25 µl 10 mg/ml), 10 µl 0.5 M phosphate buffer and 5 MBq Na[125I]I. 
After incubation for 2 minutes at room temperature (RT), the reaction was quenched 
using 200 µl metabisulphite (1 mg/ml). Reaction products were purified by reversed-
phase high performance liquid chromatography (RP-HPLC) using an Eclips XDB C18 
column (Agilent Technologies, Santa Clara, CA, USA). The column was eluted with 0.1% 
trifluoroacetic acid (TFA) in H2O (0-5 minutes), followed by a linear gradient from 3% to 
100% acetonitrile with 0.1% TFA over 30 minutes (flow rate: 1 ml/minute). The fractions 
containing [125I]IBZM were collected and diluted with RPMI 1640 medium (Invitrogen, 
Camarillo, CA, USA) containing 0.5% (w/v) bovine serum albumin (BSA). 
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Cell Culture 
The rat insulinoma cell line INS-1 was cultured as described previously [19]. In short, cells 
were maintained in RPMI supplemented with 10% fetal bovine serum (FCS) (HyClone, 
Celbio, Logan, UT, USA), 2 mM L-glutamine (Sigma Aldrich, St Louis, MO, USA), 10 mM 
HEPES (Invitrogen), 50 µM β-mercaptoethanol (ICN Biomedicals Inc, Aurora, OH, USA), 
1 mM sodium pyruvate (Invitrogen), 100 U/ml penicillin (Sigma Aldrich) and 100 µg/ml 
streptomycin (Sigma Aldrich), in a humidified atmosphere containing 5% CO2 at 37°C.
In vitro Binding to INS-1 Cells
INS-1 cells were harvested by trypsinization, transferred to Eppendorf tubes ( 3 x 106 
cells per tube) and washed twice with binding buffer (RPMI containing 0.5% BSA (w/v)). 
Approximately 1.6 kBq [125I]IBZM (20.5 fmol) was added, followed by incubation for 
4 hours at 37°C. After incubation, cells were washed twice with binding buffer and 
cell-associated radioactivity was measured in a well type gamma counter (Wallac 1480 
wizard, Perkin Elmer). 
In vitro Internalization  
The internalization kinetics of [125I]IBZM were determined as described previously [20], 
using suspensions of INS-1 cells (3 x 106 cells per tube). The cells were resuspended in 
binding buffer along with approximately 1.6 kBq [125I]IBZM (20.5 fmol) and incubated 
for 1, 2 and 4 hours at 37°C. After incubation, the cells were washed twice with binding 
buffer. To determine the surface-bound radiolabeled fraction, ice-cold acid buffer (0.1 M 
acetic acid, 154 mM NaCl, pH 2.5) was added and cells were incubated for 10 minutes 
at 4°C. After washing the cells twice with binding buffer, the cell-associated activity 
was measured in a well type gamma counter. The internalized fraction (cell-associated 
activity after acid wash) and the receptor bound fraction (activity removed by acid wash) 
were determined. 
Animals
Female Wistar Albino Glaxo (WAG)/Rij rats of 6-8 weeks old (Charles River Laboratories, 
Erkrath, Sulzfield, Germany) were used as islet donors and recipients. Animals were 
provided with food and water ad libitum. Animal experiments were approved by the 
animal welfare committee of the Radboud University Nijmegen.
Islet Isolation
In order to validate the results obtained using INS-1 cells, D2 receptor binding of the 
tracer was further analyzed using isolated islets. Pancreatic islets were isolated from 
WAG/Rij rats by collagenase digestion. Rats were euthanized by CO2/O2 suffocation 
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and 8 ml of ice-cold RPMI 1640 containing 1 mg/ml collagenase type V (Sigma Aldrich) 
was infused via the pancreatic duct in situ. After dissection, the perfused pancreata were 
collected in serum free medium containing collagenase and kept on ice until digestion. 
Pancreata were digested for 11 minutes and 30 seconds at 37°C. Digestion was stopped 
by adding RPMI medium containing 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin 
and 100 U/ml streptomycin (complete RPMI). After washing, digested pancreata were 
passed through a mesh. Afterwards, islets were purified on a discontinuous Ficoll 
gradient (densities: 1.108; 1.096; 1.037; Cellgro by Mediatech Inc, Manassas, VA, USA) 
by centrifugation at 625 x g for 16 minutes without brake. Islets were collected from the 
intersection of the second and third layer and remaining Ficoll was removed by washing 
with complete RPMI. Isolated islets were cultured overnight in complete RPMI medium 
in a humidified atmosphere containing 5% CO2 at 37°C. 
In vitro Binding to Isolated Islets
After overnight recovery, islets were collected, counted and resuspended in complete 
RPMI. Islets were divided in 24 well trans-well plates (600 islets per trans-well) (Corning 
Inc, Tewksbury, USA) and washed with binding buffer. Subsequently, approximately 1.6 
kBq of [125I]-3-IBZM was added followed by incubation for 4 hours at 37°C. To examine 
D2 receptor mediated uptake, 5 µg of unlabeled IBZM was added together with [125I]-3-
IBZM to separate wells. After incubation, islets were washed with binding buffer and 
islet-associated radioactivity was determined in a well type gamma counter.
Islet Transplantation 
Isolated islets were collected, resuspended and counted in RPMI medium without 
supplements. Healthy recipient rats were anesthetized using isoflurane (induction 
4-5%, maintenance 2% in 80% O2 and 20% N2O) (Abbott Laboratories, Toronto, Canada) 
and the right hind leg was shaved and disinfected with Betadine® (Meda Pharma B.V., 
Amstelveen, The Netherlands) prior to islet injection. Thousand islets were aspirated 
into a catheter line and infused manually at a constant, low speed into the calf muscle 
using a Hamilton syringe (100 ± 17.3 µl) (Hamilton Company, Reno, NV, USA).
SPECT Acquisition, Reconstruction and Biodistribution 
Six weeks after transplantation, the rats (n=3), transplanted with 1000 islets, were injected 
with 53.7 ± 6.1 MBq of [123I]IBZM (IBZM dose 1.7 ng in 500 µl injection fluid) in the tail 
vein. One hour after injection, SPECT images were acquired under inhalation (isoflurane) 
anesthesia on a USPECTII/CT small animal scanner (MILabs, Utrecht, Netherlands) for 
50 minutes, using a 1 mm pinhole general purpose rat and mouse collimator. CT was 
performed as an anatomical reference with the following settings: spatial resolution 160 
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µm; 65 kV and 615 µA. SPECT scans were reconstructed using the USPECT reconstruction 
software (MILabs, Utrecht, Netherlands) with following settings: selection of the I-123 
photopeak (143-175 keV) corrected for background (175–200 keV), pixel based OSEM, 
voxel size 0.75 mm3, 2 iterations and 16 subsets. After SPECT/CT acquisition, rats were 
euthanized by CO2/O2 suffocation and the muscle containing the transplant and other 
relevant tissues (blood, muscle, heart, lung, spleen, pancreas, kidney, liver, stomach and 
duodenum) were dissected, weighed and measured in a well type gamma counter to 
determine the distribution of the tracer over the different organs. Unfortunately, in vivo 
competition studies could not be performed due to the lethal effects of such high IBZM 
dose. 
Immunohistochemical Analysis
Graft containing muscles were fixed in 4% formalin, dehydrated and embedded in 
paraffin. Sections (4 µm) of the calf muscle were prepared at levels 50 µm apart from 
each other and used for Haematoxilin and Eosin (HE) staining to localize the transplant. 
Levels containing the transplant were stained immunohistochemically for the presence 
of insulin, as described previously [21], and glucagon. The primary antibody against 
glucagon (#2760, Cell Signaling, Danvers, MA, USA) was diluted in phosphate buffered 
saline (PBS), containing 1% BSA (1:500). Antigen retrieval was performed in 10 mM 
sodiumcitrate buffer, pH 6.0 for 10 minutes at 99oC. Subsequently, sections were incubated 
for 10 minutes with 3% H2O2 in PBS at RT in the dark, to block endogenous peroxidase 
activity. Non-specific binding was blocked by incubation for 30 minutes with 5% goat 
serum. Primary antibody incubation for 60 minutes was followed by incubation with the 
secundary goat-anti-rabbit biotin (1:200) (BA-1000, Vector Laboratories, Burlingame, CA, 
USA) and subsequently with the ABC complex (Vectastain, ABC kit, Elite). Finally, Bright 
DAB (BS04500, Immunologic BV, Duiven, Netherlands) was used for visualization.
 
Results 
Radiolabeling
After purification, [125I]IBZM with a specific activity of 81.4 GBq/µmol was obtained with 
a radiochemical purity exceeding 99%, as determined by RP-HPLC. Iodination using 
1.2 mg/ml chloramine-T hydrate resulted in moderate region-selectivity: 1) 7.8% [125I]-
5-IBZM, 2) 59.7% [125I]-3-IBZM and 3) 32.5% [125I]-3,5-di-IBZM, respectively (Figure 2). 
The second peak of the elution profile was identified as [125I]-3-IBZM because it showed 
equal HPLC retention time as [123I]-3-IBZM. Increasing amounts of the oxidant resulted 
in higher yields of the di-iodo analogue, [125I]-3,5-di-IBZM. The binding properties of the 
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different fractions to INS-1 cells are shown in Figure 2A. After 4 hours, 9.51 ± 1.13 fmol 
of [125I]-3-IBZM was bound to the INS-1 cells, whereas only 0.69 ± 0.07 fmol [125I]-5-IBZM 
and 1.20 ± 0,14 fmol of the di-iodo analogue [125I]-3,5-di-IBZM was bound to the INS-1 
cells. These results show that [125I]-3-IBZM had optimal D2 receptor binding properties. 
To increase regio-selectivity for [125I]-3-IBZM, the concentration of chloramine-T hydrate 
was lowered to 0.9 mg/ml and 0.6 mg/ml. The iodination using 0.6 mg/ml chloramine-T 
hydrate, shown in Figure 2B, resulted in 86.4% [125I]-3-IBZM, 9.9% [125I]-5-IBZM and 3.7% 
[125I]-3,5-di-IBZM. Iodination using 0.9 mg/ml chloramine-T resulted in only 77% [125I]-
3-IBZM.
Figure 2: A) Cell binding of the different IBZM analogues to INS-1 cells B) Elution profile of the 
reaction products at various concentrations of chloramine-T hydrate. 
Internalization Kinetics
Figure 3 summarizes the internalization kinetics of [125I]-3-IBZM by INS-1 cells as 
determined in vitro. As expected for an antagonist, there was no or very little internalization 
(0.65 ± 0.03 fmol, 3,2%) observed after 1 hour. At this time point, 13.0 ± 0.7 fmol (63.4%) 
was bound to the D2 receptor. After 2 and 4 hours respectively, no significant differences 
in binding or internalization were observed.
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Figure 3: In vitro internalization kinetics of [125I]-3-IBZM. The black line represents the surface 
bound fraction of [125I]-3-IBZM. The grey line represents the internalized fraction of [125I]-3-IBZM.
Pancreatic Islet Isolation and Transplantation 
After the islet isolation procedure, islet viability and islet purity exceeded 90%. During 
overnight recovery in complete RPMI medium, islets regained their original morphology, 
as determined microscopically. Transplantation did not cause unexpected events in the 
recipient rats. 
Binding Capacity of [ 125I]IBZM to Isolated Islets
Figure 4 shows the in vitro binding characteristics of [125I]-3-IBZM to 600 isolated islets 
of WAG/Rij rats. After 4 hours, 5.19 ± 0.51 fmol [125I]-3-IBZM was bound to the islets. 
Addition of 10 µg unlabeled IBZM reduced the binding to 0.95 ± 0.12 fmol, indicating 
specific binding of the tracer to the D2 receptor on the islets of Langerhans.
Figure 4: Binding capacity of [125I]-3-IBZM to isolated islets. The solid bar represents the binding 
of [125I]-3-IBZM. The white bar represents the binding of [125I]-3-IBZM in the presence of an excess 
[NatI]IBZM. 
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SPECT/CT Imaging 
The transplanted islets of Langerhans in the hind leg were visualized by SPECT, 1 hour 
after injection of [123I]IBZM. Six weeks after transplantation, a clear SPECT signal of 
[123I]IBZM was observed in the transplanted islets in the calf muscle (Figure 5).
Figure 5: In vivo SPECT/CT images of the islets engrafted in the muscle of rats (n=3), 6 weeks after 
transplantation, acquired 1 hour after injection of [123I]IBZM
Biodistribution Study 
Figure 6 summarizes the results of the biodistribution study. Biodistribution in WAG/
Rij rats 2 hours post-injection showed tracer uptake in various organs such as the lung, 
spleen, liver, kidney and duodenum. The relatively high uptake in the stomach (4.43 ± 
0,57 %ID/g) was caused by the presence of free iodine after hepatic breakdown of the 
tracer. Due to the small volume of the transplant, as compared to the volume of the 
calf muscle, no significant difference in tracer uptake was observed between the muscle 
containing the transplant and the control muscle. 
Immunohistochemical Analysis
All transplants could be localized within the muscle using HE staining. The transplants 
location, determined by HE staining, co-localized with insulin staining and glucagon 
staining of consecutive sections, as shown in Figure 7. Furthermore, all transplants (n=3) 
showed clear insulin and glucagon staining, indicating viable, insulin and glucagon 
producing beta and alpha cells in the transplant. 
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Figure 6: Biodistribution of [123I]IBZM in WAG/Rij rats (n=3). Values are expressed as percentages 
injected dose per gram tissue. Rats were dissected 2 hours post-injection. 
Figure 7: HE staining (A) (100x), insulin staining (B) (100x) and glucagon staining (C) (100x) of 3 
consecutive slices of muscle tissue containing the transplant
Discussion
Ever since the presence of D2 receptors on rodent and human islets was revealed, it was 
pointed out as a possible target for beta cell imaging [22]. Accordingly, IBZM imaging 
of transplanted islets has been proposed but the true potential of this tracer for beta cell 
imaging remained to be elucidated. Here, we have clearly demonstrated the possibility 
to visualize transplanted islets in vivo by specific targeting of the D2 receptor with 
[123I]IBZM in a rat model. 
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In the 1980’s, a variety of benzamide derivatives, all harboring strong anti-dopaminergic 
effects and high specificity for the D2 receptor, has been discovered [23] In 1988 Kung et 
al. described the synthesis of [125I]IBZM and its application for D2 receptor mapping in 
the central nerve system (CNS) [15]. In the labeling procedure, some ‘’minor impurities’’ 
were mentioned. Here, for the first time, we identified these ‘’impurities’’ as the para-
isomer and the di-iodo analogue. Furthermore, we determined the D2 receptor binding 
capacity of each labeled analogue in vitro and optimized the labeling to produce 
predominantly the ortho-isomer, [125I]-3-IBZM. At optimized conditions, carrier free [125I]-
3-IBZM was synthesized at a specific activity of 81.4 GBq/µmol with a radiochemical 
purity exceeding 99% after HPLC purification. The high specificity for the D2 receptor 
and the straightforward labeling procedure with high yields, make IBZM an excellent 
tracer for islet graft imaging.
After the discovery of D2 receptors on beta cells of pancreatic islets in 2005 [17], D2 receptor 
ligands are being applied to image pancreatic islets. [18F]-L-3,4-dihydroxyphenylalanine 
positron emission tomography ([18F]-DOPA PET) scans can be used to image congenital 
hyperinsulinism of infancy (CHI) [24, 25] and neuro-endocrine tumors (NET) such 
as insulinomas [26]. Due to their neuro-endocrine nature, islets hold the ability to 
decarboxylate L-DOPA and accumulate the tracer according to the amine precursor 
uptake and decarboxylation (APUD) concept of Pearse [27]. However, although the 
total pancreatic uptake of [123I]IBZM is similar to the uptake of exendin, the significant 
background signal from the exocrine tissue precludes quantitative imaging of native 
islets in the pancreas by D2 receptor targeting. Another potential issue might be the 
expression of D2 receptors on delta cells [28]. However, since delta cells only represent 
5 percent of islet cells, it is very unlikely that tracer binding to the delta cells would 
significantly influence viable graft volume measurements by D2 receptor targeting. 
Although islet imaging in the native pancreas is not feasible by targeting the D2 
receptor due to the diffuse D2 receptor expression in this organ, it might be valuable in 
the transplantation setting. In 2011, Garcia et al. showed that islets, transplanted in the 
spleen, could be visualized using [18F]-fallypride PET [29]. Furthermore, transplanted 
islets could be visualized using [18F]-DOPA PET [30]. In this study however, we preferred 
[123I]IBZM in view of the favorable spatial resolution of preclinical SPECT systems as 
compared to PET [31]. Furthermore, the spleen, kidney and the liver, wherein islets are 
most often transplanted both preclinically and clinically, show considerable [123I]IBZM 
uptake (Figure 6), precluding islet graft detection using IBZM in these organs. Therefore, 
striated muscle appeared to be an excellent transplantation site to determine the value 
of D2 receptor targeting for islet imaging. In this model, islet grafts could clearly be 
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delineated as areas of focal uptake, when compared to PET imaging of islets engrafted 
in the spleen or subcutaneously [29, 30], representing a substantial progress in molecular 
imaging of islet grafts.
Both for D2 receptor targeting and graft survival, striated muscle harbors advantages 
as a transplantation site when compared to liver and the kidney capsule. A common 
problem in both liver and kidney capsule transplantation is insufficient revascularization, 
resulting in impaired islet oxygenation [32, 33]. However, it has been shown that islets, 
transplanted in the muscle, show high vascular density and oxygenation [34]. It was even 
stated that islets engrafted in the muscle create a vascular system which resembles the 
native pancreas [35] and patients were transplanted successfully in the muscle [36]. Since 
the muscle is considered a promising novel site for clinical islet transplantation, islet 
graft imaging via D2 receptor targeting might contribute to the further improvement of 
this promising therapy, despite its limited imaging capacities for liver grafts.
In view of the D2 receptor mediated binding to isolated islets in vitro and the distinct 
tracer uptake in the SPECT images, the present study clearly demonstrates that 
[123I]IBZM can be used to monitor the viability of islet grafts following transplantation 
in future studies. Furthermore, in combination with other beta cell specific radiotracers 
such as [111In]-exendin, it might provide complementary information on the metabolic 
state of the islet graft. To summarize, IBZM imaging could provide vital complementary 
information on the viability and functionality of the islet graft. This may lead to early 
detection of aberrant processes in the transplant and eventually might improve the 
success rate of islet transplantation. 
Conclusion
The labeling procedure was optimized to produce predominantly [125I]-3-IBZM at a high 
specific activity and radiochemical purity. The tracer showed D2 receptor mediated 
binding to isolated islets and uptake within the transplant. Engrafted islets were clearly 
visualized on SPECT/CT images after injection of [123I]BZM. In conclusion, [123/125I]BZM is 
a suitable tracer for islet graft imaging in vivo and its imaging capacities for transplanted 
islets will be further elucidated.
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Abstract
Aims: A non-invasive imaging method to quantitatively and longitudinally monitor  
viable islet grafts could provide insight in the fate of islets after transplantation. 
Furthermore, it would grant the possibility to monitor effects of therapeutic 
interventions on viable graft volume and eventually, could help to improve 
transplantation outcome. Here, we investigated the use of [123I]-labeled dopamine 2 
receptor antagonist iodobenzamide ([123I]IBZM) for viable graft volume quantification 
and longitudinal monitoring of islet grafts. 
Methods: Six weeks after rats were transplanted intramuscularly with 1000, 2000 or 
3000 islets, they received 50 MBq [123I]IBZM intravenously and 1 hour post-injection, 
SPECT images were acquired. Subsequently, animals were euthanized and the graft 
containing muscles were dissected for ex vivo SPECT and histological analysis. Viable 
graft volume was determined histologically by multiplying the insulin-positive area 
by interslice distance. For longitudinal graft analysis, rats were transplanted with 
1500 islets and monitored for 10 weeks. 
Results: Six weeks after transplantation, a clear signal of all grafts was observed 
by SPECT imaging. Moreover, the intensity of the SPECT signal correlated linearly 
with viable graft volume, as determined histologically. Longitudinal graft follow-up 
showed a clear SPECT signal of the transplant from 3 weeks until 10 weeks after 
transplantation. 
Conclusion: Here, we demonstrate, for the first time, the successful application of 
a radiotracer ([123I]IBZM), for non-invasive, longitudinal and quantitative islet graft 
monitoring in vivo. Therefore, [123I]IBZM SPECT might be a valuable tool to monitor 
islet grafts after transplantation and eventually, to further improve this technique. 
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Introduction
Besides insulin therapy, islet transplantation is considered one of the most promising 
therapies for type 1 diabetic patients with poor glycemic control. Despite improvements 
in the immunosuppressant regimen [1], islet transplantation still results in only short 
term insulin independence, while long term outcome remains poor [2]. A reliable 
method to quantitatively and longitudinally monitor the islet graft, would provide 
improved insight in islet loss after transplantation. Furthermore, it would grant the 
possibility to evaluate potential therapies and interventions that might improve long 
term transplantation outcome.
During the last decade, extensive efforts have been made to develop a non-invasive 
imaging method to monitor the islet graft, resulting in a variety of graft monitoring 
methods. Several groups used pre-labeling methods to visualize the islet graft [3-8], while 
others targeted a receptor, specifically expressed on beta cells [9]. One of these receptors 
is the glucagon-like peptide 1 (GLP-1) receptor, which can be successfully targeted using 
radiolabeled exendin to visualize the pancreatic islets [10, 11]. Since a combination 
of different beta cell specific radiotracers might reveal important complementary 
information on the state of the islet graft (for example in case of receptor down regulation 
under certain conditions), the search for alternative methods to monitor transplanted 
islets is ongoing.
Since the 1980’s, dopamine 2 (D2) receptors have been used as a target for brain imaging 
[12, 13]. In view of the neuro-endocrine nature of pancreatic islets, the hypothesis arose 
that beta cells express D2 receptors. In 2005, this hypothesis was proven, when Rubi 
et al. confirmed the expression of D2 receptors on both human and rodent islets [14]. 
Furthermore, D2 receptors show excellent co-localization with insulin expression and 
mediate glucose-stimulated insulin section through a negative feedback mechanism [15-
17]. Ever since, the presence of these receptors has been exploited to image insulinomas 
[18], congenital hyperinsulism of infancy (CHI) [19, 20] and islets, both in the native 
pancreas and after transplantation [21-23], using [18F]-L-3,4-dihydroxyphenylalanine 
([18F]-DOPA) and [18F]fallypride Positron Emission Tomography (PET).
Another tracer displaying high affinity and specificity for the D2 receptor is iodobenza-
mide (IBZM), a strong receptor antagonist [24, 25]. Labeled with I-123 or I-125, it is 
extensively used as a radiotracer for Single Photon Emission Computed Tomography 
(SPECT) in neurodegenerative diseases [26, 27]. Recently, in a proof-of-concept study, 
we showed specific binding of [125I]IBZM to isolated islets in vitro and the feasibility 
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to visualize islets, transplanted in the calf muscle of rats, using [123I]IBZM SPECT/CT 
[28]. In the present study, we aimed to characterize the potential of [123I]IBZM for in 
vivo, longitudinal and quantitative monitoring of viable beta cells in the islet grafts, by 
determination of the correlation between SPECT signal and viable graft volume. 
Materials and Methods
Animals
Twelve weeks old female WAG/Rij rats (Charles River Laboratories, Erkrath, Sulzfield, 
Germany) were used both as islet donors and recipients. Animals had access to food 
and water ad libitum. The animal experiments were approved by the animal welfare 
committee of the Radboud University Nijmegen and carried out in accordance with their 
guidelines.
Islet Isolation
Islets of Langerhans were isolated from WAG/Rij rats by collagenase digestion as 
described previously [28]. Briefly, rats were suffocated using CO2/O2, and 8 ml of ice-cold 
RPMI 1640 (R0883, GIBCO, BRL Life Sciences Technologies, Bleiswijk, The Netherlands) 
containing 1 mg/ml collagenase type V (Sigma Aldrich, St Louis, MO, USA), was injected 
via the common bile duct. Pancreata were dissected and digested for 11 minutes and 30 
seconds at 37oC. Islets were purified on a discontinuous Ficoll gradient (densities 1.108, 
1.096, 1.037 g/ml, Cellgro, Mediatech Inc., Manassas, VA, USA) by centrifugation at 625 
x g for 16 minutes without brake. The islets were collected from the intersection of the 
second and third layer and cultured overnight at 37oC with 5% CO2 in RPMI containing 
10% fetal bovine serum (FCS) (HyClone, Celbio, Logan, UT, USA), 2 mM L-glutamine 
(Sigma-Aldrich), 100 U/ml penicillin (Sigma Aldrich) and 100 U/ml streptomycin 
(Sigma Aldrich). Islet purity and viability were assessed by microscopy. 
Islet Transplantation
Islets were transplanted intramuscularly as described previously [28]. After overnight 
recovery, islets were collected, spun down, resuspended in serum free RPMI medium 
and counted. The recipient rats were anesthetized with isoflurane (induction 4-5%, 
maintenance 1.5-2% in air) (Abbott Laboratories, Toronto, ON, Canada) and the right 
hind leg of the rats was shaved and disinfected with Betadine® (Meda Pharma B.V., 
Amstelveen, The Netherlands). Islets were aspirated into a catheter line and infused 
manually at low speed (injected volume 100 ± 10 µl) in the right calf muscle using a 
Hamilton syringe (Hamilton Company, Reno, NV, USA)
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Experimental Design for in Vivo SPECT Imaging of Transplanted Islets
To determine the correlation of SPECT signal with viable graft volume, 15 WAG/Rij 
rats (3 groups, n=5 per group) were transplanted in the right calf muscle with 1000, 
2000, or 3000 islets, as described above. SPECT/CT images were acquired 6 weeks after 
transplantation. For the longitudinal follow-up of the transplanted islets, 3 WAG/Rij rats 
were transplanted with 1500 islets and SPECT/CT images were acquired 7 times over a 
period of 10 weeks (in weeks 2, 3, 4, 5, 6, 8 and 10). After the last SPECT/CT scan, rats 
were euthanized and muscles containing the transplant were collected for ex vivo SPECT 
and immunohistochemical analysis. 
SPECT Acquisition 
One hour prior to SPECT acquisition, WAG/Rij rats (n=5 per group) were injected 
intravenously in the tail vein with 57.9 ± 4.8 MBq of [123I]IBZM (IBZM dose 1.7 ng in 
500 µl injection fluid) (GE healthcare, Eindhoven, The Netherlands). SPECT/CT images 
were acquired on a dedicated small animal SPECT/CT scanner (U-SPECT-II, MIlabs, 
Utrecht, The Netherlands) with a 1.0 mm multipurpose rat and mouse collimator, using 
24 bed positions and a total acquisition time of 50 minutes. CT was acquired immediately 
after SPECT acquisition for anatomical reference (65 kV, 615 µA, 1 bed position, spatial 
resolution 160 µm).
Ex Vivo SPECT of Transplant Containing Muscles
Immediately after dissection, the muscles containing the transplant were transferred to 
Eppendorf tubes with 4% formalin and SPECT/CT images of the individual muscles 
were acquired with a 0.35 mm high-resolution mouse collimator (MILabs, Utrecht, The 
Netherlands), using 42 bed positions and a total SPECT acquisition time of 6 hours.
SPECT Reconstruction and Quantitative SPECT Analysis 
SPECT scans were reconstructed using U-SPECT-II reconstruction software (MILabs, 
Utrecht, The Netherlands) with the following settings: selection of the I-123 photopeak 
(143-175 keV) corrected for 2 background regions (135-143 keV and 175-185,5 keV), pixel 
based OSEM, voxel size 0.75 mm3, 1 iteration and 16 subsets. The uptake of [123I]IBZM 
was quantified using Inveon Research Workplace (IRW) (Siemens Healthcare, Den Haag, 
the Netherlands). A volume of interest (VOI) was drawn around the graft. Total voxel 
intensity in the islet graft was corrected for background uptake using an identical VOI in 
the contra-lateral control muscle. The activity calculated in the grafts was corrected for 
the injected activity of the animal.
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Immunohistochemistry
The muscles containing the transplanted islets were fixed in 4% formalin, dehydrated 
and embedded in paraffin. Sections (4 µm) of the calf muscle were cut at levels 50 µm 
apart from each other and were stained with Haematoxylin and Eosin (HE) to localize the 
islet graft. Consecutive sections were stained for the presence of insulin and D2 receptor 
as follows. Antigen retrieval was performed using 10 mM sodium citrate buffer, pH 6.0 
heated in a PT module (Thermo scientific, Waltham, MA, USA). For insulin staining, 
non-specific binding was blocked by incubation for 30 minutes with phosphate buffered 
saline (PBS), 1% bovine serum albumin (BSA) (w/v) at room temperature (RT) while for 
D2 receptor staining blocking was performed using 5% normal donkey serum in PBS 
(w/v). Primary anti-insulin antibody (1:1000) (A0564, DAKO, Copenhagen, Denmark) 
incubation for 60 minutes at RT in the dark was followed by incubation with Alexa fluor 
488 goat-anti-guinea pig (1:500) (Life sciences technologies, Carlsbad, CA, USA) for 30 
minutes at RT in the dark. For D2 receptor staining, primary anti-D2 receptor antibody 
(1:100) (Ab5084P, Millipore, Billerica, MA, USA) 16 hours incubation at 4oC in the dark 
was followed by incubation with Alexa fluor donkey-anti-rabbit (1:200) (Life sciences 
technologies) for 1 hour in the dark. Stained sections were mounted using fluoromount 
(DAKO). 
Immunohistochemistry-Based Determination of Viable Graft Volume 
Sections, stained for insulin, were analyzed using a DM5000 microscope (Leica, Solms, 
Germany) and images were obtained with a color camera (Evolution MP; Leica using 
Axio Vision 4.4 software). The insulin-positive area of the transplant was drawn on each 
section of all levels. Finally, the insulin-positive transplant area was multiplied with the 
50 µm inter-slice distance to obtain the volume of the viable graft. 
Statistical Analysis 
All values are expressed as mean values ± standard deviation (SD). All correlations 
stated in this paper were calculated using the Pearson correlation coefficient (Pearson r) 
in GraphPad Prism v. 5.03 (GraphPad Software, Inc., San Diego, CA, USA). The level of 
significance was set at p < 0.05. 
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Results
Pancreatic Islet Isolation and Transplantation
After overnight recovery in complete RPMI medium, the isolated islets showed normal 
islet morphology, as determined microscopically. The viability and purity of the isolated 
islets exceeded 90%. No unexpected or adverse effects were observed in the recipient rats 
after the transplantation procedure.
Immunohistochemical Graft Analysis and Volume Assessment 
All grafts (n=15) could be detected in the calf muscle after HE staining. The location of 
the graft, determined by HE staining, co-localized with insulin staining and D2 receptor 
staining, as determined on consecutive sections (Figure 1). This indicates beta cell specific 
D2 receptor expression in the islet graft. The viable graft volume, calculated histologically 
from the insulin-positive graft area, increased with the number of transplanted islets. 
Viable graft volume ranged from 1.4 x 106 µm3 to 1.2 x 107 µm3. Two islet grafts were 
excluded from the volume assessment since no trustworthy viable graft volume could be 
calculated from the histological data due to technical errors during sectioning.
Figure 1: Co-localization of insulin staining (A) and D2 receptor staining of islets, engrafted in the 
calf muscle, 6 weeks after transplantation. 
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SPECT/CT Imaging and Correlation with Graft Volume
Six weeks after transplantation, all grafts (n=15) could be visualized by SPECT/CT, 1 
hour after [123I]IBZM injection. Figure 2 clearly shows differences in [123I]IBZM uptake 
on SPECT/CT images, reflecting differences in viable graft volume. Furthermore, the 
measured SPECT signal in the islet grafts, with an average signal-to-noise ratio of 2.11 ± 
0.62, showed a good linear correlation (Pearson r = 0.73, p = 0.005; n=13) with the viable 
graft volume, as determined histologically as described above (Figure 3). For the image 
analysis, CT images were fused with the concomitant SPECT images for anatomical 
reference. 
Figure 2: In vivo SPECT/CT images of a small (A), medium (B) and large (C) islet graft in the calf 
muscle, 6 weeks after transplantation, acquired 1 hour after injection of [123I]IBZM. The red arrows 
indicate the transplant. 
Figure 3: Scatter plot of the correlation between the SPECT signal in the transplant expressed in 
arbitrary units (AU) (y-axis) and the viable graft volume (µm3), as calculated from the histological 
analysis (x-axis) (Pearson r = 0.73, p = 0.005). 
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Ex Vivo SPECT Imaging
SPECT images of the dissected calf muscle samples showed a clear signal of the islet graft 
ex vivo. Furthermore, the SPECT signal of the islet graft observed ex vivo, corresponded 
nicely to the SPECT signal detected in the islet graft in vivo (Figure 4), which confirms 
that the signal observed in vivo originated from the islet graft in the muscle. 
Figure 4: A) In vivo SPECT/CT image and B) ex vivo SPECT image of a WAG/Rij calf muscle, 
transplanted with 3000 islets. The red arrows indicate co-localization of the SPECT signal in the calf 
muscle detected in vivo and ex vivo.
Longitudinal Follow-Up of Transplanted Islets
Figure 5 shows the longitudinal SPECT analysis of the intramuscular islet grafts. In all 
rats (n=3), islet grafts showed a clear SPECT signal from 3 weeks after transplantation 
until 10 weeks (end of experiment) after transplantation (Figure 5). All transplants (n=3) 
were localized in the calf muscle by HE staining and co-localized with insulin and D2 
receptor expression, as determined immunohistochemically.
Figure 5: In vivo SPECT/CT images of an islet graft in the calf muscle from 3 to 10 weeks after 
transplantation. The red arrows indicate the transplant. 
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Discussion
Recently, we have demonstrated the technical feasibility of non-invasive visualization 
of intramuscular islet grafts by D2 receptor targeting using [123I]IBZM SPECT/CT [28]. 
In this study, longitudinal and quantitative islet graft monitoring, using this technique, 
was explored. We demonstrated, for the first time, a high correlation (Pearson r=0.73) 
between the SPECT signal, obtained from a beta cell specific radiotracer, and the viable 
graft volume. Furthermore, we demonstrate the feasibility of islet graft monitoring from 
3 until 10 weeks after transplantation. These data clearly go beyond previous work 
demonstrating the feasibility of nuclear isle graft imaging, since a linear correlation of 
viable graft volume and radiotracer uptake had never been shown in vivo.
Active targeting of peptide hormone receptors, expressed on beta cells, offers potential 
advantages over pre-labeling methods. Active receptor targeting allows longitudinal in 
vivo monitoring of the islet graft by multiple radiotracer injections, providing real-time 
information on the state of the islet graft. Currently, GLP-1R targeting is being extensively 
explored for beta cell imaging in the native pancreas and after islet transplantation [10, 
11, 29, 30]. However, the availability of an alternative tracer, targeting a different receptor, 
could provide complementary information about the islet graft and might therefore help 
to improve transplantation outcome. 
Since D2 receptors are expressed on beta cells in the islets of Langerhans [14], they are 
considered a suitable target to monitor these insulin producing cells. Until now, D2 
receptor targeting was mainly applied for CHI and insulinoma imaging [19, 31, 32]. 
D2 receptor imaging is not suitable for imaging of the absolute islet mass in the native 
pancreas due to high diffuse tracer uptake in the exocrine pancreas. However, it has 
been demonstrated that islets, transplanted into the spleen of rats, could be visualized 
and semi-quantitatively analyzed by [18F]-fallypride PET [21, 22]. [123I]IBZM is widely 
commercially available or can be produced using a straightforward labeling procedure 
[28] and therefore represents a highly interesting alternative for [18F]-fallypride. In this 
study, we have demonstrated, for the first time, a high correlation (Pearson r=0.73) of 
viable graft volume and quantitative [123I]IBZM SPECT signal in the islet graft, which 
indicates that tracer uptake is a representative measure for the amount of viable and 
insulin producing islets in the graft. Commonly used transplantation sites such as the 
liver, kidney or spleen, show high background uptake of [123I]IBZM, rendering these sites 
inferior to the muscle as a transplantation site for in vivo graft analysis using D2 receptor 
targeting. Furthermore, islet transplantation in the muscle is already applied for auto-
transplantation in diabetes patients. Although skeletal muscle contains considerable 
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dopamine levels, competition of tracer binding will be negligible since the potency of 
dopamine to displace IBZM binding is very low [24].
Longitudinal graft monitoring showed the possibility to image the islet grafts with 
[123I]IBZM for several weeks. A clear SPECT signal was observed in the islet grafts from 3 
weeks until 10 weeks (end of experiment) after transplantation. Furthermore, a gradual 
increase of the SPECT signal, followed by signal stabilization was observed. We have 
previously shown that the initial absence of detectable SPECT signal and the gradual 
signal increase can be explained by ongoing revascularization of the islet graft [33, 34]. 
Islet vasculature is disrupted during the isolation process, which hampers tracer supply 
to the islet graft. However, in the first weeks after transplantation, functional blood 
supply in the islet graft is restored allowing reproducible [123I]IBZM targeting of the graft. 
Taken together, [123I]IBZM SPECT provides an attractive tool to monitor survival of 
islet grafts. It allows longitudinal graft monitoring and holds the power to detect small 
differences in viable graft volume. The limited capacities of D2 receptor imaging for islets, 
engrafted in the liver, may no longer be a major drawback, considering the increasing 
clinical interest in the muscle as a transplantation site [33, 35, 36]. Therefore, [123I]IBZM 
SPECT might provide important information on the state of the islet graft and eventually, 
might help to predict and improve transplantation outcome. 
Conclusion
In this study, intramuscular islet grafts could be visualized from 3 weeks after 
transplantation using [123I]IBZM as a tracer. The SPECT signal in the graft showed a 
high correlation with the calculated viable graft volume. In conclusion, [123I]IBZM can 
be successfully employed for non-invasive longitudinal and quantitative islet graft 
monitoring.
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Abstract 
Aims: Glucose-dependent insulinotropic polypeptide (GIP) stimulates insulin 
secretion upon receptor binding in the islets of Langerhans. Therefore, the feasibility 
of islet imaging using a novel GIP-probe was explored both in vitro and in vivo. 
Methods: A novel, acetylated GIP1-42-Cy3 probe was synthesized and characterized 
in vitro using GIP receptor (GIPR)-transfected BHK cells, NES2Y cells and isolated 
islets. C57Bl/6 WT and C57Bl/6 Glp-1r-/- mice were injected subcutaneously with 
GIP-Cy3 and pancreata were analyzed histologically. 
Results: GIP-Cy3 displayed high receptor affinity in GIPR-transfected BHK cells 
and probe binding increased with rising concentrations in vitro. GIP-Cy3 displayed 
receptor mediated binding to NES2Y cells and isolated islets. No fluorescent signal 
was observed in islets of neither WT nor Glp-1r-/- mice after GIP-Cy3 injection.
Conclusion: GIP-Cy3 shows dose-dependent, GIPR mediated binding in vitro. 
Therefore, the probe has potential for islet imaging. However, islet-specific signal 
remained absent and translation to in vivo applications needs to be explored further. 
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Introduction 
Diabetes mellitus is a disease with increasing incidence, characterized by distorted 
glucose homeostasis, which results in chronically elevated blood glucose levels. In type 
1 diabetes, the insulin producing beta cell undergo auto-immune destruction, while 
in type 2 diabetes beta cells fail to compensate for insulin resistance, causing deficient 
control of glucose homeostasis [1]. However, several processes underlying disease 
pathogenesis remain to be unraveled. An attractive approach to gain more knowledge on 
diabetes onset and progression is in vivo beta cell imaging (BCI), using beta cell targeting 
tracer molecules, which would allow longitudinal and quantitative monitoring of beta 
cell mass (BCM). Nevertheless, many obstacles need to be overcome to allow accurate 
in vivo BCM determination [2]. One of these challenges lies in the fact that the islets of 
Langerhans, containing the beta cells, represent only 1-2% of the pancreatic volume and 
are scattered throughout the pancreatic parenchyma [3, 4]. Therefore, the applied tracer 
molecule needs to be highly beta cell specific, resulting in high target-to-background 
ratios. 
Glucose-dependent insulinotropic polypeptide (GIP), is secreted from the intestinal K 
cells upon nutrient intake [5]. Together with glucagon-like polypeptide 1 (GLP-1), GIP 
is responsible for the incretin effect [6, 7]. When GIP binds its receptor on the beta cells, 
it enhances glucose-dependent insulin secretion, and upregulates transcription and 
synthesis of insulin, and expression of glucose sensors [8]. The expression of the GIP 
receptor (GIPR) on beta cells, and its suggested involvement in diabetes pathogenesis [9], 
make the GIPR an interesting, potential target for in vivo BCI.   
During the past decade, targeting of the incretin receptors for in vivo tumor and beta 
cell imaging has been extensively explored. Since the GLP-1 receptor (GLP-1R) is 
over-expressed in over 90 % of insulinomas, GLP-1R targeting tracers were proven 
successful for in vivo detection of these tumors [10-12]. Furthermore, these tracers have 
been successfully applied in the field of in vivo BCI, both in the native pancreas [13, 
14] and after transplantation [15, 16]. Recently, Sherman et al. showed GIPR expression 
in a subset of neuro-endocrine tumors (NET) [17] and the feasibility of targeting GIPR 
positive tumors was demonstrated using a radiolabeled GIP analogue [18]. Due to their 
spatial resolution however, nuclear imaging modalities such as Single Photon Emission 
Computed Tomography (SPECT) and Positron Emission Tomography (PET) will not 
allow imaging of single islets. Nevertheless, by achieving high specificity of the tracer, 
the signal obtained will be derived from beta cells without requiring resolution of single 
islets. Therefore, a fluorescent tracer could provide not only complementary information 
on the behavior of the tracers on a cellular level, but also be helpful to predict whether 
radiotracer imaging will be feasible in vivo. 
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In this study, we determined the binding potential of a newly synthesized GIP-Cy3 for 
its receptor and the feasibility to image the beta cells in the native pancreas by GIPR 
targeting. The binding properties of the tracer were characterized in vitro using two 
different cell lines and isolated mouse islets. To determine its potential to visualize 
the islets of Langerhans ex vivo, mice were injected with GIP-Cy3. Furthermore, we 
investigated the hypothesis that mice lacking the GLP-1R, over-express the GIPR, to 
compensate for GLP-1R loss, since these mice only show little abnormalities in glucose 
homeostasis [19]. This might then result in increased accumulation of GIP-Cy3.
Materials and Methods 
Fluorescent Probes 
Both exendin-4-Cy3 and GIP1-42-Cy3 were synthesized by Novo Nordisk A/S (Måløv, 
Denmark). [Leu14, Leu28]exendin-4-Cys-amide and N-alpha-acetyl-[Leu14]-GIP1-42–
Cys-amide were prepared on a rink amide resin using standard Fmoc chemistry and 
purified by reversed-phase high performance liquid chromatography (RP-HPLC). 
Both molecules (0.7 µmol) were dissolved together with 1 mg Cy3-maleimide (GE 
Healthcare, Little Chalfont, Buckinghamshire, United Kingdom) in 100 µl DMSO and 
2 µl diisopropylethylamine for 20 minutes. Afterwards, the product mixtures, with 
slight excess of Cy3-maleimide were applied on a PD10 column (GE healthcare). The 
equilibrated PD10 column was eluted using 20 mM ammonium bicarbonate. The 
first colored fractions eluted from the column represented the products: [Leu14, Leu28]
exendin-4-Cys(Cy3-Mal)-amide or N-alpha-acetyl-[Leu14]-GIP1-42–Cys(Cy3-Mal)-amide, 
respectively. Identity and purity were confirmed using liquid chromatography-mass 
spectrometry (LCMS). The products were lyophilized and diluted in 1 X Dulbecco’s 
Phosphate Buffered Saline (DPBS) (Life Technologies, Carlsbad, CA, USA) to a standard 
concentration of 20 nmol/ml and allowed to dissolve overnight prior to injection. 
Animals 
Eight weeks old C57Bl/6J WT and C57Bl/6J Glp-1r-/- mice were purchased from Taconic 
Biosciences (Ry, Denmark). C57Bl/6J Glp-1r-/- mice originate from a previously described 
line [19], bred for Novo Nordisk A/S at Taconic Biosciences. Six to eight weeks old C3H 
mice were purchased from Charles River Laboratories (Erkrath, Sulzfield, Germany). All 
animals were housed, maintained and euthanized under the regulations of the Danish 
Animal Protection Act, the Danish Act on Animal experiments, the Novo Nordisk A/S 
guidelines for animal experiments or the guidelines of the animal welfare committee of 
the Radboud University, Nijmegen. 
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Cell Culture 
Baby Hamster Kidney (BHK) cells were transfected with a pTARGET vector containing 
the gene encoding the human GIP receptor (hGIPR) (Figure 1) to over-express the 
hGIPR. The BHK-hGIPR transfected cell line was maintained in Dulbecco’s Modified 
Eagle Medium (DMEM) glutamax (cat. Nr. 6195, GIBCO, BRL Life Sciences Technologies, 
Bleiswijk, The Netherlands), supplemented with 10% fetal bovine serum (FCS), 
(HyClone, Celbio, Logan, UT, USA) and 1 mg/ml G418, in a humidified atmosphere 
containing 5% CO2 at 37°C. The human beta cell line NES2Y was a kind gift of Roger 
James (University of Leicester) and was cultured as described previously [20, 21]. In 
short, cells were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium 
(R0883, GIBCO), supplemented with 10% FCS, (HyClone, Celbio), 2 mM L-glutamine 
(Sigma Aldrich, St Louis, MO, USA), 100 U/ml penicillin (Sigma Aldrich) and 100 µg/ml 
streptomycin (Sigma Aldrich) (complete RPMI), in a humidified atmosphere containing 
5% CO2 at 37°C.
Figure 1: pTARGET vector containing the hGIPR gene, used for creation of the GIPR transfected 
BHK cell line. 
In vitro Binding to BHK-GIPR Transfected Cells
To determine the binding potential of the GIP-Cy3 probe to the GIPR, BHK-GIPR 
transfected cells were incubated with GIP-Cy3 in vitro. Since exendin-4 has been shown 
to also bind the GIPR [22], we incubated BHK-GIPR cells with exendin-4-Cy3 to examine 
its affinity towards the GIPR. BHK-GIPR transfected cells were seeded at a density of 
100,000 cells per well on a microscope glass and incubated overnight in a humidified 
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atmosphere containing 5% CO2 at 37°C to reach confluency. Cells were incubated with 0, 
10, 100 or 1000 nM GIP-Cy3 or exendin-4-Cy3 for 30 minutes at 37°C. After incubation, 
cells were washed with DMEM medium, nuclei were stained with DAPI and the 
cell bound probe was fixed to the cells using 4% paraformaldehyde (PFA) (Avantor 
Performance Materials, Center Valley, PA, USA). Binding of the probe to the cells was 
analyzed using an Olympus Fluoview FV10 confocal scanner (Olympus Corporation, 
Tokyo, Japan).
In Vitro Binding to NES2Y Cells
NES2Y cells were harvested by trypsinization, transferred to Eppendorf tubes (3 x 
106 cells per tube) and washed twice with binding buffer (RPMI containing 0.5% BSA 
(w/v)). GIP-Cy3 (2.5 µM) was added to the cells followed by incubation for 24 hours at 
37°C. After incubation, cells were washed twice with binding buffer and cell-associated 
fluorescence was determined in a fluorescent microplate reader (Tecan group AG, 
Männedorf, Switzerland).
Islet Isolation 
Islets of Langerhans were isolated from donor C3H mice by collagenase digestion. Mice 
were euthanized by CO2/O2 suffocation and 2 ml of ice cold RPMI 1640 containing 1 mg/
ml collagenase type V (Sigma Aldrich) was injected into the pancreas via the common 
bile duct. After dissection, perfused pancreata were collected in collagenase containing 
RPMI medium and kept on ice until digestion. Afterwards, pancreata were digested 
for 12 minutes at 37°C and digestion was stopped by adding complete RPMI. After 
washing, digested pancreata were passed through a mesh and islets were purified on 
a discontinuous Ficoll gradient (densities: 1.108; 1.096; 1.037; Cellgro by Mediatech Inc, 
Manassas, VA, USA) by centrifugation at 625 x g for 16 minutes without brake. Islets 
were collected from the intersection of the second and third layer and remaining Ficoll 
was removed by washing with complete RPMI. Isolated islets were cultured overnight in 
complete RPMI medium in a humidified atmosphere containing 5% CO2 at 37°C. 
In Vitro Binding to Isolated Islets
After overnight recovery, islets were collected, counted and resuspended in complete 
RPMI. Islets were divided in 24 well trans-well plates (200 islets per trans-well) (Corning 
Inc, Tewksburry, USA) and washed with binding buffer. Subsequently, 1 µM GIP-Cy3 
was added followed by incubation for 24 hours at 37°C. To examine the GIPR mediated 
binding, a hundredfold molar excess of unlabeled GIP was added together with GIP-Cy3 
to a separate set of wells. After incubation, islets were washed with binding buffer and 
islet-associated fluorescence was determined in a fluorescent microplate reader (Tecan 
group AG, Männedorf, Switzerland). 
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In Vivo GIP-Cy3 Binding
C57Bl/6 WT and C57Bl/6 Glp-1r-/- mice (n=3 per group) were injected subcutaneously 
with 4 nmol GIP-Cy3 (160 nmol/kg). One additional mouse per group was injected 
with exendin-4-Cy3 as a control. Six hours after injection, the mice were perfused using 
4% PFA. Pancreata were dissected and incubated in PFA for 2 hours. After overnight 
dehydration in 30% sucrose, pancreata were fractionated, embedded in Tissue Tek (Sakura 
Finetek, Alphen aan de Rijn, The Netherlands) and snap frozen. Ten µm cryosections 
were sliced on a Leica CM 3050 cryostat (Leica Biosystems, Nußloch, Germany). Sections 
were scanned using an Olympus VS-120 slide scanner with 20 x magnification (Olympus 
Corporation).
Immunohistochemistry 
Pancreatic sections of mice after GIP-Cy3 injection were stained for the presence of insulin. 
The primary antibody against insulin (A0564, Dako North America Inc., Carpinteria, CA, 
USA) was diluted in TNB buffer (1:1000). After washing with PBS/tween20, sections 
were incubated with TNB buffer for 40 minutes to block non-specific binding. Primary 
antibody incubation for 60 minutes was followed by incubation with the secondary 
donkey-anti-guinea pig-Cy2 (1:500) (Jackson ImmunoResearch Inc., West Grove, PA, 
USA) together with DAPI nucleus staining (1:1000) for 45 minutes. Slices were scanned 
using an Olympus VS-120 slide scanner with 20 x magnification (Olympus Corporation).
Results 
In Vitro Binding to GIPR Transfected Cells 
To determine the binding potential of the probes to the GIPR, BHK-GIPR transfected 
cells were incubated with GIP-Cy3 and exendin-4-Cy3 in vitro. The results of the binding 
assay are summarized in Figure 2. After 30 minutes, GIP-Cy3 showed dose-dependent 
binding to BHK-GIPR transfected cells (Figure 2A-D). Probe binding was observed in 
the presence of 10 nM GIP-Cy3 and increased with increasing amounts of the probe. At a 
concentration of 1000 nM GIP-Cy3, receptor saturation was reached and internalization 
was observed. Furthermore, after 30 minutes incubation with 1000 nM exendin-4-Cy3, 
traces of probe binding to the BHK-GIPR transfected cells were observed (Figure 2H), 
indicating low affinity of the GLP-1R agonist exendin-4 for the GIPR.
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Figure 2: Binding of different concentrations of GIP-Cy3 (A-D) and Exendin4-Cy3 (E-H) to BHK-
GIPR transfected cells. Nuclei are shown in white and the fluorescent dye in red. Scale bar = 40 µm
In Vitro Binding to NES2Y Cells 
NES2Y cells were incubated with GIP-Cy3 to investigate the binding potential of the 
novel probe for human beta cells. The results of this assay are shown in Figure 3. After 24 
hours of incubation, 0.31 ± 0.03 % of the added GIP-Cy3 was bound to the cells. Addition 
of a hundredfold molar excess unlabeled GIP significantly reduced the binding to 0.2 ± 
0.005 % (p = 0.007) indicating specific GIP-Cy3 binding to the cells. 
  
Figure 3: Binding capacity of GIP-Cy3 to NES2Y cells. The solid bar represents the binding of GIP-
Cy3. The white bar represents the binding of GIP-Cy3 in the presence of an excess unlabeled GIP.
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In Vitro Binding to Isolated Islets 
To investigate the binding capabilities of GIP-Cy3 for beta cells, the probe was incubated 
with isolated islets from C3H mice. The in vitro binding properties of GIP-Cy3 to isolated 
islet are summarized in Figure 4. After 24 hours, 1.7 ± 0.3% of the added GIP-Cy3 was 
bound to the islets. Addition of a hundredfold molar excess unlabeled GIP reduced the 
binding to 0.6 ± 0.6%, indicating GIPR mediated binding of the probe to the islets of 
Langerhans. 
Figure 4: Binding capacity of GIP-Cy3 to isolated mouse islets. The solid bar represents the binding 
of GIP-Cy3. The white bar represents the binding of GIP-Cy3 in the presence of an excess unlabeled 
GIP.
In Vivo Beta Cell Targeting
After in vitro characterization, mice were probed with GIP-Cy3 and their pancreata 
were analyzed histologically to determine its applicability for BCI. The results of the in 
vivo beta cell targeting studies are demonstrated in Figure 5. In the C57Bl/6 WT mice, 
no fluorescent signal, originating from the GIP-Cy3 probe, was observed in the islets 
(Figure 5A), while exendin-4-Cy3 showed a very clear islet-specific fluorescent signal 
(Figure 5G). The C57Bl/6 Glp-1r-/- mice were negative for both GIP-Cy3 and exendin-4-
Cy3 signal in the islets (Figures 5D and 5J). All observed islets were positive for insulin 
staining, indicating that viable, insulin producing islets were analyzed (Figures 5B, E, H 
and K). 
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Figure 5: Binding of GIP-Cy3 (A, D, G, J) and insulin expression (B,E, H, K) in islets of C57Bl/6 WT 
mice and C57Bl/6 GLP-1r -/- mice. Scale bar = 50 µm. 
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Discussion 
In this study, we explored the binding capabilities of a novel GIP-Cy3 probe for the GIPR 
and its potential for in vivo BCI. The probe displayed dose-dependent binding to BHK-
GIPR transfected cells, and GIPR mediated binding to NES2Y cells and isolated mouse 
islets. Despite the promising results in vitro, histological analysis of pancreatic sections 
from in vivo probed mice displayed no detectable fluorescence in the islets of Langerhans. 
Several properties of the GIPR make targeting of this receptor more challenging when 
compared to GLP-1R. Firstly, GIPR expression levels on beta cells are 75% lower than for 
GLP-1R [23]. Secondly, both receptors show different binding kinetics. Gremlich et al. 
showed that GIPR shows saturation after 15-18h [24], while GLP-1R saturation is reached 
much faster [25]. The slow GIPR turnover might hamper sufficient tracer accumulation, 
needed for islet imaging. Another important issue is that GIPR expression has been 
shown not only on beta cells, but also on alpha cells [23], while GLP-1R targeted probing 
does not occur on alpha cells [26]. Therefore, targeting of the GIPR for imaging purposes 
might also visualize non-beta cells. 
Both GLP-1 and GIP are subject to rapid degradation by dipeptidyl peptidase IV (DPP 
IV) [27]. O’Heart et al. showed that several N-terminal modifications of GIP dramatically 
increased the stability of the peptide without compromising its biological action [28, 
29]. Therefore, we acetylated the N-terminus of our GIP probe, attached a fluorophore 
and tested the binding capacities in vitro. Our novel GIP probe showed excellent dose-
dependent receptor binding in BHK-GIPR transfected cells. Moreover, we observed GIPR 
mediated binding of GIP-Cy3 to beta cells from a patient with congential hyperinsulinism 
of infancy (CHI) (NES2Y cells) [20, 21] and isolated islets, both being more representative 
models for GIPR expression levels when compared to BHK-GIPR transfected cells. 
We also observed minimal binding of exendin-4-Cy3 to BHK-GIPR transfected cells, 
indicating low-level affinity of exendin-4 for the GIPR, which is in line with previous 
observations that [125I]-GIP binding can be blocked by competition with exendin-4 and 
that exendin-4 displays activity at the GIPR [22, 24]. This indicates that there exists cross-
talk between the GLP-1R agonist exendin and the GIPR. 
Despite the excellent binding properties of the probe observed in vitro, GIP-Cy3 signal 
was absent in islets of C57BL/6J WT and Glp-1r-/- mice. Several mechanisms underlying 
the physiology of GIP and the GIPR might explain these observations. Firstly, successful 
in vitro binding does not imply in vivo stability. Although GIP showed increased DPP 
IV half-life and insulin stimulation after N-terminal acetylation [29], it might not 
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be sufficient to allow for required tracer accumulation in the islets. Therefore, in vivo 
stability might have to be further improved or in vivo targeting needs to be enhanced. For 
example, co-injection of DPP IV inhibitors might increase the circulation of intact probe 
and improve receptor targeting [30]. Secondly, fluorescent imaging provides specific 
and important information on the behavior of the tracer on a cellular level but exhibits 
lower sensitivity when compared to nuclear imaging modalities such as SPECT and 
PET. Therefore, complementary information originating from both imaging modalities is 
needed to further elucidate the potential of islet imaging via GIPR targeting. 
Conclusion 
A novel GIP-Cy3 probe was found to bind GIPR over-expressing cells in a dose-
dependent manner. Furthermore, the probe showed GIPR mediated binding to human 
NES2Y cells and isolated islets in vitro. However, when the probe was injected in vivo 
into C57BL/6J WT and Glp-1r-/- mice, no islet-specific GIP-Cy3 signal was observed. In 
conclusion, although GIP-Cy3 shows potential for islet imaging, the translation from in 
vitro to in vivo applications needs to be further elucidated. 
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Abstract
Aims: Somatostatin receptor scintigraphy (SRS) is considered the gold standard for 
non-invasive imaging of neuro-endocrine tumors (NET). However, not all NET over-
express somatostatin receptors, or the subtypes relevant for imaging, hampering 
their detection using SRS. Therefore, the search for novel targets to visualize NET, 
expressing low somatostatin receptor levels, is ongoing. Since many of these NET 
have been shown to express the glucose-dependent insulinotropic polypeptide (GIP) 
receptor (GIPR), this receptor might be a novel target for NET imaging. Therefore, 
we investigated whether imaging of NET with DTPA-conjugated GIP labeled with 
In-111 is feasible.
Methods: The N-terminally acetylated GIP analogue [Lys37(DTPA)]GIP1-42 was 
synthesized, labeled with In-111 and the stability of the tracer was assessed in human 
serum. Receptor targeting was investigated in vitro using BHK-GIPR positive tumor 
cells, NES2Y cells and isolated islets of Langerhans of C3H mice. In vivo tumor 
targeting was examined using BALB/c nude mice with a subcutaneous BHK-GIPR 
positive tumors or subcutaneous NES2Y tumors.
Results: [Lys37(DTPA)]GIP1-42 was radiolabeled with a specific activity of up to 
1.2 TBq/µmol and [Lys37(111In-DTPA)]GIP1-42 was stable in human serum. In vitro, 
[Lys37(111In-DTPA)]GIP1-42 showed receptor mediated binding to BHK-GIPR positive 
cells, NES2Y cells and isolated islets. Biodistribution studies revealed optimal tumor 
targeting 4 hours post-injection, using a peptide dose of 0.1 µg. Four hours post-
injection, co-administration of an excess unlabeled peptide lowered GIPR positive 
tumor uptake from 4.2 ± 0.2 %ID/g to 0.8 ± 0.1 %ID/g (p=0.04), indicating GIPR 
mediated binding in vivo. Also in mice with NES2Y tumors, a more relevant model 
for human diseased beta cells, tumor uptake was observed (0.5 ± 0.1 %ID/g). 
Conclusion: [Lys37(DTPA)]GIP1-42 shows receptor mediated binding in vitro in various 
models. Furthermore, the tracer specifically accumulated in BHK-GIPR positive 
tumors and tumor uptake was observed in NES2Y tumors. Therefore, [Lys37(111In-
DTPA)]GIP1-42 appears to be a promising tracer for SPECT imaging of somatostatin 
receptor negative NET. 
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Introduction
Targeting of peptide hormone receptors, expressed on tumors, is a valuable tool for in 
vivo molecular imaging and radionuclide therapy of a variety of neuro-endocrine tumors 
(NET). Successful tumor targeting relies on over-expression of the target receptors on 
cancer cells when compared to their expression levels in healthy tissues [1, 2]. Nowadays, 
somatostatin receptor scintigraphy (SRS) is a standard procedure for the detection of NET 
[3-5] and radionuclide therapy with [90Y]- and [177Lu]-labeled somatostatin analogues 
was proven beneficial for patients with NET [6]. However, not all NET show elevated 
somatostatin receptor expression levels. Therefore, false negative results may occur in 
all types of NET and SRS displays limited sensitivity for some types of NET, such as 
insulinomas [3, 5, 7] and medullary thyroid carcinoma (MTC) [8], for which the detection 
rate is below 40-60%.
A variety of alternative peptide receptors, such as cholecystokinin (CCK) receptors [9], 
vasoactive intestinal peptide (VIP) receptor [10] and glucagon-like peptide 1 (GLP-
1) receptor [11] are expressed on NET. Recent findings showed glucose-dependent 
insulinotropic polypeptide (GIP) receptor expression in gastric, duodenal and bronchial 
NET [12, 13]. Furthermore, approximately 90% of somatostatin receptor negative NET 
are GIP receptor (GIPR) positive [13]. In 2013, Sherman et al. pointed out that the GIPR is 
a promising target for NET imaging and therapy due to its favorable expression pattern 
[14] and the feasibility of GIPR targeting was shown in a GIPR over-expressing tumor 
model using a truncated GIP analogue [15]. 
GIP is secreted from the intestinal K cells after nutrient ingestion [16] and together with 
GLP-1, it enhances glucose-induced insulin secretion upon receptor binding on pancreatic 
beta cells, the so-called incretin effect [17, 18]. Since insulinomas are NET derived from 
pancreatic beta cells, the incretin receptors are expected to be ideal candidate receptors 
for insulinoma imaging. Indeed, GLP-1R targeting tracers such as [68Ga]- or [111In]-labeled 
exendin, can be applied for non-invasive in vivo insulinoma detection [19-21]. However, 
since malignant insulinomas display a differential expression pattern regarding GLP-1R 
and somatostatin receptors [22], the detection rate of these tumors remains limited to 50% 
by scintigraphy. Interestingly, GLP-1R negative malignant insulinomas and a majority of 
somatostatin negative NET express enhanced GIPR levels [13], rendering this receptor an 
interesting target for NET and insulinoma imaging. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Ch
ap
ter
 8
128
In this study, we have investigated the potential of a newly synthesized GIP analogue 
(Lys37(111In-DTPA)]GIP1-42) as a radiotracer for NET imaging, with a focus on insulinomas. 
Therefore, we optimized the radiolabeling procedure and investigated its binding and 
internalization kinetics using GIPR positive tumor cells. Furthermore, we have explored 
the tracers binding capacities for NES2Y cells, a human beta cell derived cell line, and 
isolated islets. Finally, the biodistribution of [Lys37(111In-DTPA)]GIP1-42 was determined 
in subcutaneous BHK-GIPR positive tumors and, more importantly, in mice with 
subcutaneous NES2Y tumors, a clinically relevant tumor model in terms of receptor 
expression.
Materials and Methods 
Peptides and Radiolabeling 
[Lys37(DTPA)]GIP1-42 and GIP1-42 were purchased from Peptide Specialty Laboratories 
(PSL GmbH, Heidelberg, Germany). DTPA was conjugated to the ε-amino group of 
the Lysine (K37) and the N-terminal Tyrosine was acetylated. [Lys37(DTPA)]GIP1-42 was 
dissolved in 0.5 M MES (2-(N-morpholino)ethanesulfonic acid) buffer, pH 5.5 and stored 
at 4°C until use. 150 MBq [111In]Cl3 (Mallinckrodt Pharmaceuticals, ‘s Hertogenbosch, The 
Netherlands) was added to 1 µg Lys37(DTPA)]GIP1-42 together with 5 volumes of 0.5 M MES 
buffer, pH 5.5 and incubated for 20 minutes at room temperature (RT). After incubation, 
EDTA (Sigma Aldrich, St. Louis, MO, USA) and Tween80 (Sigma Aldrich) were added 
to a final concentration of 5 mM and 0.1%, respectively. The labeling was purified by 
solid-phase extraction using a hydrophilic-lipophilic balance (HLB) cartridge (30 mg, 
Water Oasis, Milford, MA, USA), to eliminate unincorporated In-111. The cartridge was 
activated with 1 ml ethanol, washed with 2 ml water and conditioned with 1 ml of 0.5 M 
MES, pH 5.5. Subsequently, the cartridge was loaded with the labeling mixture, washed 
with 1 ml 0.5 M MES and 2 ml water and Lys37(111In-DTPA)]GIP1-42 was eluted from the 
cartridge with 200 µl 100% ethanol. For in vivo use, the purified labeled peptide was 
diluted in phosphate buffered saline (PBS), 0.5% bovine serum albumin (BSA) (w/v) to 
obtain a final ethanol concentration of less than 10%. Radiochemical purity of [Lys37(111In-
DTPA)]GIP1-42 was determined by instant thin-layer chromatography (ITLC) (ITLC-SG, 
Agilent Technologies, Lake Forest, CA, USA), using 0.1 M EDTA in 0.1 M NH4Ac (Sigma 
Aldrich), pH 5.5 as a mobile agent and by reversed-phase high performance liquid 
chromatography (RP-HPLC) using an Eclips XDB C18 column (Agilent Technologies). 
The column was eluted with 0.1% trifluoroacetic acid (TFA) in H2O (0-5 minutes) followed 
by a linear gradient from 3% to 100% acetonitrile with 0.1% TFA over 10 minutes (flow 
rate: 1 ml/minute). 
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Serum Stability Determination 
To investigate the in vitro stability of [Lys37(111In-DTPA)]GIP1-42, [Lys37(DTPA)]GIP1-42 was 
labeled with [111In]Cl3 with a specific activity of 27 GBq/µmol. The radiochemical purity 
of [Lys37(111In-DTPA)]GIP1-42 directly after labeling was determined by ITLC-SG (Agilent 
Technologies) and RP-HPLC as described above. The labeling mixture was incubated in 
human serum (1:10) at 37°C. After 1, 2, 4 and 24 hours, the radiochemical purity of the 
compound was analyzed using ITLC and RP-HPLC as previously described. 
Cell Culture 
Baby hamster kidney cells, transfected with the human GIP (BHK-hGIPR transfected 
cell line) were maintained in DMEM Glutamax (cat. Nr. 6195, GIBCO, BRL Life Sciences 
Technologies, Bleiswijk, The Netherlands) supplemented with 10% fetal bovine 
serum (FCS), (HyClone, Celbio, Logan, UT, USA) and 1 mg/ml G418, in a humidified 
atmosphere containing 5% CO2 at 37°C. The human beta cell line NES2Y was cultured 
as described previously [23, 24]. In short, cells were maintained in RPMI 1640 (R0883, 
GIBCO) supplemented with 10% FCS, (HyClone, Celbio), 2 mM L-glutamine (Sigma 
Aldrich, St Louis, MO, USA), 100 U/ml penicillin (Sigma Aldrich) and 100 µg/ml 
streptomycin (Sigma Aldrich) (complete RPMI), in a humidified atmosphere containing 
5% CO2 at 37°C.
IC50 Determination 
The 50% inhibitory concentration (IC50) of [Lys
37(111In-DTPA)]GIP1-42 was determined 
using NES2Y cells. NES2Y cells were seeded at a density of 200,000 cells/well in 24-
well plates and incubated overnight at 37°C. The cells were washed with binding buffer 
(RPMI + 0.5% BSA (w/v)) and [Lys37(DTPA)]GIP1-42 was added at a final concentration 
ranging from 1.0 – 100 µM along with radiolabeled [Lys37(111In-DTPA)]GIP1-42 (1.6 kBq = 
2.7 fmol). After incubation, cells were washed with binding buffer and the cell-associated 
activity was measured in a well type gamma counter (Wallac 2480 wizard, Perkin Elmer). 
Under these conditions, internalization may occur. We therefore designate the results of 
this competitive binding assay as “apparent IC50” values rather than IC50. 
In Vitro Internalization
The internalization kinetics of [Lys37(111In-DTPA)]GIP1-42 were determined as previously 
described [25] using BHK-GIPR transfected cells and NESY cells. BHK-GIPR transfected 
cells and NES2Y cells were seeded in 24-well plates with a density of 50,000 and 200,000 
cells/well, respectively and incubated overnight at 37°C. The cells were washed with 
binding buffer and incubated with approximately 1.6 kBq [Lys37(111In-DTPA)]GIP1-42 (2.7 
fmol) for 1, 2, 4 and 24 hours at 37°C. After incubation, the cells were washed twice 
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with binding buffer. To determine the surface-bound [Lys37(111In-DTPA)]GIP1-42 fraction, 
ice-cold acid buffer (0.1 M acetic acid, 154 mM NaCl, pH 2.5) was added and cells were 
incubated for 10 minutes at 4°C. After washing the cells twice with binding buffer, the 
cell-associated activity was measured in a well type gamma counter. The internalized 
fraction (cell-associated activity after acid wash) and the receptor bound fraction (activity 
removed by acid wash) were determined.
Animals
All animal experiments were approved by the Animal Welfare Body of the Radboud 
University, Nijmegen and carried out in accordance with their guidelines. Six to eight 
weeks old, female BALB/c nude mice and C3H mice were purchased from Janvier labs 
(Le Genest Saint Isle, France).
Islet Isolation
Islets of Langerhans were isolated from donor C3H mice by collagenase digestion as 
described previously [26]. Briefly, mice were euthanized by CO2/O2 suffocation and 
2 ml of ice cold RPMI 1640 containing 1 mg/ml collagenase type V (Sigma Aldrich) 
was injected into the pancreas via the common bile duct. Dissected pancreata were 
digested for 12 minutes at 37°C. Islets were purified on a discontinuous Ficoll gradient 
(densities 1.108, 1.096 and 1.037 g/ml) (Cellgro by Mediatech Inc, Manassas, VA, USA) 
by centrifugation at 625 x g for 16 minutes without brake. Islets were collected from the 
intersection of the second and third layer and cultured overnight at 37°C with 5% CO2 in 
complete RPMI medium.
In Vitro Binding to Isolated Islets
After overnight recovery, islets were collected, counted and resuspended in complete 
RPMI. After transwell saturation, using binding buffer, islets were transferred to 24 well 
transwell plates (200 islets per transwell) (Corning Inc. Tewksbury, MA, USA) and washed 
with binding buffer. Subsequently, approximately 8 kBq [Lys37(111In-DTPA)]GIP1-42 (13.5 
fmol) was added followed by incubation for 24 hours at 37°C. To investigate the GIPR 
mediated binding, 25 µg of unlabeled GIP1-42 (PSL GmbH, Heidelberg, Germany) was 
added together with [Lys37(111In-DTPA)]GIP1-42 in a separate set of wells. After incubation, 
islets were washed extensively with binding buffer and islet-associated radioactivity was 
measured in a well type gamma counter. 
Peptide Dose Escalation Study 
Six to eight weeks old female BALB/c nude mice were injected subcutaneously in the 
right shoulder with 0.2 ml of a 2.5 x 107 cells/ml suspension of BHK-GIPR transfected 
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cells. When the tumor reached a diameter of 2-5 mm, mice were randomly divided in 
groups of 5 mice each. To determine the optimal peptide dose of [Lys37(DTPA)]GIP1-42 for 
tumor targeting in this model, mice were injected intravenously with 5 MBq [Lys37(111In-
DTPA)]GIP1-42 in the tail vein and were co-injected with escalating amounts of unlabeled 
GIP1-42, resulting in final peptide doses ranging from 0.1 to 2 µg/mouse. Four hours after 
injection, mice were euthanized by CO2/O2 suffocation, and tumors and other relevant 
tissues (heart, muscle, lung, spleen, pancreas, kidney, liver, stomach and duodenum) 
were dissected, weighed and measured in a well type gamma counter. The percentage 
injected dose per gram of tissue (%ID/g) was determined for each tissue. 
Biodistribution Studies
Six to eight weeks old female BALB/c nude mice were injected subcutaneously in the 
right shoulder with 0.2 ml of a 2.5 x 107 cells/ml suspension of BHK-GIPR transfected 
cells. When the tumor reached a diameter of 2-5 mm, mice were randomly divided in 
groups of 5 mice each. Mice were injected intravenously with 5 MBq (peptide dose 0.2 
µg) of [Lys37(111In-DTPA)]GIP1-42 via the tail vain. At various time points after injection 
(1, 4 and 24 hours), mice were euthanized by CO2/O2 suffocation and blood, tumor and 
other relevant tissues were dissected, weighed and measured in a well type gamma 
counter. The percentage injected dose per gram (%ID/g) was determined for each 
tissue. To determine whether the GIP1-42 uptake was GIPR mediated, 25 µg of unlabeled 
GIP1-42 was co-injected in a separate group of mice (n=3). To determine tracer uptake in 
a more representative model for NET, the biodistribution of [Lys37(111In-DTPA)]GIP1-42 
was determined in BALB/c nude mice bearing NES2Y tumors. Six to eight weeks old 
female BALB/c nude mice were injected subcutaneously in the right shoulder with 0.2 
ml of a 2.5 x 107 cells/ml suspension of NES2Y cells and with 0.2 ml of a 2.5 x 107 cells/
ml suspension of NES2Y cells containing matrigel (2:1) in the left shoulder (n=3). When 
the tumor reached a diameter of 2-5 mm, mice were injected intravenously with 5 MBq 
[Lys37(111In-DTPA)]GIP1-42 (peptide dose 0.5 µg) via the tail vain. Four hours after injection, 
mice were euthanized by CO2/O2 suffocation and blood, tumor and other relevant tissues 
were dissected, weighed and measured in a well type gamma counter. The percentage 
injected dose per gram (%ID/g) was determined for each tissue.
 
Statistics 
All mean values are expressed as mean ± standard deviation (SD). Statistical analysis 
was performed using unpaired two-tailed t-test using GraphPad Prism v5.03 (GraphPad 
Software Inc., San Diego, CA, USA). The level of significance was set at p<0.05. 
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Results
Radiolabeling 
[Lys37(DTPA)]GIP1-42 could be labeled with In-111 with a specific activity of up to 1.2 TBq/ 
µmol. Radiochemical purity exceeded 95% as determined by RP-HPLC and ITLC. Figure 
1 shows the HPLC analysis of the labeling mixture. [111In]-EDTA eluted with a retention 
time of 3 minutes, whereas [111In]-labeled [Lys37(DTPA)]GIP1-42 had a retention time of 14 
minutes. After 12 minutes, a very small impurity (< 2%) eluted from the column. 
Figure 1: Radiochemical purity analysis of [Lys37(111In-DTPA)]GIP1-42 as determined by HPLC, 
immediately after labeling
Serum Stability 
Since GIP is known to be prone for inactivation by dipeptidyl peptidase IV (DPP IV), the 
stability of [Lys37(111In-DTPA)]GIP1-42 was analyzed in human serum. The results of this 
stability analysis are shown in Figure 2. Up to 4 hours of incubation in human serum, 
the [111In]-labeled [Lys37(DTPA)]GIP1-42 remained intact. After 24 hours of incubation 
in human serum, 73% of the activity was still found as intact radiolabeled peptide, as 
determined by HPLC. This decrease was mainly caused by radionuclide release from 
the chelator (20%) and to a lesser extent to increase of the impurity peak (7%), a more 
hydrophilic metabolite of [Lys37(111In-DTPA)]GIP1-42.
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Figure 2: Stability analysis of [Lys37(111In-DTPA)]GIP1-42. A) HPLC profile of [Lys37(111In-DTPA)]
GIP1-42 after 24 hours of incubation in human serum. The first peak represents the unbound In-111, 
the second peak represents radiolabeled degraded peptide and the third peak is the intact and 
radiolabeled GIP1-42. B) Overview of stability behavior after various incubation times in human 
serum. 
IC50 Determination 
The results of the IC50 determination are shown in Figure 3. The apparent IC50 of [Lys
37(111In-
DTPA)]GIP1-42 is 4.8 µM (95% confidence interval: 0.7 – 32.8 µM). 
Figure 3: Competition binding assay (apparent IC50) of [Lys37(DTPA)]GIP1-42 on NES2Y cells. 
[Lys37(111In-DTPA)]GIP1-42 was used as a radiotracer 
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Binding and Internalization Kinetics 
Figure 4 summarizes the binding and internalization kinetics of [Lys37(111In-DTPA)]GIP1-42 
by BHK-GIPR transfected cells and NES2Y cells as determined in vitro. Both cell lines 
displayed similar binding and internalization characteristics. After 1 hour, 0.6 ± 0.1% and 
0.6 ± 0.02% of the added [Lys37(111In-DTPA)]GIP1-42 was bound to BHK-GIPR transfected 
cells and NES2Y cells, respectively. At this time point, the internalization rates were 1.1 
± 0.1% and 1.5 ± 0.3%, respectively. After 24 hours, the binding values had increased to 
13.8 ± 1.7% and 8.6 ± 1.5%, respectively and the internalization values to 4.2 ± 0.6% and 
4.7 ± 3.6% for BHK-GIPR and NES2Y cells, respectively. All values were corrected for 
non-specific binding, as determined by the addition of 25 µg unlabeled GIP1-42 which 
significantly reduced the binding and internalization at all time points, indicating GIPR 
mediated binding in both cell lines (p<0.05). 
Figure 4: In vitro binding and internalization kinetics of [Lys37(111In-DTPA)]GIP1-42 in BHK-GIPR 
transfected cells and NES2Y cells. The cell bound and internalized fractions are corrected for non-
specific binding and accumulation, as determined by co-incubation with an excess unlabeled GIP1-42
Binding of [Lys37(111In-DTPA)]GIP1-42 to Isolated Islets
Figure 5 shows the in vitro binding characteristics of [Lys37(111In-DTPA)]GIP1-42 to 200 
isolated islets of C3H mice. After 24 hours, 0.22 ± 0.01 % fmol [Lys37(DTPA)]GIP1-42 was 
bound to the islets. Addition of 25 µg unlabeled GIP1-42 reduced the binding to 0.03 ± 0.01 
fmol, indicating specific binding of the tracer to the GIPR on the islets of Langerhans. 
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Figure 5: Binding of [Lys37(111In-DTPA)]GIP1-42 to isolated islets. The solid bar represents the binding 
of [Lys37(111In-DTPA)]GIP1-42. The white bar represents the binding of [Lys37(111In-DTPA)]GIP1-42 in the 
presence of an excess GIP1-42
Tumor Growth 
Since the in vivo use, as subcutaneous tumors, of neither of the applied cell lines has been 
described in literature, we analyzed the in vivo growth patterns of both tumors in nude 
mice. BHK-GIPR transfected cells showed rapid tumor growth. After subcutaneous 
injection of 5 x 106 BHK-GIPR transfected cells, tumors reached a diameter of 2-5 mm after 
approximately 10 days. After injection of 5 x 106 NES2Y cells, tumors with a diameter of 
2-5 mm were only obtained 7 weeks after injection of the cells. Therefore, tumor growth 
was analyzed using a suspension of cells and matrigel. Three weeks after injection of 5 x 
106 NES2Y cells, dissolved in matrigel (2:1), tumors reached the desired dimensions (2-5 
mm diameter). 
Peptide Dose Escalation Study
The effect of the peptide dose on tumor targeting was studied in BALB/c nude mice with 
subcutaneous BHK-GIPR tumors and the results are summarized in Figure 6. The GIP1-42 
dose had a pronounced effect on uptake in the tumor: tumor uptake decreased at higher 
peptide doses (Figures 6A and B). Highest tumor uptake of [Lys37(DTPA)]GIP1-42 was 
observed when 0.2 µg peptide was administered per mouse: 5.2 ± 1.4 %ID/g at 4 hours 
post-injection. Administration of 0.5 µg [Lys37(DTPA)]GIP1-42 resulted in a significantly 
lower tumor uptake: 2.4 ± 0.7 %ID/g (p=0.008) (Figure 6B). At a peptide dose of 0.1 µg, 
the tumor-to-blood ratio was 143.4± 15.8 which is significantly higher than the tumor-
to-blood ratio observed at a peptide dose of 0.2 µg (109.76 ± 13.06) (p=0.03) (Figure 6C). 
The difference in absolute tumor uptake using 0.1 or 0.2 µg as a peptide dose was not 
significant (Figure 6B) (p=0,55). Four hours post-injection, [Lys37(111In-DTPA)]GIP1-42 also 
showed uptake in various organs such as the lung, spleen, pancreas, liver, stomach and 
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duodenum. The extremely high uptake in the kidneys is caused by renal excretion and 
re-absorption of the tracer by the glomeruli. 
Figure 6: A) Peptide dose escalation study in BALB/c nude mice with subcutaneous BHK-GIPR 
tumors. Mice were injected with 5 MBq [Lys37(111In-DTPA)]GIP1-42 and were co-injected with various 
amounts of unlabeled DTPA-GIP1-42, resulting in a final concentration ranging from 0,1 to 2,0 µg 
GIP1-42. Values are expressed as percentage injected dose per gram tissue (%ID/g) (n=5). Mice 
were dissected 4 hours post-injection. B) Tumor uptake of [Lys37(111In-DTPA)]GIP1-42 using different 
peptide doses. Tumor uptake was significantly higher (**p=0.008) at peptide doses smaller than 0.5 
µg. C) Tumor-to-blood ratios of [Lys37(111In-DTPA)]GIP1-42 using different peptide doses. Tumor-to-
blood ratio is significantly higher using 1 µg (*p=0.03). 
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Biodistribution Studies of [Lys37(111In-DTPA)]GIP1-42 
Figure 7 summarizes the biodistribution of [Lys37(111In-DTPA)]GIP1-42 in BALB/c nude 
mice, bearing a subcutaneous BHK-GIPR transfected tumor. One hour after injection, 
highest tumor uptake was observed: 5.3 ± 0.8 %ID/g. After 4 and 24 hours, tumor 
uptake decreased to 4.2 ± 0.2 %ID/g and 1.9 ± 0.3 %ID/g, respectively (Figure 7A). Co-
administration of an excess unlabeled GIP1-42 significantly lowered tumor uptake to 0.8 
± 0.1 %ID/g (p=0.04) 4 hours after injection, indicating GIPR mediated tumor uptake. 
Tumor-to-blood ratios increased from 19.6 ± 6.3 to 109.6 ± 15.5 for 1 and 4 hours after 
injection, respectively (p=0.008) (Figure 7B). After 24 hours, tumor-to-blood ratio had 
increased to 141.5 ± 21.0 but this did not result in a significant difference when compared 
to 4 hours after injection (p=0.06). 
Figure 7: A) Biodistribution study of [Lys37(111In-DTPA)]GIP1-42 in BALB/c nude mice, bearing a 
subcutaneous BHK-GIPR tumor at 1, 4 and 24 hours after tracer injection. Values are expressed as 
percentage injected dose per gram tissue (%ID/g) (n=5). Blocking was performed by co-injected of 
25 µg unlabeled GIP1-42 (n=3). B) Tumor-to-blood ratios at 1, 4 and 24 hours tracer injection. Tumor-
to-blood ratio is significantly higher at 4 hours post-injection (**p=0.008). 
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Figure 8 summarizes the biodistribution of [Lys37(111In-DTPA)]GIP1-42 in BALB/c nude 
mice, bearing NES2Y tumors. Four hours after injection, no difference in tracer uptake 
could be observed in tumors with and without matrigel. Tumor uptake was 0.48 ± 
0.08 %ID/g and 0.49 ± 0.08 %ID/g for tumors with and without matrigel, respectively 
resulting in tumor-to-blood ratios of 16.6 ± 0.01 and 16.9 ± 0.02, respectively. 
Figure 8: Biodistribution study of [Lys37(111In-DTPA)]GIP1-42 in BALB/c nude mice, bearing 
subcutaneous NES2Y tumors with and without matrigel (n=3). Values are expressed as percentage 
injected dose per gram tissue (%ID/g). 
Discussion 
In this study, we investigated the potential of [Lys37(111In-DTPA)]GIP1-42 for the detection 
of NET. The tracer showed GIPR mediated binding to both BHK-GIPR positive cells and 
NES2Y cells, and to isolated islets in vitro. Optimal GIPR mediated tumor targeting of 
BHK-GIP receptor-positive tumors in vivo, was observed 4 hours post-injection using 0.1 
µg as a peptide dose. Furthermore, in vivo tracer accumulation was observed in NES2Y 
tumors.
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It has been described that C-terminally truncated GIP analogues, such as GIP1-30, exhibit 
reduced receptor binding affinity when compared to intact GIP1-42, while retaining their 
full insulinotropic effect [27, 28]. Since the goal of this study was to apply the analogue 
for in vivo imaging, high receptor affinity should be preserved rather than the biological 
activity. Therefore, we selected GIP1-42 as a basis for our radiotracer. Another point of 
consideration while designing a GIPR targeting radiotracer, is the susceptibility of 
the peptide to DPP IV degradation [29]. Since it was shown that several N-terminal 
modifications showed increased half-life in vitro [30, 31], we acetylated the N-terminal 
tyrosine residue to obtain a tracer that is better resistant to degradation by DPP IV. Indeed, 
we observed that the tracer remained stable in serum even after 24 hours of incubation.
In order to obtain high quality images, high target-to-background ratios are required. 
Tracer metabolites labeled with a radio-metal via a chelator, such as DTPA, can be 
trapped in the lysosomes upon tracer internalization and degradation, resulting in 
elevated tracer accumulation in the target cells [20, 32]. Therefore, we investigated tracer 
internalization rates in vitro. Internalization kinetics of the tracer were comparably slow: 
after 24 hours, both BHK-GIPR positive and NES2Y cell showed similar internalization 
rates of 4.2 ± 0.6 %ID/g and 4.7 ± 3.6 %ID/g, respectively. Interestingly, the majority of 
the tracer was bound to the cell surface in both cell lines. These observations might be 
explained by very recent findings of Ismail et al. indicating that N-terminal acetylation of 
the peptide hampers receptor internalization [33]. 
In BHK-GIPR positive tumors, GIP1-42 doses lower than 0.5 µg resulted in maximal tumor 
accumulation. This indicates that administration of higher peptide doses results in 
partial saturation of the GIPR. However, since the tracer could be labeled with a specific 
activity up to 1.2 TBq/µmol, administration of a sufficient imaging dose should not be a 
problem. For in vivo SPECT imaging, high tumor-to-blood ratios are required. Since we 
observed a significant difference in tumor-to-blood ratios at peptide doses of 0.2 µg (110 
± 13) and 0.1 µg (143± 16) (p=0.03) due to increased tracer levels in the blood at higher 
dose, 0.1 µg is considered the optimal peptide dose for in vivo imaging. 
Although [Lys37(111In-DTPA)]GIP1-42 showed high tumor uptake in BHK-GIPR positive 
tumors, tumor uptake in NES2Y tumors was lower and several tracer characteristics 
might be optimized to further improve tumor targeting. Firstly, other N-terminal 
modifications than acetylation have been shown to improve the peptides half-life in the 
presence of DPP IV [30, 31]. Application of other methods to modify the N-terminus 
of the peptide, such as the insertion of glucitol or pyroglutamil, might also result in 
higher internalization rates of the tracer. Secondly, receptor binding and internalization 
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might increase with longer circulation times. As shown in our biodistribution studies, 
[Lys37(111In-DTPA)]GIP1-42 is cleared from the blood rather rapidly, hampering longer 
tracer circulation and thus higher tumor uptake. Several methods such as PEGylation, 
mulitimerization or introduction of a free fatty acid tails might increase circulation time 
[34] and thereby tracer accumulation in the tumor. However, a good balance between 
tracer retention in blood and tracer targeting dynamics has to be found in order to obtain 
favorable target-to-background ratios for in vivo imaging.
Conclusion 
[Lys37(111In-DTPA)]GIP1-42 was produced with high specific activity. The tracer showed 
specific, receptor mediated binding to various GIPR expressing cells in vitro. Subcutaneous 
BHK-GIPR positive tumors showed GIPR mediated tracer accumulation with optimal 
in vivo targeting 4 hours post-injection, using a peptide dose of 0.1 µg. Also in NES2Y 
tumors, specific uptake could be demonstrated in vivo. We believe that modifications of 
this tracer, leading to better internalization or bioavailability, might further improve in 
vivo tumor targeting. In conclusion, [Lys37(111In-DTPA)]GIP1-42 shows promising results as 
a radiotracer for NET imaging. 
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PART V: 
GENERAL DISCUSSION 
AND SUMMARY

CHAPTER 9 
General Discussion and Future Perspectives 
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Although diabetes is a disease that has already been known for over 1000 years, and 
despite major research efforts by scientists around the world, many questions about 
the pathogenesis and progression of diabetes remain unanswered. Nowadays, over 
350 million people suffer from diabetes worldwide and its prevalence is still rising. 
Although the available treatments, such as anti-diabetogenic drugs and daily insulin 
injections, offer very good glycemic control, diabetes patients remain at risk for severe 
complications, increasing their risk for premature death. Pancreatic islet transplantation 
is a novel, promising treatment for type 1 diabetic patients potentially offering them a 
more permanent solution. Unfortunately, islet transplantation still results in short term 
insulin-independence and less than 15% of the patients are insulin-free 5 years after 
transplantation [1, 2]. 
Currently, the beta cell mass (BCM) in both the native pancreas and islets grafts is 
monitored using measures of beta cell function (BCF) such as C-peptide, HbA1c levels and 
insulin. It was shown however, that BCF does not always correlate with the remaining 
BCM [3, 4]. Unfortunately, the majority of our information on BCM in diabetes is obtained 
from post-mortem autopsy studies while dynamic in vivo BCM data are sparse [4]. Non-
invasive imaging techniques, allowing longitudinal and quantitative monitoring of BCM, 
could help to unravel the role of BCM dynamics during the course of diabetes and might 
provide crucial information on the metabolic state of the islet graft after transplantation. 
In the future, non-invasive islet graft imaging might even help to improve the outcome 
of this promising therapeutic approach. In this thesis, three receptors expressed, on the 
islets of Langerhans, are (further) characterized as targets for in vivo beta cell imaging 
both in the native pancreas and after islet transplantation. Here, the main findings of this 
thesis will be discussed. 
The choice of a suitable rodent model is crucial to study BCM dynamics using [111In]-
exendin. Although it was shown that [111In]-exendin can detect small BCM changes in a 
preclinical model of beta cell loss [5], further validation of GLP-1R radionuclide imaging 
for evaluation of BCM dynamics in animal models is required. Various animal models 
have been used to investigate BCM dynamics in vivo, but many differences in tracer 
uptake in relation to BCM were observed when using different animal models. In order 
to obtain data, which allow translation to humans, the ideal model should adequately 
mimic the human situation namely: high and specific uptake in the islets of Langerhans 
(beta cells) and low uptake in the exocrine pancreas. The findings presented in this 
study clearly indicate that these features are better reflected in rat models than in mouse 
models. In contrast to humans and rats, mice exhibit receptor mediated [111In]-exendin 
uptake in the exocrine pancreas, which explains the limited reduction of tracer uptake 
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after alloxan-induced beta cell destruction. Nevertheless, there was no detectable GLP-1R 
expression in exocrine pancreatic tissue of mice, as determined immunohistochemically, 
and only very low Glp-1r mRNA expression was observed by RT-PCR, suggesting that 
[111In]-exendin probably binds to a different receptor than the GLP-1R in the exocrine 
pancreas of mice. A variety of receptors showing homology with the GLP-1R such as 
the glucagon receptor, the GLP-2R, the GIP receptor and many more, are candidate 
receptors that might be responsible for this exocrine [111In]-exendin binding in mice. In 
the future, extensive RT-PCR analysis might help to identify the receptor responsible for 
this interesting observation. Taken together, these findings preclude the use of mice as an 
animal model for further characterization of BCM dynamics using radiolabeled exendin. 
Of the investigated rat models, Brown Norway rats display the best characteristics for 
non-invasive BCM assessment using [111In]-exendin, in view of their favorable pancreas-
to-background ratios and the confirmed beta cell specific tracer accumulation in this 
model. In the future, co-injection of a second radiotracer, targeting the exocrine pancreatic 
tissue such as [99mTc]-demobesin (unpublished data), might facilitate exact delineation of 
the pancreas and therefore improve accurate quantification of pancreatic [111In]-exendin 
uptake. 
[111In]-exendin SPECT can accurately visualize islet grafts non-invasively. The GLP-1R 
did not only appear useful for BCM determination in the native pancreas. Also engrafted 
islets have been visualized using GLP-1R targeting PET tracers [6]. To fully exploit the 
potential of this technique, characterization of BCM quantification in islet grafts using 
[111In]-exendin is required. Tracer binding correlated with the amount of islets in vitro 
and a clear difference in SPECT signal was observed between rats transplanted with 400 
and 800 islets, respectively. These findings demonstrate that [111In]-exendin SPECT is a 
suitable method for in vivo imaging of islet, engrafted in the calf muscle, providing real-
time information about the amount of viable beta cells in the islet graft. Furthermore, 
[111In]-exendin SPECT seems suitable for serial imaging and quantification of tracer 
uptake in the graft, allowing longitudinal quantitative monitoring of engrafted islets. 
Indeed, a follow up study performed by Eter et al. (unpublished data) showed a linear 
correlation between [111In]-exendin SPECT signal in the graft and the viable graft volume 
as determined histologically. Although the muscle is a relevant preclinical transplantation 
site, the standard clinical transplantation procedure is islet infusion via the portal vein, 
where islets are trapped in the sinusoidal capillaries of the liver. The low background 
uptake of [111In]-exendin in the liver and its high specificity for the target provide the 
possibility to image islets after liver engraftment. However, since islets are dispersed 
throughout the liver during transplantation, detection efficiency might be hampered due 
to partial volume effects. Further investigations will have to rule out the tracers potential 
for liver graft imaging. 
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[123I]IBZM specifically targets dopamine 2 receptors on the beta cells and allows 
non-invasive, longitudinal and quantitative islet graft monitoring. Since the islets of 
Langerhans are of neuronal origin, some neurotransmitters, found in the central nervous 
system, are expressed in the endocrine pancreas [7]. Dopamine 2 (D2) receptors are 
specifically expressed on pancreatic beta cells, where they mediate insulin secretion 
via a negative feedback loop [8, 9]. One possible tracer to target the D2 receptor is 
[123I]Iodobenzamide ([123I]IBZM), a molecule that was extensively used for D2 receptor 
mapping and imaging in neurodegenerative diseases [10-12]. Consequently, [123I]IBZM 
may be a promising candidate for beta cell imaging. In 1988, Kung et al. described an 
iodination procedure for IBZM [13]. This procedure was now optimized to produce high 
yields of the isomer showing the highest receptor affinity. This improved iodination 
protocol allows facile, high yield and low cost [125I]IBZM production. Subsequently, the 
feasibility of imaging islet grafts in the calf muscle using [123I]IBZM was investigated. 
In view of the D2 receptor mediated binding of [125I]IBZM to isolated islets in vitro and 
the distinct tracer uptake in the transplant on the SPECT images, it was demonstrated 
that this tracer has potential to monitor viability of islet grafts following transplantation. 
Indeed, the SPECT signal originating from the islet grafts correlated well with viable 
graft volume and reproducible monitoring of the islet graft was shown over time. 
These results clearly indicate that [123I]IBZM SPECT can detect differences in viable 
graft volume and can be employed for longitudinal graft monitoring. After islet 
transplantation in a diabetic patient, the remaining viable graft volume is responsible 
for maintenance of exogenous insulin independence. Therefore, in vivo determination 
of viable graft volume is important to monitor the metabolic state of the islet graft. In 
the future this technique could offer the possibility to evaluate novel interventions to 
improve long-term transplantation outcome. A major drawback of D2 receptor targeting 
for beta cell imaging is high tracer uptake in the exocrine pancreas, precluding the use of 
[123I]IBZM as a tracer for BCM determination in the native pancreas. Furthermore, 
[123I]IBZM shows considerable liver uptake, precluding its use for islet graft imaging in 
the liver. Nevertheless, since the clinical interest in intramuscular islet transplantation 
is rising [14] and represents a suitable preclinical model, the limited capacities of D2 
receptor imaging for liver grafts, may no longer be a major drawback.
Fluorescent and radiolabeled GIP tracers show potential for non-invasive imaging 
of beta cells and neuro-endocrine tumors. Together with GLP-1, GIP is responsible 
for the incretin effect [15, 16], potentiating glucose-stimulated insulin secretion upon 
receptor binding in the islets of Langerhans. The expression of the GIP receptor (GIPR) 
on the beta cells and its suggested involvement in diabetes pathogenesis [17], render 
this receptor an interesting, potential target for in vivo beta cell imaging. However, one 
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should keep in mind that some specific features of the GIPR render its application as 
a beta cell target challenging. For example, GIPR expression in the islets is 75% lower 
as compared to GLP-1R expression [18]. Furthermore, slow receptor turnover might 
hamper sufficient tracer accumulation and target-to-background ratios, required for 
successful beta cell imaging. Another important issue is that GIPR expression has not 
only been shown on beta cells but also on alpha cells [18]. Therefore, targeting of the 
GIPR for islet imaging purposes might also visualize alpha cells. Nevertheless, it might 
still be a valuable tool for islet imaging instead of beta cell imaging. Indeed GIP-Cy3, 
a novel fluorescent GIP tracer developed by Novo Nordisk, showed dose-dependent 
binding to Baby Hamster Kidney cells transfected with the human GIPR (BHK-GIPR), 
and GIPR mediated binding to NES2Y cells (a human beta cell-derived cell line) and 
isolated mouse islets. Nevertheless, no islet-specific GIP-Cy3 signal could be observed 
in WT C57Bl/6 mice nor in C57Bl/6 Glp-1r -/- mice after subcutaneous injection in vivo, 
indicating that the translation from in vitro observations to in vivo applications needs 
to be further elucidated. Although fluorescent images might provide specific and 
important information on tracer behavior on the cellular level, detection of fluorescence 
exhibits lower sensitivity when compared to radionuclide imaging techniques such as 
PET and SPECT. Complementary information, originating from both fluorescent and 
radionuclide imaging, could help to further elucidate the potential of GIPR targeting 
for islet imaging. Therefore, the novel GIPR targeting tracer [111In]-GIP1-42 was developed 
and its application for non-invasive, in vivo imaging of neuro-endocrine tumors (NET), 
such as insulinomas, was characterized. [111In]-GIP1-42 showed receptor mediated binding 
to both BHK-GIPR cells and NES2Y cells, a more clinically relevant cell line, and also to 
isolates mouse islets in vitro. In vivo, optimal tumor targeting was reached 4 hours post-
injection, using a peptide dose of 0.1 µg. Since the tracer could be radiolabeled with a 
specific activity up to 1.2 TBq/µmol, administration of a sufficient imaging dose should 
not be a problem when using this small peptide dose. Although the tracer showed high 
uptake in BHK-GIPR positive tumors, uptake in NES2Y tumors was rather low. In the 
future, several tracer characteristics, such as internalization rates and circulation time, 
might be optimized to further improve tumor targeting. Although additional, extensive 
tracer characterization is required to fully understand its in vivo applications, [111In]-
GIP1-42 shows promising results as a radiotracer for NET imaging. 
The search for a reliable in vivo beta cell imaging technique is a challenging process 
that has been going on for two decades. Clinical implementation of such an imaging 
technique might hold the power to significantly broaden our insights in the multi-
factorial pathogenesis of diabetes. Despite a wide variety of promising preclinical results 
however, it remains challenging to translate these non-invasive imaging techniques into 
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daily clinical routine. Therefore, it is of great importance to fully characterize all features 
of possible targets and tracers and unravel potential pitfalls on the road to clinical 
implementation. A first important step towards human translation is the identification 
of a reliable preclinical model which closely resembles the human features. The 
observations described in Chapter 3 of this thesis clearly indicate important differences 
between animal species and strains. The accomplishment of a more homogenous use of 
reliable animal models might facilitate the interpretation of various results and help to 
open doors towards clinical translation. 
A second relevant step towards quantitative beta cell imaging is investigating whether 
tracer uptake in the target correlates with viable BCM in the pancreas or in the islet graft. 
If this goal is reached, the applied radiotracer can provide real-time, in vivo information 
on the remaining BCM, which might be of particular interest for people at risk for diabetes 
or to monitor islet graft survival. In 2014, Brom et al. already showed that [111In]-exendin 
uptake correlates with remaining BCM in the native pancreas of rats [5]. In this thesis we 
broaden the quantitative capacities of this tracer to islets, engrafted in striated muscle. 
Although exendin displays excellent features for successful clinical translation, the use of 
alternative tracers might be helpful to obtain complementary information about the beta 
cells. During diabetes pathogenesis or during post-transplantation pathologic processes, 
such as metabolic stress, inflammation or rejection, the expression patterns of the 
various beta cell receptors might be modulated in different ways. Therefore, it seems of 
additional value to investigate the potential of other tracers, targeting other receptors. In 
this thesis, we successfully visualized islets, engrafted in the calf muscle, by targeting the 
D2 receptor and revealed its potential to quantify viable graft volume. This observation 
might be an important step forward since it is the first time that a linear correlation is 
shown between radiotracer uptake in an islet graft and viable graft volume. Although, 
clinical islet transplantation is currently performed in the liver, non-invasive imaging 
might help to further characterize striated muscle as a potential novel transplantation 
site. Next to several others targets, the GIPR was proposed as a potential target for beta 
cell imaging. In this thesis, the first steps towards the development and characterization 
of a GIPR targeting tracer are described in a tumor model. 
Next to combined tracer imaging, the implementation of simultaneous PET/SPECT and 
MR imaging, using hybrid imaging systems [19], might play an important role in in vivo 
BCM determination in the future. These novel hybrid systems might allow for parallel 
imaging of islet grafts using simultaneous PET or SPECT radionuclide imaging, targeting 
a receptor specifically expressed on the beta cells, and contrast-enhanced MR imaging 
after islet pre-labeling. In the end, these hybrid imaging modalities might significantly 
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improve islet imaging by bringing the advantages of both imaging modalities (high 
spatial resolution and high sensitivity) together. 
Taken together, we evaluated a variety of potentially promising tracers for non-invasive 
in vivo beta cell radionuclide imaging. While the characterization of GIP analogues as beta 
cell targeting tracers is still in its infancy, valuable steps were taken in the characterization 
of exendin and IBZM as beta cell tracers. Since both tracers have already been used in 
humans, their translation to clinical use seems feasible.
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Diabetes Mellitus is a metabolic disease, caused by a deficiency in glucose homeostasis. 
The main characteristic of diabetes is chronically elevated blood glucose levels 
(hyperglycemia) which might occur due to auto-immune beta cell destruction (type 1 
diabetes) or, when the beta cells fail to compensate for insulin resistance of the insulin 
responsive organs, such as the liver and skeletal muscles (type 2 diabetes). Although 
daily insulin injections and anti-diabetogenic drugs provide good glycemic control, all 
diabetic patients are at risk to develop severe micro- and macro-vascular complications. 
Nowadays, millions of people are suffering from diabetes and this number is expected to 
double within the next 15 years. 
For patients suffering from type 1 diabetes, insulin is never a cure, only a treatment. 
Transplantation of the islets of Langerhans is a novel and promising therapy for type 1 
diabetes and might provide a more permanent solution for these patients. Unfortunately, 
5 years after islet transplantation, only 15% of all transplanted patients remain insulin 
independent. These observations clearly indicate a decrease of viable beta cells (beta 
cell mass) in the islet graft over time, but the mechanism underlying this decrease is 
poorly understood. A reliable method to quantitatively and longitudinally monitor beta 
cell mass (BCM) in the islet graft would provide more insight in the processes underlying 
islet loss after transplantation. Furthermore, such a method could help to unravel the 
importance of BCM dynamics in the pancreas during the course of diabetes. Today, 
beta cell function (BCF) is usually monitored by measurements of insulin secretion, in 
parallel to blood glucose levels. However, BCF is not always a representative measure 
for BCM during disease onset and progression. Therefore, we are in desperate need of a 
reproducible method to monitor BCM dynamics over time.
A possible method to accurately and non-invasively monitor BCM is quantitative 
and longitudinal radionuclide imaging. To visualize the islets of Langerhans with 
radiolabeled compounds (tracers) using Positron Emission Tomography (PET) or 
Single Photon Emission Computed tomography (SPECT), a tracer targeting a receptor, 
specifically expressed on the beta cells, is required. In this thesis, we investigated the 
potential of various radiotracers, targeting different receptors specifically expressed on 
the beta cells, for non-invasive BCM imaging, both in the native pancreas and after islet 
transplantation. 
In the First Part, an outline of the research described in this thesis is provided (Chapter 1). 
Chapter 2 presents various imaging techniques and possible target receptors for in vivo, 
non-invasive islet imaging. Both Magnetic Resonance Imaging (MRI) and radionuclide 
imaging are often applied for in vivo visualization of the islets of Langerhans. The major 
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advantage of radionuclide imaging techniques such as PET and SPECT over other 
imaging modalities such as MRI and CT (Computed Tomography) is their high sensitivity. 
To visualize the beta cells using PET or SPECT, a tracer, specifically accumulating in 
these cells and showing low background retention in other endocrine cell types and the 
surrounding organs, is required to obtain ideal target-to-background ratios. Possible 
target receptors for these tracers are for example the Glucagon-like peptide 1 (GLP-1) 
receptor, the Glucose-dependent insulinotropic polypeptide (GIP) receptor, serotonin 
receptor and dopamine receptor. Although several tracers targeting these receptors 
showed promising results in animal models, clinical translation of these techniques 
remains challenging.
The Second Part of this thesis describes the characterization of the GLP-1 receptor (GLP-
1R) and its radiolabeled agonist [111In]-exendin for non-invasive BCM determination. A 
variety of preclinical models has been used to investigate BCM dynamics using [111In]-
exendin but contrasting results have been observed. Chapter 3 investigates which 
animal model is most suitable for preclinical, non-invasive BCM determination using 
[111In]-exendin. The most important finding of this study is that mice and rats show big 
differences in pancreatic tracer uptake. While [111In]-exendin accumulates specifically 
in the beta cells of rats, tracer uptake is observed in both the endocrine and exocrine 
pancreas of mice. Strikingly, no or only very low GLP-1R expression was observed in the 
exocrine tissue of mice, which suggests that [111In]-exendin probably binds to a receptor 
other than the GLP-1R in the exocrine pancreatic tissue of mice. At this point in time, 
it remains unclear which receptor is responsible for this exocrine tracer uptake in mice 
and further investigations will have to be performed to identify this receptor. In Chapter 
4 we aim to target the beta cells using [111In]-exendin after islet transplantation in the 
calf muscle. This study shows the possibility to visualize viable beta cells in islet grafts 
using [111In]-exendin SPECT. We observed a clear difference in SPECT signal of an islet 
graft containing 400 islets when compared to the signal of an islet graft containing 800 
islets, indicating that the intensity of the SPECT signal is a representative measure for the 
amount of viable beta cells in the islet graft. Immunohistochemical analysis confirmed 
that the observed signal originated from the viable islets in the graft. 
The Third Part investigates the application of the Dopamine2 (D2) receptor antagonist 
[123I]Iodobenzamide ([123I]IBZM) for in vivo, non-invasive imaging of transplanted islets 
of Langerhans. Chapter 5 illustrates the optimization of [125I]-3-IBZM radio-synthesis. 
Furthermore, we investigated the feasibility of intramuscular islet graft imaging using 
this tracer. Radio-iodination resulted in 3 IBZM isomers with different receptor affinities. 
Therefore, the radio-iodination procedure was optimized to produce predominantly 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Su
mm
ar
y
161
[125I]-3-IBZM, the isomer harboring the highest receptor affinity. The tracer ([125I]-3-
IBZM) showed D2 receptor mediated binding to isolated islets in vitro. Furthermore, 
the possibility to visualize islets, engrafted in the calf muscle of rats, using [123I]IBZM 
SPECT, was demonstrated. To determine the BCM based on tracer uptake, the SPECT 
signal needs to correlate with the amount of viable beta cells in the islet graft. Therefore, 
Chapter 6 investigates the use of [123I]IBZM SPECT for viable graft volume quantification 
and longitudinal monitoring of islets grafts using this tracer. In this study, we found a 
good correlation between tracer uptake in the islet grafts and the viable volume of the 
islet grafts, confirming that [123I]IBZM SPECT can be applied for non-invasive in vivo 
BCM determination in islet grafts. Longitudinal graft follow-up showed a clear SPECT 
signal of the transplanted islets from 3 weeks until 10 weeks after transplantation. 
Together, these characteristics show that [123I]IBZM is a promising tracer for non-invasive 
and quantitative islet graft monitoring. 
In the Fourth Part, the first steps towards the development of a novel beta cell tracer, 
targeting the GIP receptor, are described. The characterization of a novel fluorescent GIP 
tracer (GIP-Cy3), developed by Novo Nordisk is reported in Chapter 7. GIP-Cy3 showed 
dose-dependent binding to Baby Hamster Kidney cells over-expressing the human GIP 
receptor (BHK-GIP receptor). Furthermore, the tracer showed receptor mediated binding 
to NES2Y cells, a human beta cell-derived cell line, and to isolated islets of Langerhans. 
Despite these promising in vitro tracer characteristics, GIP-Cy3 was unable to visualize 
the islets of Langerhans in the pancreas ex vivo using fluorescent microscopy. Since the 
sensitivity of radionuclide based tracer is higher when compared to fluorescent tracers, 
we changed our focus towards the development of a radiolabeled GIP tracer. Chapter 
8 demonstrates the radiosynthesis and characterization of this novel radioactive GIP 
tracer. Furthermore, we investigated the suitability of this tracer for non-invasive, in 
vivo imaging of neuro-endocrine tumors, such as insulinomas (tumors derived from the 
insulin-producing beta cells). [111In]GIP 1-42 was produced at high specific activity and 
showed specific binding to BHK-GIP receptor over-expressing cells, NES2Y cells and 
isolated islets of Langerhans in vitro. In mice with a subcutaneous BHK-GIP receptor 
positive tumor, receptor mediated tumor uptake was observed 4 hours post-injection. 
Also in mice with a subcutaneous NES2Y tumor (a clinically more representative model 
in terms of receptor expression) tumor uptake was observed. Together, these results 
underline the promising characteristics of [111In]GIP 1-42 for non-invasive, in vivo imaging 
of neuro-endocrine tumors. Finally, Chapter 9 summarizes and discusses all the results 
described in this thesis together with the possible future perspectives for beta cell 
imaging. 
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Diabetes Mellitus is een metabole aandoening die ontstaat wanneer de glucosehuishouding 
van het lichaam ontregeld raakt. Dit kan gebeuren wanneer de insuline producerende 
beta cellen afsterven door een aanval van het eigen immuunsysteem (type 1 diabetes) 
of wanneer de beta cellen niet meer voldoende insuline kunnen produceren om te 
compenseren voor de insuline resistentie van de weefsels die op dit insuline moeten 
reageren (type 2 diabetes). Beide processen resulteren in een verhoging van de 
hoeveelheid glucose in het bloed (hyperglycemie) die meestal behandeld wordt door 
het toedienen van exogeen insuline (type 1 diabetes) of door medicatie die ofwel de 
opname of verwerking van glucose verbeteren ofwel de productie van insuline door de 
beta cellen verhogen (type 2 diabetes). Wereldwijd lijden miljoenen mensen aan diabetes 
en er wordt verwacht dat hun aantal nog zal verdubbelen in de komende 15 jaar.
Naast het dagelijks toedienen van insuline vormt transplantatie van de eilandjes van 
Langerhans (die de beta cellen bevatten) een veelbelovende nieuwe behandeling voor 
patiënten met type 1 diabetes. Helaas hebben 5 jaar na transplantatie nog maar 15% van 
de patiënten, die een transplantatie ondergaan hebben, een normale glycemie zonder 
extra toediening van exogeen insuline. Het lijkt er dus op dat de hoeveelheid beta cellen 
(beta cel massa (BCM)) in het transplantaat afneemt in de tijd na transplantatie, maar de 
precieze oorzaak is nog onduidelijk. Ook over de veranderingen in BCM in de pancreas 
tijdens het ontstaan van diabetes is nog onvoldoende bekend. Tot op heden bestaat 
er geen methode om de BCM in patiënten te bepalen en wordt er gebruik gemaakt 
van parameters die de beta cel functie (BCF), van de pancreas of het transplantaat, 
weergeven zoals bijvoorbeeld glycemie, insulinespiegel of glucose tolerantie. Aangezien 
de veranderingen in BCM en BCF niet gelijk lopen tijdens het ontstaan van diabetes, 
dringt de nood aan een manier om de BCM te bepalen zich op. 
Een aantrekkelijke methode om de BCM niet-invasief te bepalen is beeldvorming met 
behulp van radioactieve stoffen (radionuclide beeldvorming/imaging). Hiervoor 
maken we gebruik van een radioactieve speurstof (tracer) die specifiek in de beta cellen 
accumuleert door te binden aan zijn doelwit (receptor/target), dat specifiek tot expressie 
komt op de beta cellen. In dit proefschrift wordt het potentieel van verschillende tracers, 
gericht tegen verschillende receptoren, voor BCM imaging in de pancreas en na eilandjes 
transplantatie onderzocht. 
Deel 1 van dit proefschrift wordt ingeleid met het uitlijnen van de doelstelling (Hoofdstuk 
1). In Hoofdstuk 2 worden de verschillende imaging methoden en receptoren die als target 
kunnen dienen om beta cellen in beeld te brengen besproken. Magnetische Resonantie 
Imaging (MRI) en radionuclide imaging zijn de meest gebruikte beeldvormende 
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technieken voor het in beeld brengen van beta cellen (beta cel imaging). Het grote 
voordeel van radionuclide imaging technieken zoals Positron Emission Tomography 
(PET) en Single Photon Emission Tomography (SPECT) is hun hoge gevoeligheid. Om 
de beta cellen in beeld te brengen met PET of SPECT, is een tracer nodig die specifiek 
in deze cellen accumuleert en een laag achtergrond signaal heeft in de omliggende 
cellen en weefsels, zodat een optimale signaal-tot-achtergrond verhouding ontstaat. 
Veelbelovende receptoren voor deze beta cel tracers zijn onder andere de glucagon-
like peptide 1 (GLP-1) receptor, de glucose-dependent insulinotrpic polypeptide (GIP) 
receptor, de serotonine receptor en de dopamine receptor. Hoewel verschillende tracers 
veelbelovend leken in diermodellen, blijft de translatie naar patiënten moeilijk.
Deel 2 beschrijft de karakterisering van de GLP-1 receptor en [111In]-exendin voor niet-
invasieve BCM beeldvorming. Tot op heden werden verschillende diermodellen gebruikt 
voor het niet-invasief bepalen van de BCM met [111In]-exendin. In Hoofdstuk 3 wordt 
een studie beschreven waarin wordt onderzocht welk diermodel het best gebruikt kan 
worden voor het niet-invasief bepalen van de BCM met radioactief exendin. De meest 
opvallende bevinding van deze studie is dat er een groot verschil bestaat in tracer opname 
in de pancreas van ratten en muizen. Terwijl de tracer specifiek accumuleert in de beta 
cellen van ratten, zien we in muizen, naast de opname in de beta cellen, ook opname in de 
exocriene pancreas. Opmerkelijk is dat dit exocriene weefsel geen expressie van de GLP-
1 receptor vertoont. Dit impliceert dat exendin mogelijk aan een andere receptor bindt 
in het exocrien pancreasweefsel van muizen en verder onderzoek zal moeten uitwijzen 
welke receptor hiervoor verantwoordelijk is. In Hoofdstuk 4 richten we ons op het in beeld 
brengen van de beta cellen met [111In]-exendin na eilandtransplantatie in de kuitspier. 
Deze studie laat zien dat het mogelijk is om vitale beta cellen in eilandtransplantaten 
in beeld te brengen met [111In]-exendin SPECT. Er werd een duidelijk verschil in SPECT 
signaal gemeten tussen een transplantaat van 400 eilandjes en een transplantaat van 800 
eilandjes, wat bevestigt dat de intensiteit van het signaal representatief is voor het aantal 
beta cellen in het transplantaat. Immunohistochemische analyse van de kuitspier met 
het transplantaat liet zien dat de waargenomen radioactiviteit daadwerkelijk van de 
gezonde eilandjes in het transplantaat afkomstig was.
In Deel 3 onderzoeken we het gebruik van de dopamine 2 (D2) receptor en zijn 
radioactieve antagonist [123I]Jodobenzamide ([123I]IBZM) voor het niet-invasief afbeelden 
van getransplanteerde eilandjes van Langerhans. Hoofdstuk 5 beschrijft de optimalisatie 
van de radiosynthese van de [125I]-3-IBZM tracer. Verder wordt de mogelijkheid 
om intramusculair getransplanteerde eilandjes in beeld te brengen met deze tracer 
onderzocht. 
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Tijdens de radio-jodering worden er 3 isomeren gevormd, elk met een verschillende 
bindingscapaciteit voor de receptor. Daarom werden de reactieomstandigheden van de 
joderingsreactie zo aangepast om vooral het [125I]-3-IBZM isomeer te produceren. [125I]-
3-IBZM bond specifiek aan de D2 receptor van geïsoleerde eilandjes van Langerhans. 
Verder werd aangetoond dat eilandjes, getransplanteerd in de kuitspier van ratten, in 
beeld gebracht kunnen worden met [123I]IBZM SPECT. Om de BCM te kunnen bepalen 
op basis van tracer opname, moet de intensiteit van het SPECT signaal overeenkomen 
met het aantal overlevende eilandjes in het transplantaat. In Hoofdstuk 6 worden dan 
ook de kwantitatieve eigenschappen van [123I]IBZM SPECT en de mogelijkheid om 
het transplantaat langdurig te volgen op basis van deze techniek onderzocht. In deze 
studie werd een duidelijke correlatie gevonden tussen de opname van de tracer in het 
transplantaat en de grootte van het transplantaat. Deze bevinding bevestigt dat de tracer 
gebruikt kan worden om de BCM in het transplantaat te bepalen. Het transplantaat 
kon duidelijk gedetecteerd worden vanaf drie weken na transplantatie tot tien weken 
na transplantatie. Deze karakteristieken tonen aan dat [123I]IBZM een veelbelovende 
tracer is voor het niet-invasief en kwantitatief afbeelden en opvolgen (monitoren) van 
eilandtransplantaten. 
Deel 4 beschrijft de eerste stappen in de ontwikkeling van een nieuwe tracer voor beta 
cel imaging via de GIP receptor. De karakterisering van een nieuwe, door Novo Nordisk 
ontworpen, fluorescente GIP tracer (GIP-Cy3) wordt beschreven in Hoofdstuk 7. GIP-
Cy3 bond dosis-afhankelijk aan getransfecteerde Baby Hamster Kidney (BHK) cellen 
waarop de GIP receptor tot expressie komt (BHK-GIP receptor). Ook aan NES2Y cellen, 
een cellijn afgeleid van humane beta cellen, en aan geïsoleerde eilandjes van Langerhans 
werd specifieke binding van de tracer waargenomen. Ondanks deze veelbelovende 
tracereigenschappen in vitro, was GIP-Cy3 niet in staat om de eilandjes in de pancreas 
van muizen in beeld te brengen met behulp van fluorescentie microscopie. Omdat de 
gevoeligheid van detectiemethoden voor radioactieve tracers hoger is in vergelijking met 
fluorescente tracers, richtten we ons vervolgens op de ontwikkeling van een radioactieve 
GIP tracer. In Hoofdstuk 8 wordt de radiosynthese en karakterisering van deze nieuwe 
radioactieve GIP tracer beschreven. Verder wordt onderzocht of deze tracer geschikt 
is voor het niet-invasief afbeelden van neuro-endocriene tumoren zoals bijvoorbeeld 
insulinomen (tumoren ontstaan uit de insuline producerende beta cellen). [111In]GIP1-42 
kon worden geproduceerd met hoge specifieke activiteit en bond specifiek aan BHK-GIP 
receptor cellen, NES2Y cellen en geïsoleerde eilandjes van Langerhans in vitro. In muizen 
met een subcutane BHK-GIP receptor positieve tumor werd receptor gemedieerde 
tumoropname gezien vier uur na tracerinjectie. Ook in muizen met een subcutane 
NES2Y tumor (een meer representatief model voor beta cellen qua receptorexpressie) 
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werd tumoropname waargenomen. Deze resultaten bevestigen het veelbelovend 
karakter van [111In]GIP1-42 voor het niet-invasief in beeld brengen van neuro-endocriene 
tumoren. Tot slot worden in Hoofdstuk 9 alle bekomen resultaten en de mogelijke 
toekomstperspectieven voor beta cel imaging besproken.
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Dankwoord 
Belangrijk om te weten voor u (je) verder leest, dit dankwoord werd geschreven in een 
combinatie van Nederlands en Vlaams. U/je bent bij deze gewaarschuwd en ik doe hierbij 
afstand van de verantwoordelijkheid voor alle mogelijke verwarringen veroorzaakt door 
taalverschillen.
Hoewel het in het begin moeilijk was om aan Nederland te wennen, was het ook 
moeilijk om na drie jaar weer weg te gaan uit Nijmegen. Nu kijk ik met veel plezier 
terug op een heel mooie tijd waar ik heel veel mooie herinneringen en vrienden aan 
heb overgehouden. Bloed, zweet en tranen (niet noodzakelijk in die volgorde) heeft 
het gekost, maar uiteindelijk is het allemaal goed gekomen, en ik ben heel blij met het 
resultaat. Natuurlijk is dit boekje niet alleen mijn verdienste en had ik het nooit gekund 
met de hulp, de steun en het vertrouwen van een heel aantal mensen. Ik vind het dan 
ook een hele eer dat ik nu uitgebreid (uitvoerig) de kans krijg om iedereen die, op welke 
manier dan ook, heeft bijgedragen aan het tot een goed einde brengen van mijn doctoraat 
(promotie). 
De eersten die ik graag wil bedanken zijn mijn team van promotoren, Martin en Otto. 
Beste Martin, jij gaf mij de kans om te doctoreren (promoveren) in Nijmegen als deel 
van een groot Europees consortium hoewel je, zo bleek achteraf, de helft van wat ik 
had gezegd tijdens mijn sollicitatiegesprek niet had verstaan (begrepen). Bedankt voor 
de vrijheid en de inspraak die je mij gegeven hebt in het verder uitwerken van mijn 
onderdeel van het Beta-Train project. Toch deed het mij altijd veel plezier als je, op het 
moment dat ik de moed dreigde te verliezen, me er even aan herinnerde dat ik in mezelf 
moest blijven geloven en dat het allemaal wel goed zou komen. Bedankt dat ik een deel 
mocht zijn van “jouw” Beta-Image groep, ik heb veel van je geleerd. Beste Otto, ook al 
stond je soms misschien iets meer op de achtergrond, toch was ook jij super belangrijk 
voor mijn promotie en ik ben blij dat jij mijn tweede promotor bent. Ik loop nu de kans 
om te herhalen wat zoveel van je doctoraatsstudenten (promovendi) voor mij al gezegd 
hebben, maar ik ga het toch doen. Ik was altijd onder de indruk van jouw eeuwige goede 
humeur, positivisme en je open-deur beleid. Ik kon altijd bij jou terecht en als ik met een 
labjournaal vol mislukte Gallium labelingen bij jou kwam, dan zei je heel optimistisch: 
“Nou, dan weten we nu ten minste dat dit niet werkt”. Beste Maarten, ik prijs mezelf 
heel gelukkig met jou als co-promotor. Het is echt bewonderenswaardig hoeveel jij over 
alles weet. Of ik nu kwam met een vraag over proefdieren, labelingen, receptoren of 
diabetes, ik denk niet dat ik je één keer “ik weet het niet, dat moet je even opzoeken” 
heb horen zeggen. Bedankt dat je er altijd was om al mijn vragen te beantwoorden en 
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mij te ondersteunen waar nodig. Beste Martin, Otto en Maarten, bedankt voor al jullie 
hulp, steun en vertrouwen maar natuurlijk ook voor alle gezellige momenten tijdens 
mijn promotietijd. 
Naast mijn promotoren was ik omringd door nog zoveel andere mensen die het werk 
makkelijker, beter maar vooral leuker maakten. Eerst en vooral Inge, ik denk dat het 
onmogelijk zou zijn om uit te tellen hoeveel uren we samen bij PRIME, de urologie, 
het lab, de IRW of de radiotherapie hebben doorgebracht, vaak met het foute uur op 
de achtergrond. Onze gezamenlijke papers zijn een mooi, tastbaar resultaat van onze 
intense samenwerking. Toch denk ik vooral terug aan heel veel gezelligheid, gelach en 
fijne momenten op het werk en erna. Natuurlijk vind ik het dus heel spijtig dat je er niet 
bij kan zijn op 28 september, maar ja, India is ook niet bij de deur. We zullen dus dubbel 
zo hard moeten vieren op jouw promotie, die er nu ook heel snel aan zal komen!
Lieke, ook jij verdient een speciaal plaatsje in dit dankwoord. Ik denk dat ik wel mag 
zeggen dat de hoofdstukken 3 en 9 van dit boekje onze gezamenlijke trots zijn. Toen mijn 
tijd in Nijmegen op zijn einde liep, heb jij al het praktisch werk uit mijn handen genomen 
zodat ik mij kon focussen op het schrijven van mijn boekje, en toen ik in augustus 
vorig jaar wegging heb jij het GIP project van mij overgenomen en verder gezet. Ik heb 
genoten van onze samenwerking maar ook van alle gezellige momenten op het werk, 
op congressen en tijdens jullie bezoekje aan Leuven; van je vriendschap en je luisterend 
oor. Ik ben fier (trots) dat jij mijn paranimf bent en Ik ben blij dat je nu eindelijk de 
knoop hebt doorgehakt om zelf ook te gaan promoveren (doctoreren), je boekje wordt 
zeker geweldig! Cathelijne en Desirée, ook jullie waren van onschatbare waarde voor dit 
boekje. Jullie waren altijd bereid om te helpen met het plannen, opzetten en uitvoeren 
van grote of kleine experimenten, om mij nieuwe technieken aan te leren of om wat 
van het werk uit mijn handen te nemen als het te druk dreigde te worden. Ik heb veel 
geleerd van jullie expertise in al het labowerk en altijd genoten van jullie gezelschap 
en fijne babbels tijdens het uitvoeren van experimenten en op allerlei borrels, feestjes, 
beta-etentjes of shopping tripjes in Brussel. Cath, dat doen we snel nog eens! Inge, Lieke, 
Cath en Desirée, wat ik ook zeker nooit zal vergeten zijn onze, toen bijna wekelijkse, 
soms gigantische gezamenlijke eilandjes isolaties. Dat we soms tot aan onze ellenbogen 
onder het bloed zaten leek niemand te deren en niemand keek raar op bij de vraag “Mag 
ik van iemand een gaatje?”. Eigenlijk leek het meer op een koffieklets dan op werk, 
alleen de doos koekjes ontbrak nog. Ik heb altijd heel erg genoten van deze momenten! 
Annemarie, op puur basic research gebied hebben we niet veel samengewerkt maar toch 
was jij, als “regelende kracht” van de Beta-Image groep, onmisbaar. Bedankt voor alles 
wat je voor mij geregeld hebt tijdens mijn promotietraject, alle groeps- en internationale 
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meetings die je geregeld hebt en je herinneringsmails aan vergeten Beta-Train rapporten. 
Maar natuurlijk ook voor alle gezellige momenten op de afdeling en tijdens onze Beta-
Train uitstapjes. 
 
Gerben, my partner in Gallium crime! Gerben, we hebben samen heel wat milliSieverts 
verzameld op onze ringdosimeters om dat Gallium toch maar GMP aan dat exendin 
te krijgen. Bedankt voor alle truckjes die je mij hebt bijgebracht voor het labelen van 
Gallium en voor je hulp bij grote dierexperimenten. Janneke, bedankt voor alle hulp bij 
het kweken, bij het opzetten van nieuwe kleuringen en beoordelen van coupes. 
Verder wil ik ook graag mijn kamergenoten bedanken. Tessa, Sandra, Marlène, Charlotte, 
Stijn, Willem, Wietske, Peter, Wael, Selen en Susanne, bedankt voor alle wetenschappelijke 
input, hulp bij allerlei projecten en oppeppende toespraken. Maar vooral voor alle 
gezelligheid in de koffiekamer, op café (in de kroeg), tijdens congressen, bieretentjes, 
eerste paper- en alle andere soorten borrels, voetbal-kijk afspraken, afdelingsuitjes en zo 
kan ik nog wel even verder gaan. Gelukkig wisten jullie ook allemaal heel goed dat werken 
echt niet kan met een lege snoeppot (hoewel de pot wel vaker en vooral ook sneller leeg 
was dan vol), ook niet voor 10 uur ’s morgens (’s ochtens) of dat een “vrijdaggevoel” het 
best is op te lossen door de noodvoorraad te plunderen of naar de Laaf te gaan. Eigenlijk 
is het een mirakel dat ik tijdens mijn tijd in Nijmegen zelf geen diabetes heb ontwikkeld. 
Ook aan al mijn andere collega’s van de research: Floor, Samantha, Christelle, Marti, 
Mijke, Daphne, Mark, Danny en Reinier, Jacqueline en Marie-Louise en alle medewerkers 
van het secretariaat, alle beeldvormers, artsen en AIOS van de kliniek, bedankt voor alle 
hulp, gezelligheid en mooie momenten op de afdeling.
Aan alle medewerkers van de afdelingen urologie, pathologie en PRIME ook ne “helen 
dikke merci” voor jullie hulp bij de weefselkweek, snijden van coupes, injecteren en 
scannen van dieren en alle gezellige momenten van de afgelopen jaren. 
Professor Decio Eizirik and Alexander Balhuizen of the Free University of Brussels. 
Thank you for your help with all the qPCR experiments for Chapter 3 of this thesis, your 
valuable and extremely fast input for the manuscript and scientific discussions. 
Next to my colleagues in Nijmegen, I also had the pleasure to meet and work with a 
lot of amazing, international colleagues and friends. I always found it a privilege to be 
part of our big international consortium and enjoyed all our beautiful moments together. 
Therefore, I would like to take the time to thank all the members of the Beta-Train. First 
of all, Wael and Selen, my two Beta-Train colleagues in Nijmegen. Thank you for all 
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the nice times over these years, working together on experiments, writing abstract or 
papers, and worrying about yet another Beta-Train report. But of course, also for all the 
nice times we had over the years on all the meetings, congresses or going out for a nice 
dinner or drinks.
Jacob, Jonas and Janne, thank you for my amazing stay in Copenhagen. You offered me 
the opportunity to discover how it feels like to work in a big international company. I 
really enjoyed my time at the R&D site of Novo Nordisk. Janne, of all the Beta-Train 
fellows (not located in Nijmegen), you were the one I collaborated most with. Chapter 
7 of this thesis is the nice result of the experiments we performed together. I cannot 
count how many emails we have written to each other, discussing the paper, wondering 
whether it should be probe or tracer, or just to keep each other informed about our work 
and life. I always enjoyed working with you a lot and enjoyed all the nice times together 
in Copenhagen and at all our Beta-Train meetings.  
Andrea, Vineetha, Romain, Sandeep, Pim, Rita, Saba, Shweta, Greg, Philippo and Max, 
thank you for all the nice moments we have spent together in Tübingen, Copenhagen, 
Prague, Frankfurt, Nijmegen, Geneva and Umea. I could write five pages with memories 
on all our amazing times but I am sure that you all remember very well what I mean. I 
am very grateful that I got to know all of you and had the pleasure to work with you. To 
those who already defended their PhD: congrats, great job! To those who are currently 
finishing up: good luck with writing, you will do great. I hope we will see each other 
again on a Beta-Train reunion or on congresses. 
Next to the fellows, I would also like to take the time to thank all the Beta-Train 
supervisors for their scientific input during our meetings, teleconferences and input 
for papers. Thank you as well for all the nice times during the consortium dinners or 
over beers. A special thanks goes to Bernd and Valerie, Jacob and Jonas, Daniel, Monika 
and Milan, Olliver and Volker, Erik and Ulf and Maria for the organization of our Beta-
Train meetings. I always enjoyed discovering your research sites and universities, and 
exploring the lovely cities you all live in. I even had the chance to go to one of the biggest 
Christmas markets in the world and to see one of the most extraordinary things in life: 
I saw the Northern Lights! Thank you all for everything and I hope to see you all again!
Then there is one more Beta-Train supervisor to whom I owe special thanks. Dear Uwe, if 
you did not invite me to your office to discuss possible PhD projects, I would have never 
been part of this nice consortium. Thank you for bringing this wonderful project to my 
mind and for all the nice times over the last years. Now that I am back in Leuven, I hope 
we will get the chance to work together again. 
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Omdat de boog niet altijd gespannen kan staan, en omdat ik ondertussen ook geleerd 
heb dat het soms beter is om even afstand te nemen (of stoom af te laten) wil ik ook 
mijn vrienden bedanken voor alle leuke ontspanningsmomenten. Jasmien, onder het 
motto “because every blond needs a brunette by her side” hebben we in afgelopen 10 
jaar al heel wat leuke, minder leuke, knotsgekke en memorabele dingen meegemaakt en 
gedeeld. Het was dan ook geen moeilijke keuze om “mijn Brownie” te kiezen om op 28 
september naast mij te staan als mijn paranimf. Als geen ander begrijp je hoe frustrerend 
onderzoek soms kan zijn, gelukkig konden we altijd tegen elkaar zagen als er weer eens 
een paper was afgewezen, als de stapel werk boven ons hoofd dreigde te groeien of 
gewoon zonder reden omdat het gezellig is. Ik ben ongelooflijk fier op u dat je nu als 
postdoc naar Amerika gaat en ik ben er 100% van overtuigd dat je dat daar geweldig 
gaat doen! Patricia, met jou als derde musketier in ons “clubje”, vertegenwoordigen we 
de, misschien wel bekendste, eigenschappen van Leuven: de oude markt, de universiteit 
en de brouwerij. Nog geen jaar geleden woonden we allebei nog in Nederland en 
konden we onze ervaringen delen over het Belg zijn in Nederland, wat vaak hilarische 
gesprekken opleverde als we weer eens uitgelachen werden om ons taalgebruik. Dames, 
bedankt voor alle leuke momenten die we samen al hebben beleefd, ik hoop dat er nog 
heel veel mogen volgen. Kristina, ook wij kennen elkaar ondertussen al 10 jaar en ook 
al zien we elkaar niet zo veel door te drukke agenda’s, toch zijn alle momenten die we 
samen hebben altijd super gezellig. Nu mag jij bij mij in het publiek zitten, volgende keer 
mag ik in het publiek zitten voor jouw verdediging! Ik twijfel er geen seconde aan dat 
het helemaal in orde komt!
Marie-Claire, bedankt voor alle fijne koopavonden, bezoekjes in Leuven of bij jullie thuis, 
ik heb er altijd van genoten! Siska, bedankt voor alle (soms urenlange) telefoontjes toen 
ik in Nijmegen was. Ze hebben veel van mijn avonden opgefleurd. Lenny, Tim, Sticker, 
Saskia, Ivo, Tessa, Alwin, Rector, Dario, Sollie, Krikke, Jente, Jeff, Lies en nog zo veel meer 
mensen van de Plaza-familie, bedankt voor alle gezellige middagen, avonden en nachten 
vol met hilarische gesprekken, foute muziek, voetbal en geweldige herinneringen. Ik 
kijk al uit naar komende zomer vol met gezellige terras-avonden! Jeff, bedankt voor de 
prachtige tekeningen die dit boekje sieren. Elke keer was ik weer diep onder de indruk 
van hoe jij gewoon exact op papier wist te zetten wat ik gevraagd had. Met mijn eigen 
artistiek talent was het nooit gelukt!
Natuurlijk wil ik ook speciaal de mensen bedanken die het dichtste bij mij staan, te 
beginnen met mijn ouders. Mama en Papa, tien jaar geleden hebben jullie mij de kans 
gegeven om te gaan studeren in het mooie Leuven, de stad waar jullie allebei zelf zoveel 
mooie herinneringen aan hebben. Zonder deze kans had ik nooit gestaan waar ik nu sta 
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en was dit boekje er nooit geweest. Bedankt dat jullie mij altijd zijn blijven aanmoedigen 
om ervoor te gaan. Toen ik vertelde dat ik naar Nijmegen wilde gaan om te doctoreren 
was de eerste reactie: “Allez, toch ni naar Holland zeker?”. Maar ik kan jullie verzekeren 
“Holland” was het meer dan waard. Sof, ik kan wel 1000 geweldige, hilarische en 
onvergetelijke momentjes verzinnen van de tijd op ons appartementje in Leuven, van 
onze wekelijkse spaghetti-date in de Spuye tot over het terras van de buren kruipen 
omdat één van ons z’n sleutels weer was vergeten. Waarom ik die “rottige” eilandjes 
zo interessant vind is natuurlijk geen geheim voor u, en op die manier heb jij ook een 
heel belangrijke bijdrage geleverd aan het tot stand komen dit boekje. Je zei dat je altijd 
spontaan aan mij denkt als je muizen en eilandjes hoort, wel je krijgt van mij een heel 
boek vol, dan kan je nog veel aan mij denken.
En last, maar zeker not least, Karim. Lieve Tijger, we leven allebei aan hoog tempo. 
Ik meestal overdag en jij vaak ook ‘s nachts. Maar tussen alle vergaderingen, abstract 
deadlines, WK’s, EK’s, verbouwingen, presentaties, papers en zomerevenementen door, 
slagen we er toch altijd in om tijd te vinden voor elkaar. Ook al vond je het niet altijd leuk 
als ik weer eens op buitenlandse meeting ging, toch stond je er altijd in Zaventem om 
mij te brengen of te komen halen, soms zelf als Anderlecht speelde! Ik ben heel gelukkig 
dat jij aan mijn zijde staat en ik kijk uit naar het leven in ons nieuw huis in Neervelp. 
Tijgertje, tu seras toujours ma préférence à moi. X
Stefanie
Juni 2016
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resulted in her master thesis entitled: “Heterogeneous serotonin production in the islets 
of Langerhans during pregnancy”. In June 2012, she obtained the degree of Master 
of Science in Biomedical Sciences. Driven by her interest in medical imaging and her 
family-related interest in diabetes, she started a PhD study on beta cell imaging at the 
department of Radiology and Nuclear Medicine of the Radboud university medical 
center in Nijmegen, The Netherlands, under the supervision of Prof. dr. Martin Gotthardt 
and Prof. dr. Otto C. Boerman. Her PhD project was part of a prestigious Marie Curie 
initial training network (Beta-Train) for excellence in molecular imaging in diabetes, 
financed by the European Union’s seventh framework program. Part of her research 
has been carried out at the department of Imaging and Pathology of the Research & 
Development site of Novo Nordisk A/S in Måløv, Denmark, under the supervision of 
dr. Jacob Hecksher-Sørensen. Her PhD research focused on the characterization and 
possible clinical implementation of radioactive and fluorescent labeled tracer molecules 
for the visualization of the insulin-producing beta cells in the islets of Langerhans of 
the pancreas. Her work was presented on several national and international congresses 
and in 2015, she got nominated for the prestigious Marie Curie award of the European 
Association of Nuclear Medicine. During her PhD, she was the chair of Beta-Train’s 
female career development committee and was a member of the organizing committee 
of the “pre-symposium on beta cell imaging” on the occasion of the 51st annual meeting 
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of the European Association for the Study of Diabetes in Stockholm, Sweden. Since her 
in time in the Netherlands had further triggered her interest and curiosity in the world 
of Molecular and Nuclear Imaging, she aimed to preserve a career in Nuclear Medicine. 
Currently, she is working as a postdoctoral researcher at the division of Nuclear Medicine 
and Molecular Imaging of the University Hospital and Catholic University of Leuven, 
under the supervision of Prof. dr. Koen Van Laere, where she focuses on brain imaging 
for improved understanding of neurodegenerative diseases. 
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About the Cover
The human anatomy and physiology has been fascinating scientists for many generations. 
In the 15th and 16th century, anatomists such as Leonardo Da Vinci and Andreas Vesalius 
attempted to visualize and understand human anatomy by post-mortem analysis and 
sketching of the human body. At that time, they literally held a magnifier glass above 
certain organs to observe and study them. Nowadays, we are still trying to visualize 
human anatomy and physiology but the scale on which we perform our studies has 
shrunk significantly, namely to micrometers. The magnifier glass has been replaced by 
microscopes and scanners, able to visualize human anatomy and physiological processes 
in the living body without opening it. Although we have shifted from post-mortem 
and invasive to in vivo and non-invasive, we are still purchasing the same goal as the 
scientists centuries ago, namely to visualize how the human body works and how its 
function shifts during pathologic conditions. 

